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STUDY OBJECTIVES 
Amoxycillin is a broad spectrum penicillin antibiotic; suitable for paediatric use. It is used for the 
treatment of urinary tract infections, otitis media, respiratory tract infections, enteric infections and 
endocarditis, for prophylaxis of endocarditis and before surgery such as tonsillectomy. Although 
several studies have been performed to investigate the release of amoxycillin from various dosage 
forms such as capsules, suspensions and parenterals, no studies have been performed on the release 
of amoxycillin from a suppositories. 
The objectives of this study were therefore: 
(1) To develop and validate a suitable High Performance Liquid Chromatographic (HPLC) 
method with the necessary sensitivity to accurately and precisely quantitate amoxycillin 
trihydrate in aqueous solution and human serum; and to develop an efficient technique for 
the pretreatment of serum prior to HPLC analysis.-
(2) To formulate a 250 mg amoxycillin suppository in a fatty suppository base. 
(3) To utilize an appropriate dissolution technique for the measurement of the amount of 
amoxycillin released from a suppository base during in vitro testing and determination of 
the effects of ageing on drug release; to make use of Differential Scanning Calor~~etry 
(DSC) to investigate any potential interaction between amoxycillin and a suppository base. 
(4) To determine the stability of amoxycillin in aqueous solution and stored biological fluids. 
(5) To determine the bioavailabilityof amoxycillin following the administration of amoxycillin 
as single oral' and rectal doses. 
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ABSTRACT 
The investigations in this dissertation have been 'conducted to investigate the formulation and 
analysis of a paediatric amoxycillin suppository. The oral administration of antibiotics to young 
children can at times be problematic. Compliance is sometimes poor because of a sore throat, 
nausea, vomiting, a high fever or a dislike for the taste or smell of the medicine:- In-such cases the 
rectal administration of an antibiotic could provide an alternative route of administration that avoids 
some of the problems that affect oral administration. Difficulties associated with rectal 
administration are bioavailability, local irritation, acceptability to patients and rejection of the 
dosage form. Few data, however, are available on the usefulness in children of suppositories in 
general, and antibiotic suppositories in particular. 
The areas of investigation have included the formulation of an amoxycillin suppository in various 
fatty bases, the quantitation of amoxycillin in both aqueous solution and human serum, assessment 
of stability of amoxycillin in stored aqueous and biological sample'S, in vitro drug release testing 
of suppositories, and bioavailability and pharmacokinetics following administration to h,\,lman 
subjects of capsule, suppository, oral suspension and rectal suspension dosage forms. 
Suppositories containing 250 mg amoxycillin were prepared in theobroma oil and in the 
semisynthetic bases Witepso[ W35, Suppocire A32, Novata BD and Novata 299. The in vitro 
release characteristics of amoxycillin from these lipophilic suppository formulations _were 
investigated using the USP rotating basket method. The dissolution of a drug from a solid dosage 
unit is an important parameter affecting drug bioavialability. 
High Performance Liquid Chromatography (HPLC) was used as the main analytical technique. An 
original HPLC method for analysis of amoxycillin in aqueous solution, using ultraviolet detection 
at 230 nm was develcfped. The validated method was a~plied to the determination of the stability 
of aqueous amoxycillin solutions, and was utilized to determine the amount of drug released during 
dissolution testing. 
Differential scanning calorimetry (DSC) is a technique commonly used in preformulation studies. 
Dissolution testing was used in conjunction with DSC to select a suppository base suitable for 
formulation with amoxycillin trihydrate. 
iv 
An HPLC method for analysis of amoxycillin in human serum using UV detection at 230 nm is 
presented. The method involves a solid phase extraction procedure followed by chromatography 
on a reversed phase column. The limit of sensitivity of 0.3 ILg/mL in serum is sufficiently sensitive 
to monitor serum concentrations of amoxycillin in humans after the administration of a single 250 
mg oral dose. 
Pharmacokinetic parameters were calculated from data obtained following the administration of a 
capsule and oral suspension. These parameters were consistent with previously published results. 
Following administration of a lipophilic suppository and a rectal suspension, to human volunteers, 
it was concluded that amoxycillin trihydrate is not readily absorbed from the rectum. Further 
investigations into the modification of the suppository dosage form with absorption enhancers to 
improve rectal absorption of amoxycillin, as well as elucidation of the mechanism of absorption 
of the drug, could assist in improving this formulation so that it is suitable for paediatric use. 
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CHAPTER ONE 
AMOXYCILLIN MONOGRAPH 
1.1 INTRODUCTION 
1 
Amoxycillin is a broad spectrum, semisynthetic penicillin antibiotic related to ampIcillin [1,2]. It 
was first described in 1970 and was originally marketed by Beecham Pharmaceuticals in 1972 [3]. 
Amoxycillin is listed on the World Health Organization's list of essential drugs [3]. Amoxycillin 
is used as the trihydrate in oral dosage forms and as the sodium salt in parenteral products. 
1.2 PHYSICOCHEMICAL PROPERTIES 
1.2.1 DESCRIPTION 
Amoxycillin is described by several chemical names: 
a) (6R)-6-[ a-D-( 4-hydrox yphenyl)-glycylamino ]penicillanic acid, 
b) D( -)-a-amino-p-hydroxybenzylpenicillin, 
c) 6-[D-( -)-a-amino-p-hydroxyphenylacetamido penicillanic acid, 
d) hydroxyampicillin, and 
e) 4-thia-l-azabicyclo[3. 2. 0]heptane-2-carboxylic acid,6-[ (amino-4-hydroxypn-enyl 
acetyl)amino]-3 ,3..:dimethyt -7 -oxo-2S [-2a,5a,6B(S *)]. 
R=H Anhydrous amoxycillin 
R=H.3H20 Amoxycillin trihydrate 
R=Na Amoxycillin sodium 
Figure 1.1 Structure of amoxycillin 
C16H19N30SS 
C16H19N3 OsS. 3H20 
C16H19N3NaOsS 
MM 365.41 
MM 419.45 
MM 387.39 
2 
Amoxycillin occurs as either the trihydrate or the sodium salt. Amoxycillin trihydrate is an off-
white crystalline powder, while amoxycillin sodium is a white or almost white powder, sometimes 
with a pinkish tinge [1]. Freshly prepared aqueous spl.utions may show a transient pink colouration. 
Both compounds are amorphous and hygroscopic and have a bitter taste and slightly sulphurous 
odour that is typical of many penicillins. 
1.2.2 DISSOCIATION CONSTANT AND PARTITION COEFFICIENT 
Amoxycillin has three ionizable groups: the baroxyl, amino and phenol groups. The dissociation 
constants (pI(,.) for these groups in water are 2.4, 7.4 and 9.6 respectively [3,4]. The apparent 
isobutanol:water partition coefficients (P) [3] are listed in Table 1.1. 
Table 1.1 Isobutanol : water partition coefficient 
Aqueous phase P 
pH 1-3 0.79 
pH 5-6 0.13 
pH 9-9.5 0.25 
The 10gP value for partitioning into n-octanol has been calculated as 0.87 [5]. These values can 
be used to predict the partitioning of amoxycillin between a lipophilic medium such_.as a 
semisynthetic suppository base and the aqueous rectal environment, during dosage form 
development. 
1.2.3 SOLUBILITY 
The solubility of the t.rihydrate in water varies with pH [3]. The pH -solubility profile of amoxycillin 
trihydrate was determined, at 37°e and ionic strength 0.5, to be a U-shaped curve with minimum 
solubility at pH close to the isoelectric point [8]. Van't Hoff plots indicated a linear relationship 
between the equilibrium solubilities of amoxycillin to temperature in the range 20 0 to 50 0 e [8]. 
Table 1.2 lists the solubilities of amoxycillin in a variety solvents [3,4,6,7]. 
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Table 1.2 Solubility of amoxycillin 
Solvent Sofubility (mg/mL) 
Trihydrate Sodiwn 
Water 1-10 )1000 
Ethanol 1-10 10-33 
Methanol 1-10 -
Chloroform (0.1 (0.1 
Diethyl ether (0.1 (0.1 
Acetone 1.0 0.1-1.0 
Acetonitrile Insoluble -
1.2.4 SYNTHESIS 
Amoxycillin is obtained directly by chemical synthesis, or semisynthetically from the compound 
6-aminopenicillanic acid (6-APA) [4] .The route of synthesis which is generally used for large scale 
manufacture is illustrated in Figure 1.2. 
HO-GrH-COO Na + 
NH2 
Amoxycillin 
Figure 1.2 The synthesis of amoxycillin 
~- - . .,-
I 
CICOOC2Hs 
or 
y (CH3hCCOCI 
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This method involves protection of the amino group of D-(-)-p-hydroxyglycine (I) as an enamine 
by reaction with methyl acetoacetate to give the Dane salt (II). This is isolated as a solid by solvent 
removal, suspended in a solvent such as acetone or dichloromethane and reacted with 
ethylchloroformate or pivaloylchloride between -lO°C and -50°C in the presence of a basic catalyst 
such as N-methylmorpholine to form the mixed anhydride (III). A solution of the triethylamine salt 
of 6-APA in dichloromethane is added and reacts to give the N-protected amo,~ycjllin (IV). The 
en amine is then hydrolysed at about O°C by the addition of water and hydrochloric acid, which 
adjusts the pH to 1.5-2.5, and the dichloromethane layer is removed. Subsequent adjustment of the 
aqueous layer to about pH 5 (the isoelectric point) results in crystallization of amoxycillin 
trihydrate. Most major manufacturers use potassium rather than sodium for preparation of the Dane 
sait, and pivaloylchloride rather than ethylchloroformate for the mixed anhydride (III) [3]. 
1.2.5. STEREOCHEMISTRY AND STRUCTURE ACTIVITY RELATIONSlllP 
Amoxycillin has the S,R,R configuration at carbons 2,5,6 resp~t,jvely that is common to all 
penicillins. In addition, the carbon at the 10 position adjacent to the aromatic ring has the R 
configuration, formerly called D-(-) [9]. This structure, depicted in Figure 1.3, 1S numbered in 
accordance with the CA index name. Conventional penicillin numbering, which is used in much 
of the literature on amoxycillin, has S at 1, C(CH3)2 at 2, CH(COOH) at 3 and N at 4. 
HO 
Figure 1.3 Stereochemistry of amoxycillin 
The S epimer of amoxycillin at C 1 0 has been synthesized, but has inferior antibacterial activity. 
The synthesis was further extended to include isomers (6 in all) at the C10, with an ortho, meta 
and para-hydroxy functional group on the aromatic ring. The two most active isomers in vitro had 
the R configuration on the ClO position and were meta and para-hydroxy substituted compounds. 
In vivo the R p-hydroxy isomer resulted in the highest blood levels, and as a result, this has been 
5 
used as the active amoxycillin [9]. 
1.2.6 SPECIFIC OPTICAL ROTATION 
The specific optical rotation of a 0.25% w/v solution of the sodium salt, in a 0.4% w/v solution 
of potassium hydrogen phthalate was + 240 0 to + 290 0 , when calculated with- reference to the 
anhydrous substance. Calculated on the anhydrous basis in a 0.2 % w/v solution of the trihydrate 
in water, the specific optical rotation was +290 0 to +315 0 [9]. 
1.2.7 ULTRA VIOLET ABSORPTION SPECTRUM 
The ultraviolet (UV) absorption spectra of amoxycillin indicate a phenolic type chromophore [9]. 
The .single phenyl ring responsible for the UV absorption means that spectra are commonly 
detected in the region of 210-240 nm. Detection limits of the drug are generally in the order of 
0.5-1 jLg/mL [10]. The molar absorbance values of amoxycilliR tribydrate in a variety of solvents 
are listed in Table 1.3 [3,9]. 
Table 1.3 Ultraviolet spectra of amoxycillin trihydrate 
Solvent Wavelength (run) Molar Absorbance (m2/mol) 
Ethanol 230 (max) 10850 
274 (max) 1400 
281 (sh) 1160 
0.1 M Hel 229 (max) 9500 
272 (max) 1080 
278 (sh) 920 
0.1 M KOH 248 (max) 82200 
291 (max) 3000 
325 (sh) 750 
The UV spectra of amoxycillin trihydrate in mobile phase (methanol:phosphate buffer pH 7,5:95) 
are shown in Figure 1.4. These spectra correspond with those recorded in the literature [3,9]. The 
UV spectrum of amoxycillin trihydrate was recorded on a Beckman DU-68 Spectrophotomer 
(Beckman Instruments Inc, Fullerton, CA). 
3.0 
2.4 
Q) 1.8 
t) 
c 
CI1 
-e 
o 
II) 
.0 
« 1.2 
0.6 
o 
206 228.8 251.6 274.4 297.2 
Wavelength (nm) 
Figure 1.4 The ultraviolet spectrum of amoxycillin trihydrate in mobile phase 
1.2.8 INFRARED SPECTRA 
6 
320 
The frequencies and functional group assignments of the principal peaks in the infrared (rR) spectra 
of amoxycillin trihydrate and amoxycillin sodium salt are shown in Table 1.4 [3,5,9]. 
Table 1.4 IR spectra of amoxycillin sodium and amoxycillin trihydrate 
Assignment of Amoxycillin Sodiwn 
Phenol and water OH, amine and amide NH stretches 
Methyl CH stretch 
B-Iactam CO stretch 
Amide I, CO stretch 
COO· asymmetric stretch 
Amide II, NH bend CN stretch combination band and benzene ring 
C=C stretch 
Gem dimethyl CH deformation 
COO· symmetric stretch and phenol OH combination band 
Fused thiozolidine B-lactam skeletal mode 
Phenol CO and Amide III, NH bend CN stretch in plane 
combination bands 
Benzene ring CH in plane deformation 
Assignment of Amoxycillin Trihydrate 
Water of crystallization, OH stretch 
Amide NH and phenol OH stretch 
Benzine ring CH stretch 
Methyl CH stretch 
B-lactam CO stretch 
Amide I, CO stretch 
COO· asymmetric stretch and NH3 + asymmetric deformation 
Benzene ring C = C stretch 
Amide II, NH bend CN stretch combination band and NH3 + 
symmetric deformation 
Gem dimethyl CH deformation and phenol OH combination band 
COO· symmetric stretch 
Fused thiazolidine B-lactam skeletal mode 
Amide III, NH bend CN stretch in plane combination band 
Phenol CO combination band 
Benzine ring CH in plafle deformation 
1.2.9 pH 
~ 
3366 (broad) 
2969 
1764 
1671 
1601 
1513 
1457 
1398 
1321 
1248 
1173,1126 
3520 
3458, 3175 
3046 
2964 
1775 
1686 
1580 
1517 
1482 
1396, 1378 
1327 
1314 
1283 
1250 
1143, 1120 
7 
The pH of a 10% w/v solution of amoxycillin sodiumjs in the range 8.0 to 10.0. The pH of a 
0.2% w/v aqueous solution of amoxycillin trihydrate is in the range 3.5 to 6.0 [7,8]. 
1.3 STABILITY 
Amoxycillin in aqueous solution can degrade either by hydrolysis or by dimerization (Figure 1.5) 
[10,11]. The relative contributions of the two major reactions to the overall degradation process 
are concentration and pH dependent. Hydrolysis is predominant at lower concentrations, while 
8 
dimerization occurs at higher concentrations [10,12]. The degree of hydrolysis increases with 
increasing pH values while the degree of dimerization decreases [10]. In solutions with a pH 
between 8 and 10, hydrolysis is predominant at low.er concentrations, while dimerization occurs 
at higher concentrations [10,11]. 
Kinetic studies of the degradation of amoxycillin in dilute aqueous solution (OA-4. mg/mL) have 
been conducted over the pH range 0.3 to 10.5 at 35°C [13] and pH 1.1 to 10.8 at 35°C [14]. At 
constant pH, degradation followed first order or pseudo first order kinetics with a minimum 
degradation rate occurring at pH 6 [3,8,13,14]. 
The degradation behaviour of amoxycillin follows the same general pattern as other penicillins. In 
acid, both the cation and the zwitterion species undergo degradation at different rates with the rate 
constant of the zwitterion being about 15 fold faster than that of the cation [14]. In alkaline media, 
the anionic forms of amoxycillin degrade at different rates with the monohydrogen amoxycillinate 
being about 7 fold faster than that of the amoxycillinate. Howeverc;..at pH values between 5.5 and 
6.5 where specific acid-base catalysed reactions are no longer dominant reactions, the zwitterion 
(amoxycillin trihydrate) and monohydrogen amoxycillinate undergo degradation at similar rates 
[14]. The pH of maximum stability of amoxycill in is 5.77 and the rate of degradation does not 
increase until the pH is below 5.5 or above 6.5 [14]. 
In acid, amoxycillin hydrolyses to form amoxypenicillenic acid which absorbs at 230 nm !~,9]. 
Additional breakdown products are the penillic acid, penamaldic acid, penicilloic acid, penilloic 
acid, penicillamine and ultimately penilloaldehyde [3,9]. Epimerization of penicilloic acids in 
aqueous solution occurs at C5 (refer to Figure 1.3) [3,9]. The instability of penicillins in acidic 
solution is well known, and is as a result of intramolecular attack of the side chain amide on the 
6-lact::tm moeity. Introduction of an electron-withdrawing group may be expected to reduce such 
a reaction rate [13]. 1J1e electron withdrawing effect of the protonated a-amino group in the side 
chain of the amoxycillin molecule thus increases its stability, as a result of the electron attracting 
effect decreasing electron density, which subsequently decreases electron availability. Therefore 
amoxycillin and other aminopenicillins are markedly stable to acids [13]. Under acidic conditions 
the degradation half life of amoxycillin is approximately 15-20 hours [1,2,13], ampicillin 
approximately 12 hours [1,2] and penicillin G only 7 minutes [13]. 
As with other penicillins, amoxycillin hydrolyses in aqueous alkali media by opening of the 6-
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lactam ring to form penicilloic acid [3,8,12]. Penicilloic acid ultimately loses carbon dioxide (C02) 
and forms penilloic acid. The amino group in the side chain, which is electron withdrawing, makes 
amoxycillin more susceptible to alkali hydrolysis, The penicilloic acid has been isolated as the 
monosodium salt [3], which retained the 5R configuration of the parent penicillin. Penicilloic acid 
can also be obtained by reaction of amoxycillin with IHactamase enzymes [3,9]. 
In addition to hydrolysis, a base catalysed self-aminolysis reaction can occur. Degradation at higher 
amoxycillin concentrations (25 to 125 mg/mL) at pH 8.6 to 10 and 35°C gives non-first order 
kinetics, indicative of a dimerization reaction [3,12]. When two molecules of amoxycillin interact, 
dimerization proceeds through nucleophilic attack by the side chain amino group of one molecule 
on the B-Iactam carbonyl of another [11,12]. The reacting molecules are subject to general base 
catalysis by the amino and phenolic hydroxyl groups in other molecules [3,10]. Dimerization 
occu~s more readily with amoxycillin than ampicillin, because the basic nature of the amino group 
on the side chain increases when the phenol group is present in a dissociated form. Thus the rate 
of dimerization of amoxycillin at pH 9 is greater than that of other"aminopenicillins due, in part, 
to this effect of the phenolic group [3,10]. 
Although the semi-synthetic penicillins are made from 6-APA, it is not a degradation product [9]. 
Unbuffered solutions of amoxycillin sodium are most stable at pH 5.8 [8]. Degradation of this 
compound is subjectto general acid-base catalysis in citrate and phosphate buffer solutions [l~,}4]. 
The degradation is appreciably catalysed by monohydrogen and dihydrogen phosphate ions. Citric 
acid, dihydrogen citrate and monohydrogen citrate ions catalyse the hyd(olysis of amoxycillin, 
while the unprotonated citrate ion has no catalytic effect [14]. Optimum stability conditions for 
aqueous solutions of amoxycillin are therefore in the range of pH 5.8 to 6.5 using an unprotonated 
citrate buffer [8,14]. 
The stability of different concentrations of amoxycillin sodium salt in water and various 
intravenous fluids has been investigated [12]. A I {mit of 10 % inactivation was imposed. 
Degradation is faster at higher (5% w/v) amoxycillin concentrations than lower (1 % or 2% w/v) 
concentrations. Stability in potassium and sodium chloride solutions was similar to that in water. 
Solutions in lactate and bicarbonate showed intermediate stability and stability was poor in dextran, 
dextrose 5% w/v and sorbitol 30% w/v solutions [8,12]. 
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In the study of decomposition of amoxycillin in the solid state, it was demonstrated that the 
zwitterion form of amoxycillin trihydrate was more stable than amoxycillin sodium (anionic form) 
[15]. The tlO% values of amoxycillin trihydrate and amoxycillin sodium were calculated to be 3.2 
years and 1.25 years respectively at 20 o e. Solid state degradation of amoxycillin trihydrate results 
in formation of the penicilloic acid, piperazine-2,5-dione and unidentified compounds tentatively 
ascribed to amoxycillin oligomers and their penicilloates [3,15]. These degrad~tioo products may 
be present as impurities in samples of amoxycillin trihydrate, with the amoxylloate being the main 
impurity [16,17]. Samples of the sodium salt also contain piperazine-2,5-dione, the amoxycillin 
dimer and to a lesser extent higher oligomers such as the trimer and tetramer [16,17]. 
1.4 CLINICAL PHARMACOLOGY 
1.4.1 MODE OF ACTION 
The penicillin nucleus consists of a thiazolidine ring connected t-e~a 13-lactam ring to which is 
attached a side chain. The structure of the side chain determines most of the pharmacologiql and 
antibacterial properties of a specific penicillin. The benzyl ring in the amino group side chain of 
amoxycillin extends the range of antimicrobial activity to include the Gram negative bacteria, since 
it allows the amoxycillin to penetrate the outer membrane of these bacteria [4]. It is therefore more 
active than benzylpenicillin against some Gram negative bacilli. 
Amoxycillin kills bacteria by interfering with the final stage of peptidoglycan synthesis of the 
bacterial cell wall. Peptidoglycan is a heteropolymeric structure that provides the cell wall with its 
mechanical stability. The final stage in the synthesis of peptidoglycan involves the completion of 
cross-linking when the terminal glycine residue of the pentaglycine bridge is linked to the fourth 
residue of the pentapeptide, d-alanine". The transpeptidase enzyme that performs this step is 
inhibited by penicillirn; and cephalosporins. As a result the bacterial cell wall is weakened, the cell 
swells and then ruptures [4]. The action depends on the penicillin's ability to reach and bind to 
membrane-bound proteins known as penicillin-binding-proteins that are located beneath the cell 
wall. These proteins assist in maintaining cell wall structure, in cell wall synthesis and in cell 
division, and appear to possess transpeptidase and carboxypeptidase activity. Bacterial surface 
enzymes called autolysins also appear to be involved in the lethal effect of penicillins, particularly 
for Gram positive bacteria. In Gram negative bacilli, osmotic rupture of the cells may occur once 
the cell wall has been weakened [6]. It has been reported that amoxycillin predominantly inhibits 
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side-wall synthesis in susceptible bacteria, while ampicillin mainly inhibits cross-wall synthesis [6]. 
The action of amoxycillin is weakened by penicilHnase and other beta-lactamase enzymes that are 
produced during the growth of micro-organisms such as staphylococci [6]. 
The inhibiting effect of amoxycillin on cell wall synthesis in susceptible bacteria is expressed in 
terms of the minimum inhibitory concentration (MIC) and minimum bactericidal concentration 
(MBC). If local amoxycillin levels exceed these values for a given bacterium, then no increase in 
dose can be expected to improve clinical outcome [4]. 
1.4.2 SPECTRUM OF ACTIVITY 
Amoxycillin has no other clinical pharmacological effect apart from its antibacterial action [4]. 
Amoxycillin is bactericidal for both Gram positive and Gram negative organisms. It is active in 
low concentrations against Gram positive cocci, except penicilliP-resistant staphylococci, and 
against Gram positive aerobic and anaerobic bacilli [1,2,4,6,9,18]. It is also active against various 
Gram negative cocci and bacilli [2,6,18]. Table 1.5 lists some of the organisms which are-sensitive 
to amoxycillin. 
Synergy occurs between amoxycillin and clavulanic acid against bacteria usually resistant to 
amoxycillin due to the production of certain beta-lactamases. Amoxycillin may be administe~ed in 
combination with clavulanic acid as the potassium salt. Clavulanic acid is a beta-lactamase inhibitor 
that widens amoxycillin's antibacterial spectrum to organisms usually resistant due to their 
production of beta-lactamases. The combination should however be reserved for the treatment of 
infections caused by such amoxycillin resistant organisms. It is administered by mouth in a ratio 
of 2 or 4 parts amoxycillin trihydrate to 1 part clavulanic acid, or intravenously in a ratio of 5 
parts amoxycillin sodium to 1 part clavulanic acid [6]. 
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Table 1.5 Examples of the antibacterial spectrum of amoxycillin 
Organism MIC (Jtg/mL) 
Staphylococcus aureus, Staphylococcus aureus* 0.1 
Streptococcus faecalis 250 
Streptococcus pneumoniae 0.5 
- -
Streptococcus pyogenes 0.02 
Streptococcus viridans 0.01 
Corynebacterium diphtheriae 0.01 
Listeria monocytogenes 0.02 
Clostridium tetani 0.1 
Clostridium welchii 0.05 
Brucella abortus 0.05 
Bordetella pertussis 0.25 
Haemophilus injluenzae 0.5 
Neisseria gonorrhoeae 0.25 
Neisseria meningitidis 0.02 
Pasteurella septica 0.02 
Escherichia coli 0.5 
Salmonella typhi 5.0 
Shigella sonnei r.25 
Klebsiella aerogelles 2.5 
Proteus mirabilis 250 
Proteus vulgaris 2.5 -
Pseudomonas aeruginosa 250 
Serratia marcescens )500 
Vibrio cholreae 100 
* Penicillinase producing strain 
1.4.3 INDICATIONS 
As amoxycillin is the 4-hydroxy analogue of ampicillin and there are few clinical differences 
between the two penicillins, it is used for the treatment of similar infections [6]. 
Amoxycillin has been used successfully in the treatment and prevention of various infections. These 
include urinary tract infections, otitis media, respiratory tract infections, mouth infections, bacterial 
meningitis, Gram negative septicaemia and other surgical infections, enteric infections and ulcers, 
gynaecological infections and sexually transmitted diseases such as gonorrhoea and chancroid and 
endocarditis. It is also used for the prophylaxis of infective endocarditis and for prophylaxis in 
surgical procedures such as tonsillectomy [4,6,9]. Amoxycillin has been used as an alternative to 
chloramphenicol in the treatment of infections caused by Salmonella species [6]. 
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1.4.4 RESISTANCE 
Penicillinase-producing strains of bacteria such as Staphylococcus aureus are resistant to 
amoxycillin as a result of beta-lactamase activity [2]. Complete cross resistance has also been 
reported between amoxycillin and ampicillin [6]. The rising prevalence of ampicillin resistance 
among previously susceptible strains of bacteria, such as the Enterobacteriacea_e. has reduced the 
clinical usefulness of amoxycillin. 
It can no longer be recommended for first choice or sole use in life-threatening infections due to 
enteric organisms. Amoxycillin was initially very effective against Haemophilus injluenzae, but 
now, particularly in children, 6-12 % of organisms isolated are resistant to amoxycillin. Similarly, 
an increasing percentage of Salmonella spp, E coli, Proteus mirabilis and Shigella spp are not 
sensi~ive to amoxycillin. Amoxycillin is not usually effective against Pseudomonas or 
Acinetobacter. Infections due to Klebsiella and Providencia spp should not be treated with 
amoxycillin as they possess intrinsic resistance to the drug- [4]. Supra infections with non-
susceptible organisms may occur particularly with prolonged use [6]. 
1.4.5 CONTRAINDICATIONS 
Contraindications to the administration of amoxycillin include penicillin hypersensitivity, glandular 
fever, lymphatic lymphoma and bacterial resistance [4]. 
1.4.6 DRUG INTERACTIONS 
No potentially hazardous interactions have been reported. The simultaneous use of amoxycillin and 
an oral contraceptive might be expected to cause breakthrough bleeding or pregnancy on rare 
occasions, because of.leduced absorption of the oral contraceptive as a result of diarrhoea. Serum 
concentrations of amoxycillin are markedly increased after administration of probenicid, which 
blocks active secretion of the drug by the kidneys [2,4,6]. No technical interferences with clinical 
pathology tests have been reported [4]. Instability of amoxycillin trihydrate has been identified in 
infusion fluids containing substances that catalyze the degradation of penicillins. These include 
carbohydrates and polyhydric alcohols such as macrogols. 
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1.4.7 ADVERSE REACTIONS 
As with all penicillins, anaphylactic shock may oocur on very rare occasions and is more likely 
to occur following parental administration [4]. Convulsions may occur if large intravenous doses 
are given [4]. 
Acute overdosage produces very high urinary concentrations. Problems are unlikely if adequate 
fluid intake and urinary output are maintained; however crystalluria is a possibility [4]. 
Amoxycillin is removed to a certain extent by dialysis [6]. 
In addition to anaphylactic shock, amoxycillin may cause hypersensitivity reactions, such as rash 
and fever, similar to those induced by benzylpenicillin and ampicillin. The incidence of these 
reactions is probably no greater than with other penicillins. Amoxycillin should be discontinued 
in the event of any hypersensitivity reaction [4]. 
Penicillin allergy may be caused when either the penicillins or their rearrangement products formed 
in vivo react with proteins, forming a penicilloyl protein. Polymer formation may be an -antigenic 
determinant. Thus the pathogenesis of this allergy may be attributed to lymphocyte function, which 
may explain its significantly high frequency in glandular fever. 
These allergic reactions occur in sensitised persons. Skin rashes are among the most commo~ _side 
effects and are either urticarial or maculopapular. The urticarial reactions are typical of penicillin 
hypersensitivity, while the erythematous maculopapular eruptions are char.acteristic of ampicillin 
and amoxycillin and often appear more than 7 days after commencing treatment. 
Most patients with infectious mononucleosis develop a skin rash when treated with amoxycillin, 
and patients with lymphatic leukaemia also appear to have a higher incidence of skin rashes [4,6]. 
Gastrointestinal side effects, such as nausea, vomiting and particularly diarrhoea, may occur during 
the course of treatment, usually following oral administration. Approximately 5 % of patients or 
more will suffer these effects, with a higher incidence in children. The incidence of diarrhoea is 
lower with amoxycillin than with ampicillin and other penicillins. Diarrhoea is a result of 
depletion of sensitive bacteria from the bowel flora by unabsorbed antibiotic. The increasing 
resistance of Enterobacteriaceae to amoxycillin may eventually reduce the incidence of amoxycillin-
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associated diarrhoea [4,6]. Amoxycillin has been associated with a small number of cases of 
pseudomembranous colitis [4,6]. 
1.4.8 IDGH RISK GROUPS 
Because of its lack of teratogenicity and mutagenic potential, there appears to be no significant risk 
to the foetus from amoxycillin when administered during pregnancy, although there is the 
possibility of sensitising the foetus if used during the second and third trimesters. Amoxycillin can 
be given safely throughout pregnancy at the normal adult dose, if an antimicrobial agent has to be 
used for the treatment of asymptomatic bacteriurea or simple cystitis, bronchitis or the prophylaxis 
of endocarditis [4,6]. The small amount of amoxycillin secreted in maternal milk rarely causes 
problems in the infant. It can therefore be used safely during lactation [4]. 
1.5 PHARMACOKINETICS OF AMOXYCILLIN 
1.5.1 DOSAGE 
The usual adult oral dose of amoxycillin trihydrate is the equivalent of 250 mg to 500 mg 
amoxycillin three times daily. Amoxycillin is administered via the parenteral route as amoxycillin 
sodium and in moderate infections the equivalent of 500 mg amoxycillin may be given 
intramuscularly or intravenously every 8 hours. If pain is experienced with an intramuscular 
injection, this can be prepared using a 0.5% w/v solution of procaine hydrochloride or a 1 % w/v 
solution of lignocaine hydrochloride. In severe infections the equivalent qf 1 g amoxycillin may 
be given every 6 hours by slow intravenous injection over 3 to 4 minutes, or by infusion over 30 
to 60 minutes [6]. In renal failure, the usual adult dose can normally be used, although the dose 
of arr.oxycillin may have t8 be reduced owing to the prolonged plasma elimination half life [4]. 
Children up to 10 years of age may be given the equivalent of 125 mg to 250 mg or(!ll y, three 
times daily. Where indicated, a parenteral dose of 50-100 mg/kg body weight can be given daily 
in divided doses [4]. Doses of amoxycillin should be reduced to 20 to 50 mg/kg daily in divided 
doses for infants under 20 kg body weight [4,6]. 
Higher doses of amoxycillin, often in short courses have been investigated for numerous conditions 
[6]. Amoxycillin has been given as a single 3 g dose, often with probenicid (l g), in the treatment 
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of uncomplicated gonorrhoea, where gonococci have maintained sensitivity. This regimen, followed 
by a course of tetracycline has often been used for the treatment of pelvic inflammatory disease, 
or sexually transmitted diseases where the aetiolog.ic.al agent is unknown [6]. 
A single dose of 3 g may also be used for the treatment of uncomplicated urinary tract infections 
and for the prophylaxis of endocarditis in susceptible patients about 1 hour before procedures such 
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as dental extractions. A high dose of amoxycillin (3 g) twice daily may be used in patients with 
severe or recurrent respiratory tract infections [6]. 
1.5.2 ABSORPTION 
Amoxycillin is rapidly absorbed after oral administration [4,5]. The 90% bioavailability of 
amoxycillin following oral administration appears to be much higher than anticipated from its 
physicochemical properties and the pH partition theory [3-5]. 
It is more completely absorbed than ampicillin and is reported to produce peak: plasma 
concentrations (CmaJ that are 2 to 2.5 times higher than those observed after administration of 
equivalent doses of ampicillin [1,2,4,6]. Peak plasma concentrations of 4 to 6 {tg/mL have been 
observed 1 to 2 hours (1maJ after a dose of 250 mg with detectable amounts present for up to 8 
hours after administration, although there is considerable variation between individuals [4,5,6,20]. 
Following intramuscular injection of amoxycillin (500 mg), a Cmax of 14 {tg/mL has been observed 
at a tmax of 1 hour [4,6]. However, in general, similar concentrations are achieved with both 
parenteral and oral administration [6]. 
Oral studies in the rat showed that the plasma level curve is best tItted to a combined zero and first 
order kinetic functioQ.[21 ,22]. The same model also gives a good fit for human plasma level data. 
This appears to be consistent with a study of absorp'tion kinetics in humans which ,provided 
evidence for saturated carrier mediated absorption. Carrier mediated absorption may explain the 
unexpectedly high oral bioavailability of amoxycillin [3,21,22]. 
Amoxycillin is resistant to inactivation by acidic gastric secretions, therefore more of the total oral 
dose reaches the small intestine [4,6]. Neither the presence of food in the stomach, nor co-
administration with clavulanic acid appear to have a significant influence on the absorption of 
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amoxycillin [2,6,19]. 
1.5.3 DISTRIBUTION 
Amoxycillin is extensively distributed in body tissues and fluids, with levels adequate for 
antibacterial activity being achieved in most regions. Amoxycillin diffuses across the placenta, but 
r - ~ 
concentrations in umbilical cord blood have been found to be a fraction of those in maternal blood. 
Concentrations in amniotic fluid are variable, but are less than 50% of maternal blood levels. Only 
a small amount appears to be excreted in breast milk. It penetrates well into purulent and mucoid 
sputum and middle ear fluid, but only low concentrations have been found in ocular fluid. 
Amoxycillin is unlikely to pass into the central nervous system unless the meninges are inflamed. 
High concentrations have been reported in bile [3,4,6]. Amoxycillin concentrations in the 
inter~titial fluid peak around 1 hour after the serum peak, according to skin window tests [3,4,5,6]. 
The volume of distribution is approximately 0.31 Llkg body wej&-ht (range 0.2-0.4 Llkg) [4,5]. 
The use of ultrafiltration to determine the extent of binding of amoxycillin to serum proteins in 
",> 
humans revealed that the drug is 20% bound, leaving 80% of the penicillin as unbound active drug 
[2,6]. 
1.5.4 METABOLISM 
Presystemic metabolism is negligible due to the highly polar nature of the drug. Approximately 
10-20% of absorbed drug ismetabolizect via hydrolysis of the B-lactam ril!g to the corresponding 
penicilloic acid, which is excreted in the urine in a ratio of about 2 to 1 of the 5R to the 5S isomer 
[3,4,6,20]. Major metabolites are thus the respective penicilloic acids, generated by cleavage of 
the B-Iactam ring, and a-amino substituted derivatives of a-amino penicillins [20]. Interindividual 
variability in the aIllount of penicilloic acids excreted suggests their enzymatic, rather than 
spontaneous formation [20]. 
Enterohepatic circulation of the antibiotic is low, as hepatic metabolism is a relatively unimportant 
route of amoxycillin elimination. 
19 
1.5.5 ELIMINATION 
Plasma clearance ranges from 3 to 5 mUmin/kg f5}. About 60% of the oral amoxycillin dose is 
excreted unchanged in the urine in 6 hours by glomerular filtration and active tubular secretion. 
Urinary concentrations of 0.3 to 1.3 giL have been reported following a dose of 250 mg 
[4,5,6,20]. After parenteral administration, 75% is excreted via the kidneys .in tHe following 6 
hours [4,5]. 
The serum half life of amoxycillin in healthy volunteers ranges between 1 and 2 hours [4,5,6]. 
Subjects with a creatinine clearance less than 13 mUminute who are in renal failure have a serum 
half life of around 7 hours [4,6]. The need for penicillin plasma level monitoring has been 
emphasised in neonates and the elderly where the elimination half life may be longer because of 
incomplete renal function [3,4,6,20]. 
Amoxycillin displays the linear kinetics characteristic of penicilli~,that is increasing the dose oJ 
amoxycillin results in a corresponding increase in serum concentrations [2]. However, ,recent 
studies [21,22] using a rat model have investigated the non-linearity of disposition kinetics which 
are occasionally observed following intravenous administration. The intravenous study indicated 
that non-linearity arises from renal elimination mechanisms, possibly saturation of active tubular 
secretion or reabsorption at high doses. 
2.1 INTRODUCTION 
CHAPTER TWO 
RECTAL DOSAGE FORMS 
2.1.1 RECTAL DOSAGE FORMS 
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Suppositories are medicated solid dosage forms, which are inserted into body orifices other than 
the mouth, where they melt, soften or dissolve to exert a localized or systemic effect. The term 
suppository usually refers to the rectal dosage form. Suppositories vary in size and shape; those 
intended for adult use are generally about 2 g in size, and those for paediatric use about 1 g. They 
are conventionally bullet-shaped, torpedo-shaped or conical with a rounded apex. 
Suppositories have a wide range of applications and can be an effective alternative when oral 
therapy is not possible. The potential uses of suppositories as convenient delivery systems are 
expanding and now include anti-malarial drugs [23,24], controlled-release and sustain~-release 
suppositories [25], analgesic suppositories that allow patients a pain-free sleep [26], insulin 
suppositories for diabetics [27] and antimicrobial suppositories [28]. It is conceivable that any 
natural or synthetic drug can be formulated into a suppository by careful selection of the base, the 
right form of the drug itself and possible moditication of the formulation to include absorption 
promoting agents or adjuvants. 
Although the oral route is considered the most practical and acceptable, as well as the most 
economical means of administering a drug, a suppository could be an alternative treatment option 
if oral medication is contra-indicated" or it is not possible for a patient to take solids or even 
liquids by mouth. In addition the rectal route is convenient for administering drugs to patients who 
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are unwilling or unable to swallow medication, for· example unconscious patients, mentally 
disturbed patients, infants and children, patients who are vomiting, patients with pathological 
conditions of the alimentary tract and patients recovering from surgery who are unable to tolerate 
oral therapy [27]. Suppositories are used to exert a localized effect on the rectum as well as to 
avoid the disadvantages of oral medication. Drugs known to irritate the stomach, such as 
aminophylline [26] and non-steroidal anti-inflammatory drugs (NSAIDs), can be given in 
suppository form to minimize the effect of local gastric irritation, although the systemic effects of 
the NSAIDs will occur irrespective of the route of administration [27]. 
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The use of suppositories, rather than oral medicine does not only have patient-orientated 
advantages, but also has physiological and metabolic benefits. Drugs administered rectally are not 
inactivated by the enzymatic activity or acidic conditions in the stomach and upper intestine and 
the "first-pass" effect of the liver enzymes may be partially bypassed [27]. 
Suppositories may be used to exert a localized effect on the bowel or rectum,- f6r example the 
laxatives glycerol and bisacodyl exert their effect by irritating the mucosa of the rectum. Their 
formulation into suppositories enables this effect to be exerted locally without having to pass 
through the alimentary canal, causing undesirable gastric effects. 
Rectal suppositories are often used for their local effect to relieve the pain, itching, irritation and 
inflammation associated with haemorrhoids and other rectal conditions. They contain combinations 
of lacal anaesthetics, anti-inflammatory agents, astringents, analgesics, soothing emollients and 
protective agents. 
2.1.2 RECTAL ABSORPTION 
Absorption across the rectal mucosa occurs in much the same manner as in other parts of the 
gastrointestinal tract [26]. However the dose of a drug administered rectally may differ from the 
dose of the same drug given orally, because drug absorption from the rectum is sometimes slower 
and more variable than with other types of dosing, due to either physiological factors pr the 
physicochemical nature of the drug and suppository base. 
2.1.2.1 PHYSIOLOGICAL FACTORS 
The rectum is 15 to 20 cm long and has no villi, thus there is a relatively small surface area 
available for drug ai:fsorption [29]. As the rectum is ~~vered by only 1 to 3 mL of mucous and 
does not receive any liquid through the intestinal wall, dissolution of water-soluble drugs may be 
hindered [8,29]. Since the pH of the rectal t1uid is neutral and has little buffering capacity, the 
ionic form in which a drug is absorbed will generally not be changed [8,29]. The presence of 
faecal matter retards drug absorption and may lead to expulsion of the suppository [29]. Enzymatic 
processes in the lining of the rectum occur to a lesser extent than in the upper gastrointestinal tract, 
thereby minimising possible enzymatic degradation which occurs to some drugs prior to absorption 
[29]. 
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Although opinions differ, it is thought that suppositories generally remain in the lower to middle 
section of the rectum, and do not migrate higher into the region of the superior rectal vein [8,29]. 
The site of drug absorption in the rectum and subsequent transport into the inferior, middle or 
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superior rectal veins will determine whether a drug is transported directly to the general 
circulation, or via the liver [29]. The capillaries in the lower and middle sections of the rectum join 
to form the inferior and middle rectal veins which drain into the inferior vena cava, and from there 
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into the general circulation. Any drug absorbed in these regions will bypass the liver and it has 
been suggested that at least 50% of a rectal dose can be assumed to avoid the first-pass effect in 
this way [26,30]. Higher up in the rectum the superior rectal vein drains into the hepatic portal 
system. Drugs which are absorbed in this zone will pass through the liver and be metabolized by 
the liver enzymes. Avoidance of the hepatic portal system could be advantageous to patients with 
liver disease, as drug metabolism by the liver and possible subsequent damage to the liver by drugs 
is partially averted [26,27,31]. 
2.1.2.2 PHYSICOCHEMICAL FACTORS 
The relative solubility of the drug in lipid and water as well as the particle size of the }ini'g can 
affect absorption [8,29]. The smaller the particle size, the more readily the particle will dissolve 
and the greater the chance for rapid absorption. The partition coefficient of the drug and the 
lipophilic or hydrophilic nature of the suppository base will regulate the partitioning of the drug 
between the suppository and the rectal environment. The ability of the base to melt, soften or 
dissolve at or below body temperature and its ability to release the drug substance will also play 
a role in determining the release characteristics of the drug from a specific base and subsequent 
absorption [29]. Chemical interaction between the base and drug will inhibit release and drug 
absorption will be impaired [29]. 
2.1.3 SUPPOSITORY BASES 
Suppository bases playa critical role in the release of the drug and subsequent availability of the 
drug either for absorption to achieve systemic effects, or for localised effects. 
Suppository bases have been classified according to their physical characteristics as either 
(a) water-soluble or water-miscible bases that dissolve or disperse in rectal secretions and 
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include glycerol-gelatine bases and macrogols such as polyethylene glycol (PEG), or 
(b) fatty or oleaginous bases which melt at body temperature and include theobroma oil 
(cocoa butter) and semi-synthetic mixtutes of mono-, di- and triglycerides, such as 
Witepso! and Suppocire, or 
(c) miscellaneous bases, generally combinations of lipophilic and hydrophilic bases [29]. 
The ideal suppository base should remain solid at room temperature, but soften, melt or dissolve 
at or slightly below body temperature so that the drug it contains may be readily available soon 
after insertion to exert its effect [29]. The base should be innocuous, non-sensitizing, 
physiologically inactive, not cause local irritation, nor itself be absorbed through the intestinal 
wall. It should be neutral and chemically inert and should not form complexes with the active 
ingredients. The base should be compatible with a wide range of drugs and should be readily 
moulded into stable, rigid shapes that retain uniform drug release characteristics on storage. The 
interval between melting and solidification temperatures of the final composition should be 
adequate; if it is too short there is difficulty in pouring into moulds-,if it is too long there may be 
sedimentation of suspended sol id material. Most fats have a broad melting range, but those se,!ected 
for suppository bases usually melt within 3°C. Ideally the base should also contract on cOoling to 
allow easy withdrawal of the suppositories from the mould during extemporaneous manufacture 
[8]. The final product should be odourless, opaque and have a smooth uniform surface and it 
should retain its hardness and melting point over the range of temperatures at which it is likely to 
be stored [32]. 
2.1.3.1 WATER SOLUBLE AND WATER MISCIBLE BASES 
2.1.3.1.1 GLYCEROL-GELATIN 
Glycerol-gelatin bases are most frequently used for the preparation of vaginal suppositories or 
pessaries. The water soluble base dissolves slowly in the mucous secretions of the rectum {)r vagina 
[8,29]. The solution time depends on the quality and content ofthe gelatin and the age of the base, 
the relative properties of the constituents and reaction with the active drug [8,26]. 
Glycerol-gelatin suppositories have several disadvantages, which cause them to be used less 
frequently than other types of suppository bases. They are difficult to prepare and handle and 
lubrication of the mould with a mineral or vegetable oil is necessary to prevent adhesion to the 
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mould [26]. They must be protected from heat and are hygroscopic, therefore they must be 
protected from atmospheric moisture in order for them to maintain their shape and consistency 
[26,29]. The suppositories support microbial gro<wth so the inclusion of preservatives such as 
methyl and propyl hydroxybenzoates may be necessary [8]. Glycerol-gelatin suppositories are also 
less frequently used than fatty base suppositories because they have a laxative action which has 
been attributed to the hygroscopic nature of the base causing dehydration with coosequent irritation 
of the rectal tissue [29]. 
2.1.3.1.2 MACROGOLS 
The macrogols or polyethylene glycols (PEG) are polymers of ethylene oxide and water, prepared 
to various chain lengths, molecular weights and physical states. Various admixtures of high and 
low "molecular weight polymers may be combined to prepare suppository bases of desired 
consistency, melting point ranges, physical characteristics and dissolution rates [8,29]. 
PEG with molecular weights of 200 to 600 are clear colourless liquids and molecular weights of 
greater than 1000 occur as wax -like solids. Hardness increases with increasing molecular' weight. 
High molecular weight polymers form hard bases that disintegrate and release their drug slowly. 
Softer, less brittle preparations that disperse and liberate the drug quickly are obtained by mixing 
the high with medium, or medium and low molecular weight polymers, or by addition of 
plasticisers such as hexane-l,2,6-triol [26]. 
PEG suppositories generally have a melting point above 42°C. The macrogols thus present fewer 
storage problems than bases that melt at lower temperatures and they are therefore satisfactory in 
hot climates, and administration is easy because they are not slippery to handle [26,29]. 
The macrogols hav!! the advantages of inertness, sta?ility, high water absorbing capacity and 
freedom from rancidity. They are therefore useful vehicles for drugs such as chloral hydrate and 
ichthammol which tend to lower the melting point of other bases [8]. The macrogols do not melt 
at body temperature, but rather gradually dissolve and disperse in the body fluids resulting in a 
slow release of medication from the base and a more prolonged action than is found with fatty 
bases [26]. However their good solvent properties can result in retention of the drug in the liquified 
base, resulting in reduction in therapeutic activity [26]. Substances that are incompatible with 
macrogols include penicillin, bacitracin, benzocaine, phenols, quinine salts, salicylic acid, sorbitol 
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and sulphonamides [8]. Suspended solid materials may display crystal growth in macrogol bases; 
such crystals may show delayed dissolution and cause irritation of the rectum, as well as making 
the product brittle [26]. 
Unlike glycerol-gelatin, macrogols do not stick to the mould, since they contract on cooling, thus 
no lubrication is required. However macrogol suppositories may be brittle unle..ss the molten base 
is poured into the mould at as low a temperature as possible. Brittleness can be reduced by the 
addition of surfactants or plasticisers such as castor oil or propylene glycol [26]. 
Because of their high molecular weights, macrogols form solutions of high viscosity when they 
disperse in the body, and leakage from body cavities is minimised [8,26]. PEG suppositories are 
hygroscopic and irritating to the rectal mucosa due to dehydration. Discomfort can be reduced by 
advis.ing a patient to dip the suppository in water before use or incorporating about 20% of water 
in the mass [26,29]. However products that contain water sometimes fracture on storage. The 
dehydrating effect may also be reduced by application of coatin~~ of cetyl or stearyl alcohol, 
although these may retard dissolution as a result of their lipophilic nature [8]. 
2.1.3.2 FATTY BASES 
2.1.3.2.1 THEOBROMA OIL 
Theobroma oil or cocoa butter is considered an ideal suppository base, melting just below body 
temperature, between 30 to 36°C, yet maintaining its solidity at normal rQom temperature [26]. 
Theobroma oil shows ready liquification on warming and rapid setting on cooling. It is miscible 
with many excipients and is bland, a valuable feature when a suppository is intended to soothe 
irritation [26]. 
However, because of its triglyceride content, theobroma oil exhibits marked polymorphism 
[8,26,29]. When melted and cooled it solidifies in different crystalline forms depending on the 
temperature of melting, rate of cooling and size of the mass, so great care must be taken to avoid 
overheating the base. 
Theobroma oil has the disadvantage that it shrinks only slightly on soliditication necessitating a 
mould lubricant such as alcoholic solutions of soft soap and glycerol, silicones or sodium lauryl 
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sulphate in aqueous solution or in propylene glycol. A further undesirable property is that 
sometimes base escapes from the rectum or vagina due to its low viscosity when melted [26]. 
The melting point of theobroma is reduced by the addition of drugs such as volatile oils or chloral 
hydrate. If the melting point is lowered to such an extent by an excipient that the suppositories are 
too soft for use, solidifying agents such as cetyl ester wax (about 20% w/w) 9r_ b~eswax (3 % to 
5% w/w) may be added [8,26,29]. If the softening point of theobroma suppositories is too low for 
hot climates, white beeswax may be added to the suppositories to raise the softening point [26,29]. 
Theobroma has a poor water absorbing capacity that can be enhanced by addition of emulsifying 
agents or surfactants such as cholesterol (2 % w/w), emulsifying wax (up to 10% w/w), 
polysorbates (5% to 10% w/w) or wool fat (5% to 10% w/w) [8,26]. However, addition of 
surfactants may lead to drug-base interactions, affect the release of drug from the suppository, or 
influence absorption. 
2.1.3.2.2 SYNTHETIC FATS 
To produce an alternative base free from the disadvantages of theobroma, it has been necessary 
to use semisynthetic methods, because theobroma is the only natural fat with suitable properties 
for a suppository [26]. More modern bases, the hard fats, were developed in Germany in the 
1940's and have slowly displaced theobroma oil by virtue of their superior properties and relative 
ease of high speed manufacture [26]. 
The hard fats are mixtures of triglyceride esters of saturated ClO-C 18 fatty acids with varying 
proportions of mono- and diglycerides. They are virtually ubiquitous nowadays because of their 
chemical and physical stability, broad compatibility with nearly all active compounds, neutrality 
towards mucous memrranes and their favourable processing properties even in high performance 
machines. 
The semisynthetic fats are hard, brittle and unctuous to touch, and melt to a colourless or slightly 
yellow liquid when warmed [33]. They produce suppositories that are white and almost odourless 
and have a very attractive, clean and polished appearance [26]. They are available in various 
grades with different melting ranges, hydroxyl values and other physicochemical characteristics. 
Examples include the fractionated palm kernel oils Extracoa and Supercoa and the hard fats Massa 
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Estarinum, Massuppol, Suppocire and Witepso[ [26]. Synonyms include adeps solidus, semi-
synthetic glycerides, massa esterinica, adeps neutralis, synthetic fats, and hydrogenated vegetable 
oils. Special grades, identified by the manufacturets by means of suitable letters or numbers, may 
contain additives such as beeswax, lecithin, polysorbates, ethoxylated fatty alcohols and ethoxylated 
partial fatty glycerides [8,32,33]. 
Additives may also be incorporated during formulation if required. Water is undesirable as an 
additive because it enhances oxidation, crystallisation and the potential for chemical reaction 
between suppository constituents. In low concentration it plays little part in drug release and it can 
serve as a medium for microbial growth [8,33]. 
The most common method of manufacture involves hydrolysis of natural vegetable oils such as 
cocoJ?ut or palm kernel oil, and then isolation of the free saturated acids by fractional distillation. 
Various fractions of the C l2 to Cl8 series are re-esterified under controlled conditions with glycerol 
to yield a mixture of tri-, di- and monoglycerides, thus providingft~series of bases with a range 
of physical characteristics appropriate for differing requirements [26,33]. Further diversification 
is gained by the inclusion of adjuvants as well as by blending available grades [32]. Suppository 
Base IV Novata and Witepso! are manufactured by this method. 
An alternative procedure involves the direct hydrogenation of vegetable oils, followed by vacuum 
dehydration, analytical verification, grading, and finally heat treatment. Thus part o! _ the 
triglyceride esters are split onto mono- and diglycerides (partial esters) and fatty acids are released. 
The liberated free fatty acids participate in trans-esterification reactions w.ith available hydroxyl 
groups, resulting in mixed ester formation [32,33]. Controlled moditication of this process yields 
a wide range of materials and subsequent blending of selected fractions, or the incorporation of 
adjuvants gives the desired grades [26]. Suppocire is an example of a base manufactured using this 
method. 
The pharmacopoeial specifications for semisynthtic bases are listed in Table 2.1 [7,33]. 
28 
Table 2.1 Pharmacopoeial specifications for semisynthetic fats 
Test < Value 
Melting point* 33-36°C 
Acid value ::;0.5 
Hydroxyl value ::;50 
Iodine value ::;3 
Peroxide value ::;6 
Saponification value 225-245 
Unsaponifiable matter ::;0.5 % 
Alkaline impurities + 
Decomposition products + 
Ash ::;0.05% 
*Melting point ranges are defined by several pharmacopoeias as rangingpetween 33°C and 36°C, though 
proprietary grades may melt outside this range [32]. 
The iodine value is an inverse measure of the extent of hydrogenation and partial ester content is 
determined by the hydroxyl value [32]. The hydroxyl value of a base is determined by the 
proportions of mono- and di-glycerides it contains and is an indication of its potential reactivity. 
High hydroxyl values indicate that the base can adsorb water more readily and is therefore less 
suitable for formulations containing drugs that are easily hydrolysed [33]. Hydroxyl values are 
related to hydrophilic properties which in turn can modify both release and absorption rates of 
drugs from bases. Bases with high hydroxyl values produce irritancy and have longer solidification 
times, but give products with better rele.ase from moulds and improved elasticity to counteract the 
risk of brittleness incurred with a rapid cooling rate [8,33]. 
~ 
The large range of suppository bases available has reduced the incidence of chemical reaction 
between the hard fats and drugs. For example, the risk of hydrolysis of aspirin may be reduced 
by the use of a base with a low hydroxyl value and additionally by minimization of the water 
content of both base and aspirin [33]. 
The semi-synthetic suppository bases display varying degrees of solubility in certain solvents. They 
are practically insoluble in water and ethanol (90%), but are freely soluble in carbon tetrachloride, 
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chloroform, toluene and xylene. Solubility in ether and petroleum spirit varies between grades from 
slightly soluble to very soluble [33]. 
Hard fat bases are superior to theobroma oil in that they do not exhibit polymorphism and their 
solidification is not affected by overheating [8,26,32]. Hard fat bases are resistant to oxidation and 
hydrolysis. Peroxide values are a measure of the resistance of the base to o~idaHon, and are a 
guide to the onset of rancidity [33]. Water content is usually low and deterioration due to the 
absorption of water is infrequent [26,33]. Because they usually contain a portion of partial 
glycerides some of which, for example glyceryl monostearate, are water/oil emulsifying agents, 
their emulsifying and water absorbing capacities are good [8,26]. 
Mould lubrication is unnecessary since these bases show marked contraction on cooling [8,26]. A 
tendency to fracture due to brittleness on cooling when poured into chilled moulds can be 
overcome by including 0.05% of the surfactant polysorbate 80 [8,26]. 
On prolonged storage, semi-synthetic suppository bases have been shown to be subject to hardening 
and lengthening of the melting time [8]. The degree of hardening may be controlled by storage in 
a cold place, but melting characteristics, hardness and drug release profiles alter with time, and 
the melting point may rise by 0.5°C after storage for several months [33]. Due to the complexity 
of bases it is difficult to elucidate the mechanisms which induce these changes on ageing. 
2.1.3.3 MISCELLANEOUS BASES 
These include chemical or physical mixtures of the water-soluble or water-miscible materials and 
contain mainly non-ionic surfactants, either alone or mixed with vegetable oils or waxy solids. 
Some are preformed emulsions, generally of the water in oil (w/o) type or they may be capable 
of dispersing in aqueous tluids. The most frequently us~ surfactants are the polysorbates, polyoxyl 
stearates and sorbitan fatty acid esters. These bases can be handled at high temperatures; are non-
toxic and do not support microbial growth. Hydrophilic bases are compatible with a wide range 
of drugs, but have a potential for interaction because of their surfactant content. Such interactions 
may increase or decrease the rate or extent of drug absorption [8]. 
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2.1.4 SELECTION OF A SUPPOSITORY BASE 
The release and absorption rates of drugs from dijf~rent bases is dependent on the nature of the 
base. Theobroma oil melts quickly at body temperature, but since the resulting oil is insoluble with 
the body fluids, fat-soluble drugs will remain in the oil and have little tendency to partition into 
the aqueous physiological fluids. In the case of water-soluble drugs incorporated into theobroma 
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oil or semisynthetic fats, the reverse is generally true, and the drugs will partition into the aqueous 
rectal fluid more readily. Fat-soluble drugs seem to be better released from bases of glycerol-
gelatin or macrogols, both of which dissolve slowly in body fluids. When irritation or 
inflammation is to be relieved, theobroma oil appears to be the superior base because of its 
inherent emollient or soothing, spreading action [29]. 
Selection of a suitable base cannot be made in the absence of knowledge of the physicochemical 
properties and intrinsic thermodynamic activity of the drug substance which is to be incorporated 
into the suppository. Other drug-related factors that can affect _rele~e and subsequent absorption 
which must be considered include the particle size distribution of insoluble solids, the oil-water 
partition coefficient and the dissociation constant. The displacement value should also be known, 
as well as the ratio of drug to base. 
Properties of the suppository base which mayor may not be modified by the drug, or which may 
influence drug release are the melting characteristics, chemical reactivity and rheology [33]. Most 
manufacturers market a series of grades with slightly different melting point ranges and degrees 
of hardness. Fatty suppository bases intended for systemic use should Iiqu~fyat just below body 
temperature whereas softening or dispersion may be adequate for suppositories intended for local 
action or modified release. High melting point bases may be indicated for fat soluble drugs that 
tend to depress the melting point, and .for suppositories used in warm climates [26,33]. Drugs 
which dissolve in the base when hot may create problems if they deposit as crystals of different 
~ 
form or increased size on cooling or storage [33]. Low melting point bases, particula~Iy those 
which melt to liquids of low viscosity, can be of value when large volumes of insoluble solids are 
to be incorporated [26,33], although there is a risk of sedimentation in such instances. 
An important factor during processing is the time required for setting. This is affected by the 
temperature difference between melting and solidification points [33]. Semi-synthetic bases are 
more fluid than theobroma when melted so thickeners such as magnesium stearate or bentonite may 
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be added to reduce sedimentation [8,26]. However this is seldom a problem since the difference 
between melting and setting points is smail, seldom over 3°C, a prime requirement for the efficient 
manufacture of suppositories. Hence they set rela.tiyely quickly, the risk of sedimentation is low 
and they are easier to administer [8,26,32]. When the setting point of a base is below the melting 
point, the suppositories soften quickly when handled and become too slippery to administer [26]. 
The rheology of a suppository base may influence drug release, and may itself be influenced by 
the addition of active ingredients. The viscosity of molten base can affect the uniform distribution 
of suspended solids during manufacture and it may also influence the release and absorption of the 
drug in the rectum [33]. Reduction in particle size of insoluble solids is the method used to 
minimize sedimentation of drug during manufacture. 
Additives are sometimes included to modify rheological properties and to maintain homogeneity, 
but their effect on drug release should first be assessed. Release from a base in which the viscosity 
has been enhanced by an added thickening agent may be valiab!e and related to the aqueous 
solubility of the drug itself [33]. 
2.2 FORMULATION OF AMOXYCILLIN SUPPOSITORIES 
2.2.1 DESCRIPTION OF SUPPOSITORY BASES USED 
The bases used in this study were Novata BD (Henkel, RSA), Novata 299 (Henkel, RSA), Witepsol 
W35 (Hiils, RSA) and Suppocire A32 (Hiils, RSA). Theobroma oil (Elabtech, RSA) was used as 
a well known base for comparative purposes. Products were used as received from the 
manufacturer or distributor with no further puritication or adjunct addition. The characteristics of 
these bases are listed in Table 2.2 [33].' 
The bases each differed slightly in terms of physicochemical properties, widening the scope of 
options for a base suitable for formulation with amoxycillin trihydrate in a paediatric suppository. 
Amoxycillin trihydrate, compacted (Clinimed, East London, RSA), the commonly used oral form 
of the drug, was used in the formulation of the amoxyciilin suppositories. 
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Table 2.2 Characteristics of suppository bases used in investigations 
Parameter THEOBROMA Novata BD Novata 299 Suppocire Witepso[ 
A32 W35 
ACID VALUE <4 =:;;0.3 =:;;0.3 =:;; 0.5 =:;;0.3 
HYDROXYL - =:;; 15 =:;;5 32 (20-30) 40-50 
VALUE ~ -
IODINE VALUE 35-40 =:;;3 =:;;3 =:;;2 =:;;3 
MELTING POINT 30-36 33.5-35.5 33.5-35.5 35-36.5 33.3-35.5 
SAPONIFICATION 188-196 230-245 253-250 225-245 225-235 
POINT 
SOLIDIFICATION - 30-32 31.5-33.5 - 27-32 
POINT 
2.2.2 MANUFACTURE OF SUPPOSITORIES 
The volume of a suppository from a particular mould is uniform but its weight will vary bepuse 
the densities of medicaments usually differ from the density of the base with which-the m'ould was 
calibrated [26]. To prepare suppositories accuratel y, allowance must be made for the change in the 
density of the mass due to added medicaments. The most convenient way of making this allowance 
is to use the displacement value, defined as the number of parts by weight of the medicament that 
displaces one part by weight of the base. 
Displacement values of amoxycillin for the various suppository bases were determined [26]. Six 
suppositories of base only were prepared and weighed (a mg) and six suppositories containing x% 
of medicament were prepared and weighed (b mg). The amount of base (c mg) and medicament 
(d lllg) in the 6 supposituries was calcul"ated. 
c = (1()()-x)11fXJ.b 
d = xI1()().b 
The weight of base displaced by d mg of medicament was equal to (a-c) mg. 
The amoxycillin trihydrate powder was size reduced. The mass of base required was calculated 
using the displacement values and the suppository base was heated to 60°C to melt. The 
suppositories were produced manually on a small scale by homogenising 250 mg amoxycillin base 
(290 mg of the trihydrate) per suppository into the melted suppository base. The melt was poured 
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into 1 g stainless steel moulds, and the suppositories were left to set at room temperature. 
The suppositories were stored in a dark cupboard at rpom temperature (21°C) until required. Fresh 
suppositories were manufactured prior to the in vitro dissolution release experiments and for the 
purposes of the in vivo pilot study. 
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CHAPTER THREE 
THE IN VITRO ANALYSIS OF AMOXYCILLIN 
.~ . 
3.1 INTRODUCTION 
The quantitative analysis of amoxycillin and other 13-lactam antibiotics has been accomplished using 
a variety of techniques including microbiological assays [1,2,18], immunoassays [7,34], chemical 
assays such as the iodometric assay [35] or the hydroxylamine assay [35], spectrophotometry 
[7,36,37] and high performance liquid chromatography (HPLC) [16,17,34-36,38-41]. HPLC is 
superior with respect to specificity, rapidity of analysis, precision and simultaneous analysis of 
compounds. 
HPLC has been used for the detection of amoxycillin in biological samples [42,43] and the 
separation of amoxycillin from other drugs [38,44]. A number of reports in the literature refer to 
its use in the determination of amoxycillin in pharmaceutical dosage forms [17,36] and it has been 
widely used by manufacturers for the assay of amoxycillin in bulk raw material. 
A summary of techniques used for the analysis of amoxycillin in pharmaceutical dosage forms and 
raw materials follows. 
3.1.1 THE ANALYSIS OF AMOXYCILLIN IN PHARMACEUTICAL DOSAGE FORMS 
AND RAW MATERIAL 
3.1.1.1 REQUIREMENTS OF A SUITABLE METHOD 
A suitable analytical technique for amoxycillin should be able to quantify the drug and indicate 
stability of the compotmd as a raw material and in the _dosage form. The ideal assay should be 
precise, accurate, sensitive, rapid and specific with regard to metabolites and co administered drugs. 
It should also be capable of processing small sample volumes, be inexpensive and simple to 
perform. 
3.1.1.2 MICROBIOLOGICAL ANALYSIS 
The agar diffusion plate and turbidometric assay have traditionally been used for routine 
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monitoring of amoxycillin and other antibiotics [1,2,7,18,34,35]. These microbiological assays are 
versatile, simple, inexpensive and provide high capacity throughput. 
The potency of a sample of an antibiotic is determined by comparing the dose that inhibits the 
growth of a suitable susceptible micro-organism with the dose of a standard preparation of that 
antibiotic that produces the same degree of inhibition [7]. However the lowest detectable 
~ - -
concentration is only 0.1 to 1 J-Lg/mL in most microbiological assays and this sensitivity is 
inadequate for pharmacokinetic investigations [24]. Furthermore microbiological assay is relative 
rather than absolute, lacks accuracy and is not as reproducible as HPLC, immunoassays or other 
chemical methods. Microbiological assay has a long turn-around time of 4 to 8 hours before the 
desired information can be obtained. These assays lack specificity as the presence of other 
antimicrobial agents interferes with the results of the test. This technique cannot differentiate 
between microbiologically active metabolites and drug. 
Microbiological assays are thus generally reserved for measuripg_ T-~ potency of those antibiotics 
which, because of their complex composition, cannot be measured adequately by chemical or 
physical means [35]. HPLC has virtually replaced all microbiological techniques, but these methods 
are still of value if the structure of an antibiotic is not fully known and no realistic choice of a 
chemico-physical method can be made [35]. Antibiotics assayed by biological techniques include 
tetracyclines, aminoglycosides and macrolides [7,35]. 
3.1.1.3 IMMUNOASSAY 
The immunoassay technique is less frequently employed to measure antibiotic levels. 
Immunochemical methods are based on the selective, reversible and non-covalent binding of 
antigens by antibodies and are used to detect or quantify either the antigens or antibodies in these 
complexes [35]. 
The amount of complex formed is measured by a variety of techniques which include the use of 
a labelled or an unlabelled antigen or antibody. Because antigen-antibody reactions are 
stoichiometric, the determination of either free or bound labelled antigen results in a direct 
calculation of the antibiotic level [34]. Labelling immunoassay techniques may use either a specific 
radioactive isotope, or a non-isotopic molecule as the label. Radioimmune assays are sensitive, 
specific, accurate and require only a small volume of sample but require the use of radioactive 
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isotopes which in turn need special precautions. Non-isotopic immune assays such as enzyme 
immunoassays (eg ELISA) or immunoelectrophoretic methods have the same advantages as isotopic 
immune assays, are more rapid and do not use raqiC?active materials. The use of immunoassay is 
however limited, as commercial tests are only available for a few antibiotics and few laboratories 
have the necessary expertise to raise their own antisera or prepare labelled antibiotics. 
Immunoassays are essentially applied to the quantitation of aminoglycosides and vancomycin [34]. 
3.1.1.4 CHEMICAL ASSAY 
The official compendia specify methods for the analysis of amoxycillin in pharmaceutical 
preparations which include chemical, spectrophotometric and HPLC techniques. The iodometric 
assay is provided by the United States Pharmacopoeia (USP) [35] for the assay of most 
pharmacopoeial penicillin antibiotics, including amoxycillin. The British Pharmacopoeia (BP) [7] 
assay of amoxycillin sodium and amoxycillin trihydrate in bulk is based on a potentiometric 
titration following reaction with mercury nitrate. 
3.1.1.5 ULTRAVIOLET SPECTROPHOTOMETRIC ANALYSIS 
The BP [7] adopts a spectrophotometric method of assay for amoxycillin in pharmaceutical dosage 
forms that involves complexation of the drug with an imidazole-mercury reagent and measurement 
of absorbance of the complex at 325 nm [7]. This colorimetric method described by the BP was 
adopted from the procedure developed by Bundgaard and lIver [37]. It measures penicillenic acid 
mercuric mercaptides of the penicillins formed in quantitative yield in an imidazole and mercuric 
chloride solution. This method permits detection of penicillins at a 0.5 j-tg/mL level, is specific and 
can be used to assess stability since the intact penicillin is required for penicillenic acid formation. 
The hydroxylamine assay with spectrophotometric detection at 480 nm [35] may be used as a 
~ 
method of analysis of antibiotics such as cephalosporiils and penicillins that possess a B-Iactam 
structure. 
An alternative spectrophotometric method has been proposed by Buurs and Bundgaard [45], for 
the quantitative determination of ampicillin, amoxycillin and cyclacillin. The method involves the 
conversion of the aminopenicillins to the corresponding piperazine-2,5-dione derivatives by 
treatment with a diethanolamine-zinc ion solution, and subsequent treatment of these derivatives 
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with sodium hydroxide to give a highly absorbing compound with ~x at 322 nm. This method 
is free of interference from degradation products, and was used to assess the stability of 
aminopenicillins. 
3.1.1.6 HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY 
High-performance liquid chromatography (HPLC) which was developed in the 1960's has made 
an important contribution to the analysis of antibiotics and is the chromatographic procedure 
primarily used for the quantitation of antibiotics as it is sensitive, selective, accurate and rapid. The 
versatility of HPLC and its application to an enormous variety of compounds have allowed its use 
in clinical laboratories for the monitoring of a number of therapeutic agents. HPLC is also 
extensively used to quantify drugs in pharmaceutical formulations and is a powerful tool used in 
the development of new drugs, particularly for pharmacokinetic investigations and metabolism 
studies as its selectivity permits separation of drug, prodrug, metabolites and closely related 
compounds [34,36,38]. Unlike the responses in microbiological assays, those in a validated HPLC 
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assay are not subject to random error, thus confirmation of the validity of each estimate is thought 
to be unnecessary [46]. A reversed phase HPLC method with UV detection at 230_nm is, specified 
by the USP for determination of amoxycillin in bulk raw material and in pharmaceutical 
preparations [35]. 
To confirm the supremacy of HPLC as an analytical technique for penicillin antibiotics, several 
pharmacopoeial methods and reversed phase HPLC were compared for three penicillins; 
phenox ymethyl penicillin potassium, benzylpenicillin sodium and ampicill in trihydrate [47]. Of the 
six methods investigated, which included a microbiological test, an iodometric test, two 
spectrophotometric tests, mercury titration and HPLC, the HPLC assay was superior in terms of 
selectivity, reproducibility and analytical time requirement [47]. 
The quantitative determination of penicillins, their degradation products and impurities is one of 
the more difficult problems in pharmaceutical analysis, because of the need to separate the parent 
compounds from precursors, impurities and various degradation products and the fact that they are 
relatively unstable in aqueous solutions. Fong et at [38] developed an HPLC method for the 
determination of amoxycillin as well as degradation products such as the penicilloic acid, p-
hydroxyphenylglycine, 6-aminopenicillanic acid and several unidentified materials present in an 
amoxycillin capsule. 
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Amoxycillin and its decomposition products, amoxylloates, amoxycillin oligomers and amoxycillin 
piperazine-2,5-dione, have been separated by reversed phase HPLC with gradient elution [16,17]. 
The results of a comparison of HPLC with mercurimetric titration corresponded well for 
amoxycillin trihydrate, which has the penicilloate as the main impurity [17]. 
Five isocratic HPLC methods were examined by Zhu et al [48] for the separatiQn _of amoxycillin 
and its related substances on C18 and C8 columns. These methods included two applications 
reported in the literature [36], a method from the USP [35] and two methods developed by 
manufacturers of amoxycillin. Of these methods, the USP method was the most selective, and 
based on the USP method a gradient method was developed for the analysis of amoxycillin and 
related substances. 
As tJ:te choice of suitable conditions for an HPLC procedure is governed by the polarity and 
ionizable groups of the drug molecule, Huang et al [44] studied the separation of amoxycillin and 
four other 6-lactam antibiotics to investigate their retention behilvioj1! on C18 and phenyl columns. 
In the absence of ion-pairing agents the retention times were shortest between pH 4 and 6. The 
addition of tetraethylammonium acetate (TEA), an ion pairing agent, to the mobile phase did not 
result in significant ion pair formation, except at pH values higher than 5.5. A strong ion-pairing 
effect was noted at pH values higher than 6 when tetrabutylammonium phosphate (TBA) was added 
to the mobile phase, and the retention was decreased at pH values lower than 4. In contrast, 
heptane sui phonic acid (HSA) showed an ion-pair retention effect at pH values lower than 5. 
The molecular structures ana pKa· values were used to account for the retention behaviour of 
amoxycillin and the other IHactam antibiotics in various mobile phases [44]. Amoxycillin has a 
carboxylic acid group on the 6-lactam ring with a pKa value of 2.4 and an amino function with pKa 
of 7.4 [4]. In addition amoxycillin has a phenolic substitution with a pKa of 9.6, as well as higher 
polarity than other syuilar 6-lactam antibiotics. Amoxycillin shows a V -shaped plot of capacity 
factor versus pH on a C18 column [44]. Amoxycillin is totally ionized between pH 4 and 6 and 
shows its shortest retention times in this range [43]. With a pH approaching 2.4 the carboxylic acid 
is only half ionized, so the retention time increases significantly at pH values below this. Similarly 
as the pH approaches 7.4 the amino group is only half ionized leading to increased retention times 
[44]. 
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3.2 METHOD DEVELOPMENT 
Previously published methods, listed in Table 3.1,< were referred to for development of a suitable 
HPLC method. However several problems were encountered when attempting to duplicate methods 
reported in the literature. It was often difficult to reproduce results due to instrumental variation 
or the unavailability of specific reagents or analytical columns. A further prQblejll encountered 
which made it difficult to duplicate methods, was incomplete reporting of the experimental 
conditions, column temperature, the way in which the mobile phase was prepared and type and 
concentration of buffer used. Method validation procedures were occasionally not performed or 
were inadequately dealt with. 
Table 3.1 HPLC methods used for in vitro analysis of amoxycillin 
Ref Stationary Phase Mobile Phase A Internal Standard 
16,17 Cg Gradient elution, methanol, 0.2 M - c ~ 274 sulphadimidine 
potassium phosphate buffer pH 7, 
water ,> 
,-
35 CIS Acetonitrile: potassium phosphate 230 -
buffer pH 5,4:96 
36 Cs Methanol:phosphate buffer pH 5, 254 phenoxyacetic acid 
6:94 
38 CIS Gradient elution, phosphate buffer pH 220 -
5.9, methanol, acetonitrile 
- -
39 Cs Methanol:S6rensen buffer pH 7, 240 phenoxymethyl 
38:62 penicillin potassium 
40 CIS Methanol:phosphate buffer:water, 235 -
15: 1:84 
41 CIS 0.05 M potassium phosphate buffer 228 -
pH 5.9 
48 CIS ~ 0.02 M phosphate buffer pH 230 -
5:methanol, 93:7 or 0.1 M~phosphate 
buffer pH 4.5:methanol, 95:5 
Using the details listed in Table 3.1 as guidelines, as well as the knowledge of the physicochemical 
properties of amoxycillin trihydrate and the variables of an HPLC system which can be modified, 
various columns and mobile phases were investigated in order to optimize the analysis of 
amoxycillin trihydrate using the HPLC system. 
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3.2.1 EXPERIMENTAL 
3.2.1.1 REAGENTS 
All the chemicals used were at least of analytical reagent quality. Methanol (MeOH) was distilled-
in-glass UV grade (Burdick and Jackson Laboratories, Muskegon, Michegan, USA) and 
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HiPerSolv~ acetonitrile (AcN) (BDH Laboratory Supplies, Poole, England) was of HPLC grade. 
Amoxycillin trihydrate, compacted (batch 94154303) was donated by Clinimed (East London, 
RSA). Salicylic acid, crystalline chloramphenicol and crystalline furosemide were obtained from 
Sigma Chemical Company (Midrand, RSA). Benzoic acid was obtained from E Merck 
(Johannesburg, RSA) and sulphadimidine from Maybaker (Port Elizabeth, RSA). Sodium 
hydroxide pellets and phosphoric acid (85%) were from Holpro Analytics (Pty) Ltd (Johannesburg, 
RSA). 
Water used for buffer preparation, extraction and chromatogral2hY£I-IPLC grade) was purified by 
a reverse osmosis Milli-RO 15 Water Purification System (Millipore, Bedford, MA, USA) that 
consisted of a Super-ClIl carbon cartridge, two lon-X~ ion exchange cartridges and-an Oganex-Q~ 
cartridge. The water was filtered through a 0.22 }Lm Millipa~ stack filter prior to use. 
3.2.1.2 IDGH PERFORMANCE LIQUID CHROMATOGRAPIDC SYSTEM 
Two modular HPLC systems, System A and System B, were used for the in vitro analysis of 
amoxycillin. 
SYSTEM A 
A model M 6000A Solvent Delivery System (Waters Associates, Milford, MA, USA), a Rheodyne 
~ 
injector, Model 7125 (Rheodyne, California, USA), with a Pressure Lok~ l00}Ll Syringe, Model 
160225RN (Dynatech Precision Sampling Corporation, Louisiana, USA) and a Hewlett Packard 
1040A Diode-Array HPLC-Detection System (Hewlett Packard Company, CA, USA) were initially 
used to develop an analytical method. Various reversed phase columns, discussed in Section 
3.3.3.4 were used in this system at ambient temperature. 
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SYSTEM B 
A model M 6000A Solvent Delivery System (W"at,ers Associates, Milford, MA, USA) with a 
Waters Intelligent Sample Processor (WISP) Model 710B Automated Sample Injection System 
(Milford, MA, USA), a Waters M 490 Programmable Multiwavelength Detector (Waters 
Associates, MA, USA) and model 561-3002 strip-chart recorder (Perkin-Elmer Corp, Norwalk, 
.-- - " .. 
Conn, USA) were used for the in vitro analysis of amoxycillin. Separation was achieved on a 
Nova-P~ C1S 60 A 4 JLm 3.9x150 mm HPLC cartridge column (Waters Associates, Milford, 
MA, USA). An Upchurch guard column kit, part no 1603, with Perisorb RP-18 pellicular packing 
material (C603) (Upchurch Scientific, WA, USA) was used. An in-line mobile phase filter, model 
A340 (Upchurch Scientific, W A, USA) was installed between the pump and the autosampler. 
3.2.1.3 ULTRAVIOLET DETECTION 
The most frequently used detector in the HPLC analysis of antibiotics is the fixed or variable 
- ~ 
ultraviolet (UV) photometer [49]. Penicillins do not have specific chromophores and eluents must 
.. ' 
be monitored at low wavelengths where many endogenous compounds interfere [34]. Most of the 
solvents used in HPLC have broad windows in the UV -visible region, making them compatible 
with the UV detectors even at low wavelengths. 
A Hewlett Packard 1040A Diode-Array HPLC-Detection System with accessories was used for 
method development. Diode-array detection is advantageous for analytical method development 
because it allows simultaneous monitoring at several wavelengths and h~ the ability to acquire 
spectral information without stopping flow. Higher sensitivity was achieved because of the variable 
bandwidth option which allowed the optimization of signal to noise ratios in relation to wavelength 
as well as time. 
The Millipore Waters M 490 Programmable Multiwavelength Detector was then used in the 
stability and dissolution studies once a method had been developed. 
3.2.1.4 COLUMN SELECTION 
Each stationary phase imparts a unique selectivity towards sample components. The choice of an 
analytical column is based on physical properties of the analyte, such as molecular weight, 
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solubility and ionic character. Strongly polar substituents (alkali, acids or ionizable groups) may 
require ion-exchange chromatography, while weakly polar substituents (alkyl groups, halogens) 
may be analyzed by reversed phase partition chr{)matography, and substituents of intermediary 
polarity can be analyzed by either partition or adsorption chromatography. A large number of 
HPLC methods use reversed phase partitioning, possibly because of the great stability and ease of 
use of non-polar coated silica (C2 , Cs, CIS) stationary phase [49]. Moreove,r >- relatively polar 
antibiotics may be analyzed on these stationary phases either by ion pairing chromatography or by 
suppression of ionization. 
The retention of a drug on the HPLC column is also a function of column packing and column 
dimensions. The smaller the microparticle, the better the resolution and sensitivity. The 10 J-tm 
particles provide adequate resolution for most analytical separations, while particles of 5 J-tm and 
small~r are used for more demanding tasks. Smaller particles sizes give more theoretical plates and 
better sensitivity, but higher backpressure than the larger particles. The number of theoretical 
plates is an indication of bandspreading. The sample capacity oLa column increases with the 
volume of the stationary phase, the column length and the column internal diameter. Different 
brands of CIS and Cs columns have very different selectivities and retention characteristics that 
often cannot be predicted accurately by examining the specifications supplied by manufacturers, 
necessitating in-house method validation [50]. 
Three types of analytical columns were compared to determine which provided the most favou_r~ble 
retention of amoxycillin during the development of the HPLC method. The columns used were a 
Cs column (4.5x250 mm, custom packed in our laboratory with TechsilO? Cs), a CIS cartridge 
column (Nova-Pak®) and a CIS end-capped column (Nova-Pak<!!l). 
3.2.1.5 MOBILE PHASE SELECTION AND PREPARATION 
The mobile phase moves the sample components through the chromatographic column. In~ddition 
the mobile phase interacts with the solute molecules and often the stationary phase itself. It is those 
solute-mobile phase-stationary phase interactions that make HPLC a powerful separation technique. 
Alkyl bonded stationary phases are essentially used with buffer and methanol or acetonitrile as 
mobile phases. The organic modifier content in the mobile phase depends on the polarity of the 
drug being investigated and on the type of the reversed phase packing. For any given stationary 
phase, a strong solvent will cause the solute to partition into the mobile phase and consequently 
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the retention time will be short. A weak solvent will cause the solute to favour the stationary phase 
and the retention time will be longer. The pH of the buffer component is selected to provide 
sufficient retention and complete separation, in the. qlse of ionizable drugs. The retention times of 
weak acids decrease with increasing pH values while those of weak bases increase with increasing 
pH [51]. 
The mobile phase should not alter the stationary phase by reacting with it or changing its structure 
and it should be chemically pure to prevent trace impurities collecting on the column. The presence 
of UV -active impurities is undesirable therefore HPLC or spectroscopic quality solvents must be 
used. The solvent should exhibit a low absorbance at the operating wavelength. Water and 
acetonitrile can be used at wavelengths down to 195 nm. The solvent viscosity must be taken into 
account when selecting a mobile phase. As columns age and particles accumulate on the inlet frit, 
backpressure will increase. If the pressure is initially high because of the solvent viscosity, the 
upper pressure limit of the chromatographic method will be reached as columns age. If a lower 
viscosity solvent is selected this will be avoided and the column }ViH"be able to be used for a longer 
time before the backpressure limit is exceeded. 
The mobile phases used in several published HPLC techniques were investigated (Table 3.1). 
When none of these methods proved suitable without major alterations, an original mobile phase 
was developed. 
The establishment of the mobile phase was conducted with simple aqueous solutions of amoxycillin 
trihydrate in water, to ensure that it single peak corresponding to the antipiotic was monitored. 
Retention times from the time of injection, rather than capacity factor were measured, as it was 
difficult to identify a non-eluting peak or the solvent front. A mobile phase of weak eluotropic 
strength was used as a starting point (acetonitrile:water, 75:25). The mobile phase was then 
adjusted to reduce the retention time for the peak of interest to approximately 10 minutes. 
~ 
However, due to the high polarity of amoxycillin, the drug tended to be eluted from these~systems 
more rapidly than desired, therefore further modifications of the mobile phase were considered. 
The ways to improve the definitive mobile phase are numerous and include slight variations of pH, 
an increase or decrease of ionic strength and changes in the amount of organic modifier in the 
mobile phase. In order to determine an optimum mobile phase system, it was decided to 
experiment both with organic phases, and various buffer compositions, as well as different ratios 
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of organic phase to aqueous phase, in separate experiments. 
Ionization control by means of a buffer was coqs~dered when the drug appeared to be poorly 
retained with weakly eluting mobile phases. Modifiers of mobile phase pH or ionic strength such 
as buffers or salts, as well as counter ions influence the mobile phase selectivity. Different pH 
values and concentrations of salts were tested until a suitable retention time and symmetrical peaks 
~ - -
were obtained. 
3.2.1.6 GUARD COLUMNS AND PRE-COLUMNS 
The use of a guard column (part number 1603, Upchurch Scientific, W A, USA) dry packed with 
Perisorb RP-18 pellicular packing material (part number C603, Upchurch Scientific, WA, USA) 
was initiated because both biological samples and samples containing fatty material from molten 
suppositories were to be injected onto the analytical column. The guard column served to trap 
particulate matter and high molecular weight constituents such '!S prptein and fat globules, thereby 
prolonging the life of the analytical column. Samples were loaded onto the analytical column, both 
with and without the guard column in line, and it was confirmed that the guard column ,made no 
significant contribution to dead volume or extra column effects. When the guard column lost 
efficiency or caused the backpressure in the system to rise when it became blocked, the frits and 
column packing were replaced. 
Since the mobile phase was continuously recycled, an in-line filter (model A430, Upchurch 
Scientific, W A, USA) was installed between pump and injector in order to p~otect the system from 
sample contaminants in the mobile phase. The frit of the in-line filter was replaced if the filter 
became less efficient or caused the backpressure to rise. 
3.2.1.7 INTERNAL STANDARD 
Internal standards are needed when an analytical method results in highly variable recovery of the 
anal yte , most often in multi-step preparations. The internal standard compensates for varying 
injection volumes and day to day instrumental changes [138]. The internal standard should have 
physicochemical properties and chromatographic behaviour close to those of the drug to be 
measured [49]. The introduction of an internal standard implies that the entire developed procedure 
should be suitable for both molecules. 
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The drugs mentioned in the literature for use as internal standards in the assay of amoxycillin 
include phenoxymethylpenicillin potassium [39], phenoxyacetic acid [38], hydroflumethiazide [42], 
benzoic acid [43] and sulphadimidine [16,17]. CbJpramphenicol has been used in the assay of 
benzylpenicillin, and benzyl alcohol in ampicillin assay [131]. Perusal of the literature revealed that 
furosemide and salicylic acid have absorption spectra similar to that of amoxycillin [5], suggesting 
that they may exhibit similar chromatographic behaviour. 
3.2.1.8 PREPARATION OF STOCK SOLUTIONS 
Stock solutions of 1.0 mg/mL amoxycillin were prepared by accurately weighing 116 mg of 
amoxycillin trihydrate and dissolving this in HPLC grade water, with the aid of the ultrasonic 
cleaner (model 8845-30, Cole-Parmer Instrument Company, Illanois, USA) and making up to 
volume with HPLC grade water in a 100 mL volumetric flask. 
Stock solutions of 1.0 mg/mL salicylic acid were prepared hy a£-curately weighing 100 mg of 
salicylic acid and dissolving this in HPLC grade water and making up to volume with HPLC grade 
water in a 100 mL volumetric flask. 
Serial dilutions were made with HPLC grade water to produce the concentrations required. 
3.2.2 OPTIMISATION OF CHROMATOGRAPHIC CONDITIONS 
3.2.2.1 DETECTOR WAVELENGTH (A) 
Amoxycillin was monitored at 200, 230 and 254 nm using diode array detection (Figure 3.1). 
From Figure 3.1 it can be seen that a· wavelength of approximately 200 nm gives the highest 
absorptivity, but maID' endogenous compounds also tend to absorb at this wavelength. It was 
decided to set the detector wavelength to 230 nm as -amoxycillin also displays relativ.ely high 
absorptivity at this wavelength, as discussed in Section 1.2.5. Some published methods have used 
alternative wavelengths [16,17,36,38,39], but detection in this region has been employed by several 
authors [15,40,41], and it was shown to be suitably sensitive for the purposes of this in vitro study. 
Figure 3.1 
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array detection 
3.2.2.2 MOBILE PHASE SELECTION 
The effects of different organic modifiers, buffer concentration, pH and ratios of organic to 
inorganic phase on the...retention of amoxycillin on a CI8 Nova-Pak® column were investigated, and 
the results are summarized in Table 3.2. 
The mobile phase was prepared by pipetting a specific volume of methanol or acetonitrile into a 
1 litre volumetric flask and making up to volume with phosphate buffer solution. A 0.05 M 
phosphoric acid solution was prepared by adding 7 mL phosphoric acid (85 %) to HPLC grade 
water in a 2 litre volumetric flask, then making to volume. Sodium hydroxide pellets were then 
added to adjust the buffer to the pH required for the mobile phase. The mobile phase was degassed 
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and filtered through a 0.45jLm membrane filter (type HVLP, Millipore Corp., Bedford, MA, USA) 
prior to use, by aspiration with an Eyela® aspirator (model A-35, Tokyo Rikakikai Co Ltd, Tokyo, 
Japan). 
Table 3.2 Retention time of amoxycillin using various mobile phase combinations 
- ~ 
Mobile phase Ratio Retention time 
(min) 
AcN:water 75:25 1.4 
AcN:water 50:50 1.6 
AcN:water 25:75 1.6 
AcN:0.05 M Phosphate buffer pH 2.4 25:75 2.5 
AcN:0.05 M Phosphate buffer pH 7 25:75 2.4 
AcN:0.05 M Phosphate buffer pH 3 10:90 3.2 
AcN:0.05 M Phosphate buffer pH 7 10:90 3.3 
-
-AcN:0.05 M Phosphate buffer pH 5 10:90 3.4 
MeOH:water 20:80 2.7 
, 
MeOH:water 10:90 3.4 
MeOH:0.05 M Phosphate buffer pH 3 10:90 5.7 
MeOH:0.05 M Phosphate buffer pH 7 10:90 8.2 
MeOH:0.05 M Phosphate buffer pH 5 10:90 4.8 
MeOH:0.05 M Phosphate buffer pH 3 5:95 11.4 
MeOH:0.05 M Phosphate buffer pH 7 5:95 12.0 
MeOH:0.05 M Phosphate buffer pH 5 5:95 7.2 
MeOH:0.05 M Phosphate buffer pH 7 8:92 8.4 
MeOH:0.05 M Phosphate buffer pH 7 6:94 11.1 
Altering the ratio of acetonitrile:water did not appear to have a marked effect on retention time 
whereas decreasing the organic fraction slightly increased the retention time by a few seconds. 
Changing the methanol:water ratio made a more noticeable difference, with a change from 2.7 to 
3.5 minutes, as the methanol portion was decreased from 20 to 10%, although only two different 
ratios were monitored. When a buffer was used in the mobile phase, a similar trend was observed, 
with the methanol : buffer systems showing a longer retention time than acetonitrile:buffer systems 
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with the same pH. It was decided to concentrate on a methanol:buffer system for this reason. A 
difference in solubility in these two organic phases may account for this result. Amoxycillin 
trihydrate is insoluble in acetonitrile, but is soluble 7.5 mg/mL in methanol [6,7]. 
Since amoxycillin is an amphoteric compound, with pI<,. values of 2.4, 7.4 and 9.6, the retention 
time was best controlled by a buffered system, as proposed by Huang et aI144J.. A phosphate 
buffer system was used. The pH values reported are those of the buffer solutions before mixing 
with the organic phase. 
A 10:90 mixture of methanol:0.05 M phosphate buffer (PH 7), gave a retention time of 6.9 
minutes. As the fraction of methanol was decreased, an 8:92 mixture, a 6:94 mixture and a 5:95 
mixture gave increasing retention times of 8.4 minutes, 11.1 minutes and 12 minutes respectively. 
The retention times, for a 10:90 mobile phase mixture, with a buffer pH of 3,5 and 7 were 5.7, 
4.8 and 6.9 minutes respectively. These results supported the t1ndings of Huang et ai, that when 
the pH of the mobile phase was close to the pI<,. values of amoxycillin, the drug was retain,~ on 
the column for a longer time, since around these pH values amoxycillin is approximately 50% 
ionized and is therefore less polar, and tends to be bound to the stationary phase. Between pH 4 
and pH 6 amoxycillin is totally ionized and is therefore not well retained, corresponding with the 
V-shaped curve described by Huang et al [44]. 
The effect of buffer molarity was investigated, using a 10:90 methanol:phosphate buffer pH 7 
mobile phase and a Nova-Pak® C18 analytical column. The retention times which resulted when 
buffers of 0.005, 0.025, 0.05 and 0.1 molarity were used are summarized in Table 3.3. 
The eff~ct of buffer molarity on retention time of amoxycillin 
-
Molarity (M) Retention Time 
(min) 
0.005 5.7 
0.025 7.3 
0.05 8.2 
0.1 9.2 
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The higher the molarity of the phosphoric acid solution used in the buffer, the longer was the 
retention time of amoxycillin when a 10:90 methanol:phosphate buffer pH 7 mobile phase was 
used. 
3.2.2.3 INTERNAL STANDARD 
Several drugs were tested as potential internal standards for the amoxycillin assays which were to 
be performed. 0.5 mg/mL solutions of benzoic acid, chloramphenicol, sulphadimidine, furosemide 
and salicylic acid were tested using mobile phases of 10:90 and 5:95 methanol: phosphate buffer, 
with a buffer pH of either 3, 5 or 7. 
Only salicylic acid and benzoic acid were detectable under these conditions. The effect of various 
methanol:0.05 M phosphate buffer mobile phases on the retention of these compounds on a Nova-
Pak:® CIS column is shown in Table 3.4. 
Table 3.4 Retention time of amoxycillin, salicylic acid and benzoic acid 
Mobile phase Retention time (min) 
Amoxycillin Salicylic acid Benzoic acid 
5:95 pH 7 12.0 9.1 5.0 
5:95 pH 5 7.2 9.8 6.5 
5:95 pH 3 lL4 * * 
10:90 pH 7 8.2 6.8 4.2 
10:90 pH 5 4.8 6.6 * 
10:90 pH 3 10.4 * * 
* No peaks eluted within 20 minutes 
~ 
As the fraction of organic phase was decreased, the retention times of both amoxycillin and the 
internal standards under investigation increased. When the ratio of methanol to phosphate buffer 
was kept constant, at 5:95, and the pH changed, the sequence of retention times changed. At pH 
5, the salicylic acid eluted after the amoxycillin, whereas the benzoic acid still eluted earlier. At 
pH 3 no peaks appeared within 20 minutes for either benzoic acid or salicylic acid. This could 
possibly be explained by the state of ionization of these drugs; pKa values are 4.2 for benzoic acid 
and 3 and 13.4 for salicylic acid. At pH 7 retention times were 12, 9.1, and 5 minutes for 
50 
amoxycillin, salicylic acid and benzoic acid respectively. The retention times of the mobile phases 
with a 10:90 methanol:phosphate buffer combination were slightly lower than the 5:95 
combination. 
The retention times of benzoic acid under the mobile phase conditions tested, were not suitable for 
the purposes of this study. Since the salicylic acid peak eluted near to the amoxycillin peak but was 
~ - ~ 
well separated from it, under the mobile phase conditions tested, it was chosen as the internal 
standard for the HPLC method for in vitro analysis of amoxycillin. 
3.2.2.4 COLUMN CHOICE 
A comparison of the reversed phase columns described in Section 3.2.1.4, using the mobile phase 
combinations listed in Table 3.5, revealed that a CIS column retained amoxycillin and salicylic acid 
to a greater extent than a CIS end-capped or a Cs column. Optimum retention was achieved on a 
CIS column with a methanol:phosphate buffer pH 7 mobile ph,!se."c> 
Table 3.5 
Colwnn 
C 18 
Cg 
CIS end 
capped 
Retention time (min) of amoxycillin and salicylic acid on a CIS' a Cs and -<lC ls end 
capped column 
Mobile phase Amoxycillin Salicylic acid 
50:50 MeOH:water" 1.6 1.1 - -
10:90 MeOH:water" 3.4 1.2 
10:90 MeOH:O.OS MPhosphate buffer pH 3 10.4 * 
10:90 MeOH:0.05 M Phosphate buffer pH 5 4.8 6.6 
10:90 MeOH:0.05 M Phosphate buffer pH 7 8.2 6.8 
50:50 MeOH:water" 1.4 1.0 
10:90 MeOH:water" 2.4 1.4 
10:90 MeOH:0.05 M Phosphate buffer pH 3 4.9 * 
10:90 MeOH:0.05 M Phosphate buffer pH 5 2.4 4.2 
10:90 MeOH:0.05 M Phosphate buffer pH 7 3.9 3.5 
50:50 MeOH:water" 1.1 0.9 
10:90 MeOH:water" 1.7 1.1 
10:90 MeOH:0.05 M Phosphate buffer pH 3 5.9 * 
10:90 MeOH:0.05 M Phosphate buffer pH 5 2.0 6.0 
10:90 MeOH:0.05 M Phosphate buffer pH 7 7.4 5.7 
a pH of MeOH:water mixtures not measured * no peaks seen in 20 minutes 
3.2.2.5 CHROMATOGRAPIDC CONDITIONS 
HPLC 
Mobile Phase 
Flow Rate 
Attenuation 
Recorder Input 
Injection Volume 
Temperature 
Retention Time 
System B 
Methanol:0.05 M phosphate buffer pH 7 (5:95) 
1.0 mLimin 
0.05 AUFS 
10 mV 
10 JLL 
Ambient 
Amoxycillin 12 minutes 
Salicylic acid 7 minutes 
51 
A typical chromatogram showing amoxycillin and the internal standard, using the chromatographic 
- . . 
conditions listed above, is depicted in figure 3.2. 
3.2.2.6 CONCLUSION 
The effects of the parameters involved in HPLC analysis were identified by systematic examination 
of detector wavelength, mobile phase composition and stationary phase. By optimizing these 
chromatographic conditions, an HPLC method which provided distinctly resolved peaks, retention 
times within the required ranges and minimal baseline noise was developed. A suitable internal 
standard, salicylic acid, was identified. 
Figure 3.2 
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Typical chromatograms of low (A) and high (B) concentrations of amoxycillin (a) 
with salicylic acid (b) 
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3.3 METHOD VALIDATION AND STABILITY OF AMOXYCILLIN 
TRIHYDRATE IN AQUEOUS SOLUTION 
3.3.1 INTRODUCTION 
Following optimization of an HPLC system for the in vitro analysis of amo£ycillin, it was 
necessary to validate the method in terms of linearity, accuracy and precision and to determine the 
limit of quantitation of the method. A series of aqueous samples was processed in order to validate 
these parameters. 
An investigation of stability is also a crucial part of method development. A study was conducted 
to establish the stability of amoxycillin trihydrate in unbuffered aqueous solution. The results of 
this study were useful in determining the length of time for which samples could be left in the 
autosampler during an extended run. The results obtained after storage at room temperature 
(21°C), in a refrigerator (4°C) and in a freezer (-15°C) alloweo aa~cision to be made on the best 
way of storing samples that could not be assayed immediately. Samples were stored both with and 
,. 
without internal standard in order to determine whether it was feasible to add internal standard 
before storage, or if it was necessary to add the internal standard immediately before assay due to 
reaction between amoxycillin and salicylic acid. 
Amoxycillin degrades either by hydrolysis or dimerization depending on the pH and- the 
concentration of a solution (SectiQn 1.3). Hydrolysis is predominant at low concentrations and 
higher pH values, whereas dimerization occurs more readily at high concentrations in acidic 
solutions. 
3.3.2 EXPERIMENTAL 
3.3.2.1 REAGENTS 
All reagents have been detailed in Section 3.2.1.1. All the chemicals used were at least of 
anal ytical reagent qual ity . 
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3.3.2.2 CHROMATOGRAPmC CONDITIONS 
The chromatographic conditions have been descrmed in Section 3.2.2.5. 
3.3.2.3 CALIBRATION CURVES 
Calibration curves were constructed on the days that samples were assayed. Fresh stock solutions 
of amoxycillin trihydrate and salicylic acid were prepared as described in Section 3.2.1.8 on each 
assay day. Concentrations of 0.005, 0.01, 0.02, 0.05, 0.07 and 0.1 mg/mL were obtained by serial 
dilution of the stock solution of 1.0 mg/mL amoxycillin trihydrate with HPLC grade water. Before 
making to volume, salicylic acid (1.0 mg/mL) was added to each dilution to give a final internal 
standard concentration of 0.01 mg/mL. Each calibration sample was assayed six times. The linear 
regression line is shown in Figure 3.4. 
3.3.2.4 LINEARITY 
Linearity of the ratio of amoxycillin peak height to internal standard peak - heighf versus 
concentration, over the concentration range studied was established. The linearity data are tabulated 
in Table 3.6. 
3.3.2.5 PRECISION AND ACCURACY 
The precision of the assay was determined by calculating the percent relative standard deviation 
(RSD) of the peak height ratios of six replicate samples of standards (Table 3.6). Accuracy was 
assessed at two concentrations from three samples prepared by an independent analyst, by 
comparing the mean concentrations found with the actual concentrations. Sample concentrations 
were calculated by interpolation of peak height ratios from the calibration curve. The results are 
summarized in Table 3.7. 
3.3.2.6 LIMIT OF QUANTITATION AND DETECTION 
The limit of quantitation was determined by diluting the amoxycillin stock solution until the peak 
on the HPLC trace was detectable but no longer measurable. The lower limit of quantitation was 
taken to be twice this value. 
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3.3.2.7 pH 
The pH of solutions of amoxycillin, salicylic acid 1md a mixture of amoxycillin and salicylic acid 
was determined. The results are summarized in Table 3.10. 
3.3.2.8 STABILITY 
An aliquot of the amoxycillin trihydrate stock solution was diluted to 0.005 and 0.1 mg/mL. 
Salicylic acid (0.01 mg/mL) was included in one batch of both of the dilutions, but was excluded 
from the other batch. 10 mL aliquots of each solution were set aside for storage at -15°C, 4°C and 
21 ° C in transparent glass screw-cap tubes. 
On Day 1, Day 2, Day 3, Day 7 and Day 14 samples were allowed to thaw naturally to room 
temperature and were assayed in triplicate. In the case of the amoxycillin sample stored without 
internal standard, salicylic acid was added just prior to the ass~y ptocedure. 
Fresh calibration curves were made up on each day of sampling. The concentration of drug 
remaining in solution after storage was calculated from the peak height ratio. The results were 
evaluated to determine whether there was a significant change in concentration on storage under 
the various conditions over the 14 day period. 
3.3.2.9 STATISTICAL INTERPRETATION OF THE DATA 
The statistical procedure used was adapted from the study described by Timm et al [52]. In this 
study a procedure was developed for investigating the stability of drugs based on sound 
experimental design and the use of a siatistical procedure which allowed conclusions to be made 
concerning stability -with an acceptable degree of certainty (95 %). The relative difference in 
response between stored samples and the initial concentration and a 90% confidence interval for 
the true change in response was calculated. This confidence interval allowed the detection of a 
pharmacokinetically relevant degradation. It is argued that this approach is superior to stability test 
procedures based on the Student's t test. 
The measurements of peak height or peak height ratios, when the internal standard was used, are 
referred to as the response in the study. For the purpose of the calculations in the statistical 
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treatment described, it was necessary that the analytical methods used resulted in a relationship 
between response and concentration that could be described by a linear curve starting at the origin. 
The linearity results are shown in Tables 3.9 and -3.-10 in Section 3.3.3.1. 
The measured percentage difference (D) between stored samples and original concentrations was 
calculated. The true percentage difference in response after storage (d), which is equal to the 
percentage difference in concentration, may differ from D because of the imprecision of the 
analytical procedure. In other words ..1. and D become identical only in the absence of measurement 
errors. Therefore a 90% confidence interval ford was calculated. The true change of response on 
storage is contained by the lower limit (LL) and the upper limit (UL) of the confidence interval 
with a probability of 90%. That is, there exists a probability of 5% that ..1. ~ LL and a probability 
of 5% ..1. ~ UL (Figure 3.3). 
This statistical interpretation distinguishes between significant and relevant instability. A change 
of response during storage is statistically significant if the -vallie ..1. = 0% lies outside the 
confidence interval. Three possibilities are considered: 
(a) a significant decrease, LL ~ UL ~ 0%, 
(b) no significant change, LL ~ 0% ~ UL, 
(c) a significant increase, 0% ~ LL ~ UL. 
However a significant degradation is only important when it reaches pharmacokinetically relevant 
proportions. A substance should be denoted as stable only if a relevant degradation can be excluded 
with high certainty. Timm et al considered a degradation of ..1. = -10% to be relevant. Thus if ..1. 
= -10% falls within the 90% confidence interval for ..1., the substance is not denoted as stable. 
There are therefore three additional possibilities: 
(a) no relevant decrease, -10% ~ LL ~ UL, 
(b) a possibly relevant decrease, LL ~ -10% ~ UL, 
(c) a relevant decrease, LL ~ UL ~ -10%. 
Figure 3.3 shows the various combinations arising from these definitions. The bars above the axis 
characterise the ranges of the 90 % confidence intervals for the true percentage response difference, 
..1., between stored and freshly prepared samples. 
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The drug is classified as stable in cases (a) and (b), as no relative instability is observed. In case 
(c) a relevant degradation of 10% or more cannot be excluded with a statistical probability of95% 
and in case (d) a significant and relevant decrease pf. concentration on storage is observable, both 
cases indicating the compound is not stable according to the definition. Example (e) leads to the 
decision that the compound is not stable. However the wide confidence interval indicates poor 
precision. Case (f) indicates that the compound is stable. However the experiments should be 
~ - -
repeated because of the possibility of a systematic error [52]. 
a 
b 
-
c 
d 
-
o 
-
-20 -10 o 
% Change from Initial Concentration 
(a) change of respons ... e, not significant and not relevant 
(b) decrease of response, significant but not relevant -' 
(c) decrease of response, significant and possibly relevant 
(d) decrease of response, significant and relevant 
(e) decrease of response, not significant but possibly relevant 
(f) increase of response, significant 
Figure 3.3 Key to definitions 
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3.3.3 RESULTS 
3.3.3.1 LINEARITY AND CALIBRATION CURVES 
A calibration curve was constructed by linear regression of a plot of peak height ratio of 
amoxycillin to that of the internal standard versus amoxycillin concentration. Th~JiI]ear regression 
equation was y=31.8195x-OJXJ26 with a correlation coefficient of 0.9998. The calibration curve 
for aqueous amoxycillin is shown in Figure 3.4. 
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Figure 3.4 Calibration curve for aqueous amoxycillin (y=31.8195x-0.0026, R2=0.9998) 
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The validation data for linearity and precision are shown in Table 3.6. 
Table 3.6 Linearity and precision data for aqueous amoxycillin solutions 
Calibration Standards 
Concentration Peak Height Ratio %RSD 
(pg/mL) Mean ± SD (n=6) 
0.1 3.16 ± 0.05 1.6 
0.07 2.26 ± 0.07 3.1 
0.05 1.57 ± 0.04 2.5 
0.02 0.63 ± 0.02 3.2 
0.01 0.30 ± 0.01 3.3 
0.005 0.17 ± 0.01 5.9 
3.3.3.2 PRECISION AND ACCURACY 
Results from the precision study are tabulated in Table 3.6. The method of analysis was fo~nd to 
be reproducible with RSD values less than 6% at all concentrations. 
Results from the accuracy study are tabulated in Table 3.7. The percentage bias was calculated as 
the difference between the calculated concentration and spiked concentration as a percentage of the 
spiked concentration. The difference between the calculated and spiked concentrations was les~ than 
3 % in both instances. 
Since the criteria for acceptable precision and accuracy were taken to be :::;;; 10% RSD and :::;;; 10% 
bias [132], these results were considered acceptable for the purposes of this study. 
Table 3.7 Calculation of spiked concentration for accuracy determination 
Spiked Calculated Percentage 
Concentration Concentration (pg/mL), Bias 
(pg/mL) Mean ± SD (n=3) 
0.035 0.0360 ± 0.0000 2.8% 
0.080 0.0799 ± 0.0002 -0.2% 
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3.3.3.3 LIMIT OF QUANTITATION AND DETECTION 
The limit of detection of aqueous amoxycillin was 0.001 mg/mL, determined by a 10 ILL injection 
volume and a sensitivity of 0.05 AUFS. This peak was detectable, but not measurable. The lower 
limit of quantitation was found to be 0.002 mg/mL with a signal to noise ratio of 3. 
3.3.3.4 pH 
The pH values of aqueous amoxycilIin, salicylic acid and amoxycillin with salicylic acid were 
recorded and are shown in Table 3.8. All solutions were acidic, and the addition of salicylic acid 
to the amoxycillin solutions decreased the pH of these solutions slightly, from pH 4.46 to pH 4.12. 
The implications of the effect of salicylic acid on amoxycillin are discussed in Section 3.3.3.5. 
Table 3.8 pH values of aqueous solutions 
Solution pH 
Amoxycillin 1.0 mg/mL 4.46 
Salicylic acid 1.0 mg/mL 2.50 
Amoxycillin with 4.12 
salicylic acid 
3.3.3.5 STABILITY 
Calibration curves were constructed in a similar manner to that described in Section 3.3.2.3, on 
each day of the stability study. The details of the calibration curves used for the determination of 
the concentrations ot..aqueous solutions of amoxycillin stored both with and with out salicylic acid 
are shown in Tables 3.9 and 3.10. 
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Table 3.9 Linearity data for amoxycillin solutions stored with internal standard 
., 
Day Slope Y -intercept Correlation Coefficient 
0 31.8195 -0.0026 0.99983 
1 34.6255 -0.0238 0.99965 
2 34.1911 -0.0106 0.99983 
3 34.1764 -0.0101 0.99988 
7 38.5732 0.0026 0.99993 
14 342.5597 -0.0205 0.98560 
Table 3.10 Linearity data for amoxycillin solutions stored without internal standard 
Day Slope Y -intercept Correlation Coefficient 
- .-
0 38.8125 -0.0106 0.99972 
1 34.8342 0.0354 0.99950 
2 34.8234 0.0310 0.99934 
3 42.5597 -0.0205 0.98560 
7 34.6579 -0.0199 0.99934 
14 33.6808 0.1650 0.99986 
The stability of the aqueous amoxycillin samples of high and low concentration, stored at 21°C, 
4°C and -15°C for two weeks without an internal standard is indicated by the change in 
concentration of these solutions, as shown in Tables 3.11 and 3.12. 
Table 3.11 
Table 3.12 
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Stability data for aqueous amoxycillin 0.005 mg/mL stored over a 14 day period 
without internal standard 
Day Concentration (mg/mL), Mean ± SD (n=3) 
21°C 4°C -15°C 
0 0.0052 ± 0.0001 0.0052 ± 0.0001 0.0052 ± O.OOOC-
1 0.0051 ± 0.0000 0.0058 ± 0.0006 0.0051 ± 0.0000 
2 0.0051 ± 0.0000 0.0051 ± 0.0000 0.0051 ± 0.0000 
3 0.0056 ± 0.0000 0.0045 ± 0.0000 0.0056 ± 0.0000 
7 0.0043 ± 0.0000 0.0043 ± 0.0000 0.0053 ± 0.0000 
14 0.0012 ± 0.0000 0.0028 ± 0.0010 0.0034 ± 0.0000 
Stability data for aqueous amoxycillin 0.1 mg/mL stored over a 14 day period 
without internal standard 
Day Concentration (mg/mL), Mean ± SD (0=3) 
21°C 4°C -15°C 
0 0.1028 ± 0.0000 0.1028 ± 0.0000 0.1028 ± 0.0000 
1 0.1007 ± 0.0000 0.1004 ± 0.0006 0.1024 ± 0.0006 
2 0.0900 ± 0.0012 0.0903 ± 0.0010 0.0979 ± 0.0017 
3 0.1006 ± 0.0000 0.0981 ± 0.0006 0.0914 ± 0.0027 
7 0.0952 ± 0.0000 0.0963 ± 0.0000 0.0843 ± 0.b006 
14 0.0827 ± 0.0000 0.0925 ± 0.0000 0.0716 ± 0.0006 
The stability of the aqueous amoxycillin solutions of high and low concentration, stored at 21°C, 
4°C and -15°C for two weeks with an internal standard is demonstrated by the change in 
concentration of these solutions, as shown in Tables 3.13 and 3.14. 
Table 3.13 
Table 3.14 
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Stability data for amoxycillin 0.005 mg/mL stored for a 14 day period with 
internal standard 
Day Concentration (mg/mL), Mean ± SD (n=3) 
21°C 4°C -15°C 
0 0.0051 ± 0.0000 0.0051 ± 0.0000 0.0051 ± 0.(){)()6 -
1 0.0053 ± 0.0000 0.0056 ± 0.0005 0.0053 ± 0.0000 
2 0.0045 ± 0.0000 0.0050 ± 0.0005 0.0053 ± 0.0000 
3 0.0054 ± 0.0000 0.0051 ± 0.0005 0.0054 ± 0.0000 
7 0.0051 ± 0.0000 0.0042 ± 0.0000 0.0042 ± 0.0000 
14 0.0021 ± 0.0006 0.0045 ± 0.0000 0.0049 ± 0.0006 
Stability data for amoxycillin 0.1 mg/mL stored for a 14 day period with internal 
standard 
Day Concentration (mg/mL), Mean ± SD (n=3) 
21°C 4°C -15°C 
0 0.1001 ± 0.0005 0.1001 ± 0.0005 0.1001 ± 0.0005 
1 0.1052 ± 0.0000 0.1052 ± 0.0000 0.1018 ± 0.0000 
2 0.0983 ± 0.0006 0.0997 ± 0.0006 0.0993 ± 0.0006 
3 0.1017 ± 0.0058 0.0983 ± 0.0006 0.0970 ± 0.0000 
7 0.0998 ± 0.0024 0.0986 ± 0.0002 0.0850 ± 0.0000 
14 0.0657 ± 0.0012 0.0960 ± 0.0006 0.0674 ± 0.0007 
The percent of drug remaining was calculated from the ~easured percentage difference in response 
(Table 3.15 and 3.16). The results which were calculated as greater than 100 % were as a result 
of the differences in the daily calibration curves. 
Table 3.15 
Table 3.16 
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Percent amoxycillin remaining in solution after storage for 14 days without internal 
standard 
Day 21°C 4°C -15°C 
0.005 0.1 0.005 0.1 0.005 0.1 
mg/mL mg/mL mg/mL mg/mL mg/mL mg/mL-
0 100% 100% 100% 100% 100% 100% 
1 98% 98% 108% 98% 96% 100% 
2 98% 88% 96% 88% 96% 95% 
3 108% 98% 85% 95% 106% 89% 
7 83% 93% 81 % 94% 100% 82% 
14 23% 80% 49% 90% 64% 70% 
Percent amoxycillin remaining in solution after storage for 14 days with internal 
standard 
Day 21°C 4°C -15°C 
0.005 0.1 0.005 0.1 0.005 0.1 
mg/mL mg/mL mg/mL mg/mL mg/mL mg/mL 
0 100% 100% 100% 100% 100% 100% 
1 104% 105% 109% 105% 104% 102% 
2 88% 98% 98% 100% 104% 99% 
3 106% 101 % 100% 98% 106% 97% 
7 100% 100% 82% 99% 82% 85% 
14 39% 66% 88% 96% 94% 67% 
The fact that an apparent increase occurred showed that it was necessary to differentiate between 
the true percentage response after storing (~) and the measured percentage difference in response 
(D). The signiticance and relevance of each change in concentration was determined, using the 
~ 
method of Timm et al [52], and these results are depicted in Figures 3.5 to 3.8. 
Figure 3.5 
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Figure 3.7 Percent change from initial concentration of an aqueous solution of 0.005 mg/mL -
amoxycillin stored over a 14 day period without internal standard .. 
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amoxycillin stored over a 14 day period with internal standard 
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The solutions used in the study were slightly acidic, with a pH of approximately 4.5 for 
amoxycillin solutions, and a slightly lower pH of 4.1 for the amoxycillin solutions to which 
salicylic acid (PH 2.5) had been added (Table 3.8).·Jn this pH range and for the two concentrations 
studied, there is likely to be a combination of dimerization and hydrolysis reactions since the 
solutions were acidic, which is conducive to dimerization, but of relatively low concentrations, 
which is more favourable for degradation by hydrolysis [10,13,14]. 
All samples were stable for the first 24 hours of storage, according to the definition of Timm et 
al [52], as shown in Figures 3.5 to 3.8, with either a change of response that was not significant 
and not relevant (a), or a decrease of response that was significant but not relevant (b), or an 
increase of response that was significant (t). This result meant that it was not necessary to store 
samples below room temperature, if they were to be assayed within a day of preparation. This also 
meant that samples could be left in the autosampler for 24 hours if necessary. This result supports 
those of Tsuji et al [13] and Sutherland and Rolinson [1], who observed a degradation half life of 
approximately 15 to 20 hours, at lower pH, but otherwise similar conditions. The lower pH 
conditions used by these researchers, being pH 2.35 and 1.5 respectively, would cause acid 
.. ' 
hydrolysis to occur to a greater extent than at the pH values observed in this stability study. This 
could explain why most samples were still stable under all conditions after 3 days, with the 
exception of the 0.1 mg/mL amoxycillin solution stored at room temperature and at 4 DC, and the 
dilute amoxycillin solution which was refrigerated. After seven days discernable degradation was 
noted in all solutions. 
Solutions at lower concentrations seem to be more affected by the pre~ence of salicylic acid. 
Although salicylic acid has been shown to be stable when stored on its own, the presence of 
amoxycillin may cause it to degrade. There may be a salicylic acid degradation peak occurring at 
the same time as the major amoxycillin peak, which has more of an obvious effect on the smaller 
amoxycillin peaks. .. 
The increase in the concentration ofthe frozen 0.005 mg/mL solutions at Day 14 (Table 3.13) can 
be explained by the fact that the test tubes containing amoxycillin 0.005 mg/mL and SA cracked 
while thawing and some of the sample was lost. 
If it were necessary to store aqueous solution of amoxycillin for a prolonged period of time, it 
would probably be necessary to buffer the solutions to a pH of approximately 6, which is the pH 
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of maximum stability for amoxycillin in solution [14]. 
3.3.4 CONCLUSION 
It is possible to leave aqueous samples of amoxycillin trihydrate at room temperature in an 
autosampler for a day, while analysis is in progress, without special storage cop.ditlons. Although 
the samples appear to be stable for longer periods, when presented as percent drug remaining 
(Tables 3.15 and 3.16), storage of solutions for longer periods would necessitate freezing and 
possibly the addition of a buffer, since aqueous solutions of amoxycillin are not very stable 
according to the stringent requirements of Timm et al. To avoid potential interactions between 
salicylic acid and amoxycillin, the internal standard should be added immediately before analysis. 
CHAPTER FOUR 
IN VITRO RELEASE OF AMOXYCILLIN FROM SUPPOSITORY 
BASES 
4.1 INTRODUCTION 
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The absorption of drug from a suppository base entails release from the vehicle and subsequent 
diffusion of the drug through the rectal mucosa to available absorption sites. Drug release from 
suppository bases into the rectal environment is influenced partially by factors related to the 
suppository base such as drug-vehicle interactions, suppository base composition, melting point, 
crystal I ine form of the base and viscosity of the base at body temperature, as well as characteristics 
of the drug such as solubility, partition coefficient and drug permeability in the vehicle, solubility 
of drug in the rectal fluid, particle size of the drug and drug concentration. The fraction of drug 
substance in relation to the total suppository weight may influence the rate of absorption due to an 
improved rectal spreading of the melted suppository mass whentl1~> fraction of drug substance is 
low [53]. The dissolution rate might also be influenced by the area of contact between the 
,-
suppository and the rectal fluid and is regulated by the volume of fluid. As the spread of the 
suppository mass is limited to between 5 cm to 7 cm into the rectal cavity, a formulation should 
be designed that utilizes the available absorption area as effectively as possible [54,55]. 
Pharmacopoeial specifications state, as part of the definition of rectal suppositories,' that 
suppositories should soften, melt or dissolve at body temperature [8]. This statement is however 
meaningless unless a standard method of determining these qualities is given. Release rates of 
drugs may influence the bioavailability of drugs from suppositories but as different methods give 
different results, suppositories may be accepted as suitable despite not adequately melting, 
softening or dissolving in the rectal environment. This suggests that quality control of suppositories 
by in vitro release tests is needed for the bioavailal)ility certification. An in vitro dissolution 
technique should discriminate between dissolution profiles from suppositories of different 
composition, be reproducible and enable in vitro-in vivo correlation in humans. 
A number of studies have been performed for bioavailability determination of rectally administered 
drugs, but there are no official tests or guidelines for drug release from suppositories or dissolution 
from rectal dosage systems in vitro. The only official guideline is a disintegration test for 
suppositories and pessaries in the British Pharmacopoeia [7], which determines whether these 
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disintegrate or soften within a prescribed time, when placed in a liquid medium under the 
prescribed experimental conditions. 
Vastly varied systems have been used to investigate in vitro drug release and techniques that are 
in use differ mainly in the extent to which they mimic in vivo conditions. Two basic systems are 
employed; those that use membranes and those that do not. The former may cons.i.st of a sample 
chamber separated from a reservoir by a membrane; or it may utilize dialysis tubing or a natural 
membrane [64,65,67,68]. The latter systems may range from simple placement of a suppository 
in a beaker or flask, to use of existing tablet dissolution apparatus [35,56-58]. 
4.1.1 SIMPLE IN VITRO METHODS 
BaicQwal et al [56] explored the release of salicylic acid, copper sulphate and boric acid from fatty 
suppository bases, using an apparatus claimed to simulate body conditions. The suppository was 
supported on a cotton plug in a glass funnel, mounted in a-hot.-water jacket thermostatically 
controlled to 37 ±0.5°C. Normal saline was allowed to flow onto the suppository at a rate o.f 100 
drops/minute. The suppository was immersed in normal saline at all times. -Samples were 
withdrawn periodically over 1 hour and analyzed to determine the amount of medicament released. 
The release of drug from the bases was linear after an initial non-linear period, and the drug 
release was related inversely to the consistency of the bases. 
In their investigation of sustained release sodium diclofenac suppositories, Toshiaki Nishihata et 
al [57] used a simple in vitro dissolution technique. Each test suppository was wrapped with two 
sheets of gauze and immersed in a beaker containing 100 ml saline warmed to 38°C. Aliquots 
(lOOJLI) were withdrawn at designated time intervals, passed through a 0.5 JLm millipore filter and 
analyzed. Since the data obtained from this dissolution technique were comparable to the apparent 
urinary excretion rate..{)f sodium diclofenac, it was suggested that the method used was suitable for 
the relative estimation of sustained release of sodium diclofenac from a suppository containing 
lecithin in the rectal lumen. It was also proposed that the permeating rate of rectal fluid into the 
suppository's matrix may regulate the release of diclofenac from the suppository, as shown by this 
dissolution method. 
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4.1.2 METHODS BASED ON USP APPARATUS 
The apparatus most commonly used by researchers to measure dissolution appear to be the 
dissolution apparatus for tablets and capsules described in the USP as Apparatus I, the basket 
apparatus; Apparatus II, the paddle apparatus; and Apparatus III, the flow-through cell apparatus 
[35], or modifications thereof. 
Several comparative studies of rectal formulations have been performed using the basket, the 
paddle and flow-through methods [58-60]. One of the aims of these studies was to determine 
whether these in vitro dissolution methods established for oral dosage forms, are applicable to 
rectal dosage forms. The dissolution medium used was either water or phosphate buffer (PH 7.4), 
deaerated and maintained at 37 ±0.5°C. Samples were collected manually. In these studies [58-60] 
Apparatus I was used unmodified with a rotation speed of 100 rpm, and a basket of mesh size 0.42 
rnm. Apparatus II, the paddle method, consisted of a stainless steel net (mesh width 1 rnm) placed 
between the paddle and the suppository. A metal helix was used ar~und the suppository to prevent 
it from floating up to the interface of the dissolution medium after insertion into the beaker. The 
rotation speed of the paddle was 50 rpm. The flow through cells used in these studies had a 
diameter of 12 rnm. The flow rate of the non-circulated, deaerated water or buffer was 16 
mllminute, or 8 ml/minute when it was necessary to decrease the flow rate to prevent certain fatty 
bases from clogging the filter. The suppository was placed in the first chamber and an upward 
stream of water flowed past the suppository, through the second chamber, through the filter into 
the collecting bottle. Dissolving suppositories stayed in chamber 1, while melting suppositories 
which are less dense than the fluid, flowed into chamber 2, where the m~lt was collected on the 
top. There was continuous contact between dissolution fluid and melted mass. Unlike the other 
techniques, the agitation was constant throughout the whole experiment. Six suppositories were 
used for each dissolution technique. These methods were used by the authors to determine the 
release of ibuprofen,...paracetamol and dextropropoxyphene. The concentration of drug in the test 
samples was determined spectrophotometrically. 
From these studies [58-60], it could be concluded that the release pattern of drug from different 
suppositories is determined by both composition and dissolution technique. Hydrophilic 
suppositories appear to be less sensitive to the dissolution technique and gave more consistent 
results than the melting suppositories. Therefore the basket, paddle and flow-through techniques 
could be considered equivalent for dissolving suppositories. However, when it was necessary to 
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predict a rank order between different suppository compositions, the basket method proved more 
suitable. The lipophilic suppositories deform and spread, and as the different techniques permit 
various kinds of spreading, different in vitro patterns may result. The drug was more easily 
dispersed by the paddle than the basket. When the basket was used to test dissolution of melting 
suppositories, the melted fat sometimes escaped from the basket through the gap between basket 
and holder, resulting in faster dissolution rates. The different spreading condition~ of the molten 
base in the flow cell show that this apparatus would result in more rapid dissolution than the other 
methods. There is a constant flow of fresh dissolution medium past the melting base, compared 
to the beaker techniques where the volume of dissolution medium was constant. The flow-through 
technique could be applied to all tested compositions, if the flow rate is kept low (0.8 mLiminute). 
The basket, paddle and flow-through methods have been employed by numerous other researchers. 
Kellaway and Marriott [61] used a modified rotating basket apparatus to investigate the release of 
prednisolone from water miscible suppositories made from polyethylene glycol. A rotating basket 
(125 rpm) in a dissolution medium of 2 litres deionised water, maintained at 37 ±0.2 °C was used: 
Samples were withdrawn at intervals from a fixed point in the medium. The release was fo~nd to 
be linear. 
Rosny et al [62] also used a modification of the USP rotating basket to assess the in vitro release 
of ampicillin from various suppository bases. They used a dissolution medium of 200 mL distilled 
water maintained at 37 ±0.5°C. Using this method, the authors were able to demonstrate the ~ffect 
of ageing on various suppository formulations. 
Roseman et al [63] developed a flow-through technique in which the suppository was enveloped 
by a bed of glass beads. This continuous flow bead-bed dissolution apparatus controlled the 
interface exposed for dissolution for th°e fatty suppository bases used in this study, and allowed 
direct contact between suppository and dissolution medium. This proposed bead-bed dissolution 
-
apparatus was claimed to offer an improved means of measuring drug release from suppositories. 
Gjellan et al [53] used a flow-through cell to investigate the in vitro release rate and bioavailability 
of paracetamol and codeine from hard fat suppositories. The dissolution profiles correlated with 
the plasma concentration profiles obtained. The lower tlow rate of 8 mLimin reflected in vivo 
conditions more approximately than the higher rate of 16 mL/min. A change in flow rate indicated 
a change in agitation and amount of vehicle available. The dissolution data seemed to indicate that 
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the rate-controlling step for paracetamol and codeine is the diffusion process through the melt to 
the interface between fat and dissolution medium. 
4.1.3 METHODS UTILIZING MEMBRANES 
One difficulty in testing for drug release from a suppository is that on S,Oftening, melting, 
deformation or disintegration, a non-constant interfacial area is exposed to the dissolution medium. 
The variability of the interfacial area leads to poor test reproducibility, since release rates are 
dependant on this factor. Membranes have been used to limit the surface area, on the supposition 
that when the suppository softens, it will spread over the entire membrane, controlling the area 
exposed to the dissolution liquid. 
Othman and Muti [64] used a dialysis method to investigate the in vitro release characteristics of 
indomethacin from different suppository formulations. Dialysing bags prepared from cellophane 
dialysis tubing (lOOx35 mm) were tied with cotton thread ana soaked overnight in a phosphate 
buffer solution (PH 8). The bags were rinsed twice and filled with 20 mL phosphate buff~r and 
one suppository. The bags were suspended in a 500 mL wide-mouth bottle confaining 400 mL 
phosphate buffer solution. The bottle was placed in a water bath at 37°C and stirred with a 
magnetic stirrer at a slow and constant speed. At time intervals a sample was withdrawn for UV 
spectrophotometric analysis. The dissolution fluid in the bottle was kept constant by addition of 
phosphate buffer after each sample had been taken. 
De Muynck and Reman [65] made use of a dialysis method to determille the influence of fat 
composition on the in vitro release of indomethaCin suppositories. Dialysis tubing was washed with 
boiling water and distilled water. Before use the remaining water was removed and one end of the 
tubing tied. A suppository was inserted and the 5 cm dialysis tube sealed. An 8 g weight was 
connected to the end .and the tubing was immersed in the 900 mL of 0.1 M buffer solution pH 7.2 
-[35] heated to 37 ±0.2 °C which was used as the dissolution medium. The dialysis tubing was 
placed in such a way that the lowest knot was 3 cm above the paddle and 2 cm from the side wall 
of the dissolution vessel. A USP dissolution vessel equipped with a paddle, rotating at 50 rpm at 
a height of 1.5 cm above the bottom of the vessel was used. These researchers [65] used the 
dialysis tubing method as described by Aoyagi et al [66] because the correlation between this in 
vitro method and the bioavailability in rabbits and pigs, as animal models, was found to be good. 
The small amount of water in the rectal compartment and the spreading after melting, according 
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to the surface active properties appear to be quite well simulated by this system. The polyethylene 
glycol (pEG) suppositories behaved quite differently from the fatty bases (Suppocire AP, Mesuro 
PS, Witepsol Hi5). Due to the osmotic effect of PuG the dialysis tubing was filled with dissolution 
fluid. The indomethacin was completely dissolved in the resultant mixture of PEG and dissolution 
medium. This phenomenon was not observed with the fatty suppositories, although the 
indomethacin release was not significantly different from that of the PEG foql1ulation after 480 
minutes. 
Masaru Yamazaki et al [67] used a modification of the dialysis membrane method, in an attempt 
to overcome some of the difficulties which occur when using this apparatus. This revised apparatus 
included a rack assembly made of stainless steel and a 1000 mL tall beaker. The rack assembly 
involved two agitator rings, a bent wire and a hanging clip. The rings were held vertically at 4.5 
cm ip.tervals by the wire. One litre of 0.05 M phosphate buffer was placed in the flask and 
maintained at 37 ±0.2 0c. The dialysis tubing was cut into 17 cm sections, soaked in purified water 
for 24 hours and rinsed. As manual methods had proved ineffu:ient;>a tilm squeegee was used to 
remove any remnant water. Instead of tying the tubing with thread, which wrinkles the end?f the 
tubing and causes the surface area of the tubing to be irregular and the inside liquid at the bottom 
of the tubing not to be stirred satisfactorily, a snap closure was used with a 5 g weight. A 
suppository was placed into the dialysis tubing, which was suspended from the rack assembly. The 
rack assembly was immersed in the beaker and moved vertically, avoiding any horizontal 
movement or deviation of the axis from the vertical. The water pressure expelled any air rem,!iD-ing 
in the tubing. 
Uekama et al [68] examined the in vitro release of morphine from Witepsol Hi5 hollow type 
suppositories, using a suppository release apparatus prepared as described by Muranishi [69]. Each 
suppository was placed in a cylindrical'chamber, which was lined with a 30 /-tm membrane filter 
to eliminate diffusion~of the suppository base. The chamber was lowered into a flask containing 
a degassed, isotonic phosphate buffer maintained at 37°C. The receptor phase was agitated with 
a magnetic stirrer at 100 rpm. A steel rod in the suppository chamber was rotated at 25 rpm. A 
1 mL sample was withdrawn at predetermined intervals from the receptor phase and 1 mL of the 
buffer medium used to replace the sampling volume. The in vitro results correlated with in vivo 
bioavailability in rabbits. 
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4.1.4 COMPARISON OF MEMBRANE AND NON-MEMBRANE METHODS 
Ermis and Tarimci [70] performed in vitro release and diffusion rate tests for ketoprofen in 
polyethylene glycol bases according to the USP XXII basket method [35] and the Muranishi [69] 
method respectively. This study effectively demonstrated the difference between membrane and 
non-membrane methods. In in vitro tests, each suppository was placed in the,ha&ket which was 
lowered into a vessel containing 500 mL phosphate buffer solution, pH 7.2. The basket was rotated 
at 50 rpm at a temperature of 37 ±0.5°C. Samples were withdrawn at set times and assayed to 
obtain a dissolution profile. To compensate for sampling phosphate, buffer was immediately added 
to the dissolution medium. A modification of the Muranishi apparatus [69J was used for diffusion 
rate tests. A suppository was placed in the test solution (PH 7.2 phosphate buffer) in a cylindrical 
cell which was fitted with a 3 mm millipore filter, and stirred with a rod at 25 rpm. The test 
soluti.on in the glass vessel to which the cell was connected was agitated at 250 rpm with a 
magnetic stirrer. Drug release across the membrane was determined spectrophotometrically. 
Release profiles obtained by the basket method and diffusion -rates· {rom the Muranishi method 
differed significantly, as in the Muranishi method the drug had to diffuse across a membrane 'Yhich 
exposed a constant surface area to the aqueous medium. However in the basket method'the drug 
was released directly into the aqueous medium from the surface of the suppository. Both methods 
displayed slower release for lipophilic bases than hydrophilic bases. 
Aoyagi et al [66J investigated inter-laboratory reproducibility of release tests for fatty and :v~ter 
soluble suppositories. For the fatty suppositories (Witepsol) , Muranishi [69J and dialysis tubing 
methods were employed. For the water soluble suppositories (PEG), modified Muranishi [69] and 
paddle methods were used. The Muranishi method was modified such that the suppositories were 
not stirred with a steel rod, and no membrane was used. The release rates from the fatty 
suppositories were determined by a dialysis tubing method in 900 mL of the test medium and in 
500 mL by the Muranishi method. For the dialysis method one of the tube ends was tied, after 
washing in distilled water. The tubing was soaked in test liquid, then used after the test fluid had 
been squeezed out manually. A suppository was placed in the tubing and submerged in 900 mL 
test fluid, with a lead weight. For the Muranishi method, a membrane filter was attached to the 
base of a cylindrical cell, which was immersed in the test fluid. A test suppository was stirred with 
a steel rod at 10 rpm. The test medium in the outer vessel was agitated at 100 rpm. The opinion 
at the end of this study was that while both paddle and modified Muranishi methods may be used 
as a quality control for water soluble suppositories, neither Muranishi nor dialysis methods should 
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be employed for fatty suppositories unless reproducibility is substantially improved. This could be 
explained by the difficulty in achieving the exact set of the Muranishi cell at the specified position, 
and the difficulty in completely removing the test.medium from the dialysis tubing by manual 
methods. In the presence of test fluid, the suppository did not spread well in the dialysis tube thus 
possibly causing a delay in release. 
Vidras et al [71] used the USP rotating basket apparatus (Method A and B) and dialysis (Method 
C) to investigate indomethacin release from various bases. For Method A, a suppository was 
placed in the basket, which was lined with filter paper, and lowered into a vessel containing 600 
mL phosphate buffer, pH 8. The filter paper was used as a barrier to the diffusion of the 
suppository base. The basket was rotated at 100 rpm at a constant temperature of 37 ±0.5°C. The 
same apparatus and conditions were used for method B, except that the suppository was placed in 
a cel.lophane membrane before exposure to the buffer solution. For Method C the dialysing bags 
were prepared from dialysing tubing tied with plastic cord, and soaked overnight in phosphate 
buffer solution. The bags were rinsed twice, filled with 20 mL of byffer solution and a suppository 
and suspended in a 500 mL wide-mouth bottle containing 400 mL phosphate buffer, kept in a 
waterbath at 39±0.5°C and agitated with a magnetic stirrer. In all experiments 5 mL samples were 
withdrawn for analysis, and were replaced with 5 mL phosphate buffer to compensate for 
sampling. The resulting data indicate that the total amount of indomethacin was released about 10 
times faster from the polyethylene glycol base than from the fatty bases, when the USP basket 
apparatus was used. The researchers concluded that the USP apparatus cannot be used to determine 
release from water soluble suppositories without the use of membranes or filter media. The 
inability of the USP dissorution "apparatus to be used with water sol)lble bases led to the 
introduction of membranes to hinder the erosion process. However the use of cellophane 
membranes and the dialysis technique (methods B and C), may represent a further slow step in the 
overall release of indomethacin which may preclude a comparison of techniques. Therefore, 
although a membran~ may control the interfacial area, it does introduce an additional physical 
process of membrane transport, which may mask the real release characteristics of particular drug-
suppository base combinations. 
Fassihi et al [72] made use of a combination of aspects of several methods to determine 
theophylline release rates from polyethylene glycol suppositories. The system incorporated a 
membrane, bead-bed and basket. The basket was modified to keep constant hydrodynamic 
conditions and to provide better and more precise control over the interfacial area for drug 
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dissolution. The setup consisted of a stainless steel 20 mesh screen, chemically resistant glass beads 
of 3-6 mm diameter and a dialysing membrane. After soaking the cellophane dialysing bags 
overnight in distilled water, a suppository and 15 mL distilled water were placed in each. The bag 
was placed in a basket, which was half filled with glass beads, then the rest of the basket was filled 
with beads and the basket was mounted and lowered into the litre beaker containing 500 mL 
distilled water at 37±0.5°C. 
4.1.5 ANIMAL MODELS 
Some investigators have used live tissue, in order to simulate a living system as closely as possible. 
Izgu and Gunger [73] studied the in vitro rate of absorption of paracetamol using isolated rectums 
of rabbits as dialysis membranes. An isotonic buffer solution (100 mL pH 7.4) was placed in a 
special glass funnel which had a heated outer jacket. The terminal 10 cm section of the rabbit colon 
was used. The intestine was tied 0.5 cm from the colon end and a suppository, two glass beads 
and 2 mL of the buffer solution were inserted and the other end ofJhe bag was tied. The dialysis 
bag, which remained viable during the test, was suspended in the buffer solution in the funnel. The 
solution was stirred with a propeller-type stirrer at about 120 rpm. From the Tn vivd'-iil vitro 
correlation obtained, it was concluded that the isolated rectums of albino rabbits can be used 
successfully as dialysis membranes in the investigation and control of formulation parameters of 
suppositories in respect to the absorption characteristics. 
4.1.6 CONCLUSION 
When appraising the suitability of a dissolution test, it is necessary to consider the physicochemical 
properties of the drug as well as the behavioural changes which occur in the rectal dosage form 
in an in vitro method. The release pattern of a drug is influenced by both the suppository 
composition and the djssolution technique adopted. Factors such as flow rate and temperature of 
the dissolution solvent must be considered, as they can influence drug release trends. 
Non-membrane techniques, such as the USP basket, paddle and flow-through cell, appear to be 
equivalent when used to assess hydrophillic suppositories [58,59,60] as these water soluble bases 
are less sensitive to the type of experimental equipment used, than the lipophilic suppository bases, 
and give more consistent results. Vidras et at [71] have suggested that the USP dissolution 
apparatus should be modified with membranes, if they are to be used for hydrophilic suppositories. 
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Lipophilic suppositories deform and spread when subjected to dissolution tests, resulting in 
different in vitro release patterns, because the methods allow various kinds of spreading [58,59,60]. 
The flow-through cell is a more rapid techniquetban the basket or paddle, because of different 
spreading conditions and the constant flow of fresh dissolution medium past the melting base. The 
flow-through cell can be applied to all types of suppository bases, if the flow rate is kept low at 
0.8 mLiminute. 
The results of membrane and non-membrane methods are not always comparable. Membrane-type 
techniques have been employed in an attempt to regulate the interfacial area of the suppository 
exposed to the dissolution medium, when the suppository melts, softens, deforms or disintegrates 
during dissolution testing. Aoyagi et al [66] claim that membrane-based methods such as the 
Muranishi cell and dialysis methods are not reproducible when used to analyze release from fatty 
supp<?sitories, since in such membrane methods, the drug has to first diffuse across the membrane 
before it reaches the test medium. The use of a membrane in a test system introduces an additional 
physical process of membrane transport to the release profile. Oil the-other hand for non-membrane 
methods, such as the basket and paddle, the drug is released directly into the aqueous m~ium 
from the surface of the suppository. It has been postulated [74] that when a membrane is usoo with 
a fatty base, a lipophilic barrier is formed through which the drug has to first diffuse before 
entering the aqueous medium. 
4.2 METHOD 
4.2.1 EXPERIMENTAL 
4.2.1.1 REAGENTS 
Suppositories were m<tnufactured as outlined in Sectio!,! .2.2.2. All other chemicals are listed in 
Section 3.2.1.1. 
4.2.1.2 HPLC SYSTEM 
HPLC analysis was performed on System B (Section 3.2.1.2) using the validated HPLC method 
described in Section 3.3. 
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4.2.1.3 STOCK SOLUTIONS 
Stock solutions were prepared as described in Section 3.2.1.8. 
"~ ~ 
4.2.1.4 CALIBRATION CURVES 
Fresh stock solutions of amoxycillin and salicylic acid were prepared for each analytical run. A 
calibration curve was constructed prior to each dissolution run. Six calibration standards of 0.002, 
0.005, 0.02, 0.05, 0.07 and 0.1 mg/mL were prepared by serial dilution of amoxycillin stock 
solutions. Before making up to volume, salicylic acid was added to each standard to give a final 
internal standard concentration of 0.01 mg/mL. Each calibration standard was assayed six times. 
The linearity of peak height ratio to concentration was established. 
4.2.1".5 PROCEDURE 
Six amoxycillin suppositories formulated with Novata BD, Novata 299, Suppocire A32, Witepso! 
W35 and theobroma were weighed prior to dissolution. The mean mass values are shown. in Table 
4.2. 
The in vitro dissolution of amoxycillin from the suppositories was examined by means of the basket 
apparatus (Apparatus I USP) [35]. 
Based on the recommendations for oral· dosage forms, 900 mL deaerated ~PLC-grade water, at 
37 ±O.5°C, was used as the dissolution medium. The speed of rotation was 100 rpm and the mesh 
width of the basket was 40 mesh. 
The dissolution tests were performed on six separate dosage units for each type of base. Three 500 
~ 
JLL samples of test solution were collected manually aftet5, 10, 15,30,60,90, 120, 180 and 240 
minutes and filtered through a 0.2 JLm filter. 100 JLL of each sample was mixed with 200 JLL of 
the internal standard solution. The amount of dissolved amoxycillin was quantitated by the 
validated HPLC method described in Section 3.3, with UV detection at 230 nm. 
The suppositories were tested within one week of manufacture, and again at one month, to 
determine whether ageing had an effect on the amount of drug released from the suppositories. 
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A mass balance was carried out on each suppository melt remaining in the baskets after the 240 
minute dissolution run, in order to assess and account for any drug that had not been released from 
the base and dissolved during the dissolution test.~e basket containing the melt was left to stand 
in a beaker containing 200 mL water, kept at approximately 40°C for 10 minutes, until the base 
had remelted. The contents of the beaker were then sonicated (Ultrasonic Cleaner, Model 8845-30, 
Cole-Parmer Instrument Company, IIIanois, USA) to dissolve any amoxycillin before the base 
~ - ~ 
resolidified. An aliquot was removed and tiltered through a 0.2 /-Lm filter. A 0.1 mL sample was 
then mixed with internal standard solution and made up to 10 mL with water and an aliquot was 
analyzed in triplicate. 
4.2.1.6 STATISTICAL INTERPRETATION OF THE DATA 
The statistical method of Timm et al [52], as described in Section 3.3.2.9, was adapted for the 
purposes of this dissolution study, in order to determine whether ageing had an effect on the 
release characteristics of amoxycillin from the suppository bas~s. .. 
4.2.2 RESULTS 
4.2.2.1 LINEARITY AND CALIBRATION CURVES 
Calibration curves were constructed as described in Section 4.2.1.5 and linearity was established 
over the concentration range 0.005 to 0.1 mg/mL on each day that a different type of suppository. 
was studied. The linearity data are described in Table 4.1. 
Table 4.1 
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Linearity data from calibration curves constructed for each types of suppository 
base assayed 
Suppository Slope Y -intercept Correlation 
Assayed Coefficient 
t=O months 
Novata BD 39.4349 -0.0042 0.99935 
Novata 299 41.2065 0.0020 0.99999 
Witepsol 41.3188 -0.0018 0.99996 
Suppocire 38.4954 0.0151 0.99923 
Theobroma 36.1980 0.0062 0.99995 
t=l month 
Novata BD 36.3844 0.0275 0.99990 
Novata 299 41.1459 0.0239 0.99515 
Witepsol 36.3844 0.0275 0.99990 
Suppocire 41.1459 0.0239 0.99515 
Theobroma 40.2583 0.0238 0.99981 
4.2.2.2 AMOUNT OF DRUG RELEASED FROM SUPPOSITORIES 
The mean masses of the suppositories used in the dissolution tests are listed in Table 4.2. 
Table 4.2 Mean mass of suppositories used for dissolution tests 
Suppository . t=O months t=l month 
Mean Mass (g)± SD Mean Mass (g) ± SD 
(n=6) (n=6) 
Novata BD 1.13 ± 0.01 1.13 ± 0.02 
Novata 299 1.13 ± .0.02 1.11 ± 0.01 
Witepsol 1.12 ± 0.00 1.14 ± 0.01 
Suppocire 1.12 ± 0.02 1.13 ± 0.02 
Theobroma 1.13 ± 0.01 - 1.05 ± 0.08 
The amount of amoxycillin released from each suppository during the 240 minute dissolution 
period was calculated for both the freshly made and the one month old suppositories, and the 
results have been summarised in Table 4.3. 
Table 4.3 
Time 
(min) 
t=O months 
0 
5 
10 
15 
30 
60 
90 
120 
180 
240 
Mas.s 
balance 
% Total 
drug* 
t=1 month 
0 
5 
10 
15 
30 
60 
90 
120 
180 
240 
Mass 
balance 
% Total 
drug* 
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Mass of amoxycillin released from suppository bases within 240 minutes, at t=O 
and t= 1 month 
Mean Mass (mg) ± SO (n=3) 
Novata DO Novata 299 Witepsol W35 Suppocire A32 Theobroma 
- -
~ 
0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
18.90 ± 4.55 10.35 ± 1.87 7.35 ± 1.05 1.35 ± 1.24 2.25 ± 0.75 
45.45 ± 6.61 24.00 ± 3.20 17.70 ± 2.71 3.30 ± 3.05 4.50 ± 0.99 
90.45 ± 6.61 43.35 ± 6.17 28.35 ± 2.40 5.55 ± 4.24 6.00 ± 1.09 
141.15 ± 16.67 82.20 ± 23.97 54.75 ± 10.79 10.20 ± 8.44 9.00 ± 1.14 
170.70 ± 17.16 120.45 ± 27.37 92.85 ± 18.46 29.85 ± 24.67 14.10 ± 1.77 
201.15 ± 14.07 145.35 ± 33.34 106.80 ± 20.03 52.95 ± 44.76 16.50 ± 2.18 
203.85 ± 10.89 201.15 ± 32.48 108.90 ± 21.52 77.85 ± 63.58 18.00 ± 1.51 
205.65 ± 9.77 198.75 ± 34.10 114.75 ± 25.25 111.00 ± 71.09 20.25 ± 1.48 
218.93 ± 20.45 213.00 ± 41.10 126.30 ± 30.78 111.00 ± 71.09 22.05 ± 1.87 
8.61 ± 6.67 48.33 ± 16.64 89.13 ± 19.65 120.83 ± 54.44 220.53±21.90 
91% 104% 86% 92% 97% 
-
-
0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0:00 
-
15.60 ± 1.23 13.05 ± 0.94 6.60 ± 1.09 5.13 ± 0.03 1.32 ± 0.58 
37.35 ± 4.21 26.25 ± 1.84 14.10 ± 1.35 7.52 ± 0.16 3.28 ± 0.18 
64.35 ± 9.94 39.30 ± 0.73 21.90 ± 0.93 8.73 ± 0.07 5.11 ± 0.49 
150.60 ± 24.42 71.55 ± 3.36 44.55 ± 1.68 10.47 ± 0.09 9.28 ± 1.63 
219.30 ± 17.41 123.00 ± 3.45 62.55 ± 2.03 12.94 ± 0.32 17.13 ± 4.64 
223.20 ± 20.43 147.75 ± 4.64 67.95 ± 3.97 15.83 ± 0.04 21.90 ± 6.16 
232.80 ± 18.26 168.30 ± 4.59 74.40 ± 3.54 17.56 ± 0.89 25.03 ± 6.80 
232.80 ± 18.12 170.70 ± 4.61 76.95 ± 3.89 19.35 ± 0.03 28.98 ± p"42 
248.15 ± 23.90 186.30 ± 7.91 79.95 ± 6.56 19.91 ± 0.01 29.27 ± 9.85 
12.45 ± 14.18 60.89 ± 7.85 154.77 ± 23.58 203.28 ± 6.16 206.97±20.40 
104% 99% 94% 89% 94% 
* % Total drug = 100(Mass of drug released by 240 minutes + Mass balance)/250. 
In vitro release dissotution profiles from the various b~~es are shown in Figures 4.1-4.5. In the 4 
hour dissolution of newly made suppositories, 87.57 ± 8.18 % amoxycillin was released-from the 
Novata ED base, 85.20 ± 16.42 % from the Novata 299, 44.40 ± 28.43 % from the Suppocire 
A32, 50.40 ± 12.31 % from the Witepso[ W35 and 8.82 ± 0.75 % from theobroma oil. When 
one month old suppositories were tested, 99.66 ± 6.63 % was released from Novata ED, 74.52 
± 3.16 % from Novata 299,7.98 ± 0.27 % from Suppocire A32, 31.98 ± 2.07 % from Witepsol 
W35 and 11.22 ± 4.04 % from theobroma oil. 
83 
The amount of drug which was recovered when a mass balance was performed approximately 
accounted for the amoxycillin which was not released from the suppository bases during the 
dissolution period of 240 minutes, as shown in Table 4.3. In total, 91 % and 104% of the drug in 
the Novata BD new and old suppositories respectively was accounted for, 104% and 99% of the 
drug in the Novata 299, 86% and 94% of the drug in the Witepso! W35, 92 % and 89% of the drug 
in the Suppocire A32 and 97% and 94% of the drug in the theobroma suppositgr:ieS. 
The statistical method used by Timm et a! [52] to describe stability data was adapted to describe 
the change in the amount of amoxyci\lin present in the different suppositories from the time of 
manufacture (t=O months) to one month later (t= 1 month). This is represented in Figure 4.6 as 
the percent change from initial amount of amoxycillin released during the 240 minute dissolution 
period. 
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4.2.2.3 DISCUSSION 
The different brands of semisynthetic bases showed different dissolution profiles. Each !>~and 
contains an unique combination oftri-, di- and mono-glycerides which confer certain characteristics 
to that base. The nature of the base clearly has an effect on the dissolution rate and the amount of 
drug which is released. Theobroma, being primarily a mixture of fatty acid triglycerides, also 
shows a different dissolution profile. 
It would appear that tke hydroxyl value of a suppository base is of some significance to the release 
-
of the drug from a suppository. This finding is consistent with that of Othman and Muti [.64]. The 
synthetic suppository bases are mixtures of fatty acid esters with certain amounts of glycerides. The 
hydroxyl value of a base is determined by the presence of mono- and diglycerides and therefore 
represents the availability of free hydroxyl groups. The potential reactivity of a base is usually 
indicated by the magnitude of its hydroxyl value, with a high hydroxyl value indicating that the 
base can adsorb water more readily and is therefore less suitable for formulations containing drugs 
that are easily hydrolysed [8]. Amoxycillin, which is susceptible to hydrolysis may interact with 
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these hydroxyl groups and degrade. 
Drug release from bases with lower hydroxyl values,(eg the Novata bases) was shown to be faster 
and more complete than from those with a higher hydroxyl value (Figures 4.1 and 4.2). These 
results could be accounted for on the basis of simple partitioning between aqueous and lipid phases 
[64]. The partitioning of the drug when using bases with high hydroxyl vlPue~, such as the 
Witepso[ and Suppocire (Figures 4.3 and 4.4), appears to favour the lipid phase. 
Consideration of hydroxyl value alone could not account for these dissolution results however, 
since Novata BD, despite having a higher hydroxyl value than Novata 299, showed a slightly 
higher rate and extent of release. Examination of the melting point showed that Novata BD has a 
slightly lower solidification point (30-32°C) than Novata 299 (31.S-33.3°C), which could result 
in a faster release of the drug [64]. 
On prolonged storage, semi-synthetic suppository bases have been shown to be subject to hardening 
and lengthening of the melting time [8]. The degree of hardening may be remedied by stor~ge in 
a cold place, but melting characteristics, hardness and drug release profiles alter with time, and 
the melting point may rise by O.5°C after storage for several months [33]. Storage can thus result 
in a marked reduction in drug release from suppositories [62] and this effect is more pronounced 
in those bases which have a very low hydroxyl value. This could explain, in part, why after 
storage for a month, less amoxycillin was released when Novata 299, with a hydroxyl value_of ::; 
S was used, whereas the amount of amoxycillin released from Novata BD, which has a hydroxyl 
value of ::; IS, increased. 
The greatest quantity of amoxycillin released in 240 minutes was released from the Novata bases, 
and the release rate for the first hour of dissolution was also highest with these bases. Both newly 
prepared and aged Novata bases showed a rapid release and dissolution of drug over the first 60 
minutes, then the drug seemed to be retained in the matrix and released at a slower rate between 
1 and 4 hours. Within the first hour of dissolution, 68% of the drug in the fresh Novata BD 
suppositories had dissolved, 88% from the aged Novata BD suppositories and almost SO% from 
both fresh and aged Novata 299 suppositories. No more than 40% was released from the Witepso[ 
suppositories and the fresh Suppocire suppositories, while not even 10% of the drug in the 
theobroma suppositories and the aged Suppocire suppositories was dissolved within the same time. 
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4.2.3 CONCLUSION 
The USP basket apparatus was successfully used to compare the release of amoxycillin from 
Novata ED, Novata 299, Witepso[ W35, Suppocire A32 and theobroma suppository bases. This 
in vitro assessment of the suppositories enabled the identification of the base with the best release 
characteristics. The Novata bases showed the highest rate and extent of drug-release over the 
dissolution period. For this reason these bases were considered to be most appropriate for the 
formulation of a paediatric amoxycillin suppository. 
CHAPTER FIVE 
DIFFERENTIAL SCANNING CALORIMETRY 
5.1 INTRODUCTION 
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Differential Scanning Calorimetry (DSC) is a technique of thermal analysis in which the difference 
in energy inputs into a substance and reference material is measured as a function of temperature, 
whilst the substance and reference are subjected to a controlled temperature programme [75]. DSC 
has been recognised for its usefulness in the pharmaceutical field, where it is used in the 
determination of melting and boiling points, stability and drug-excipient compatibility, thermal 
kinetic parameters, drug purity and detection of polymorphism. 
5.1.1 USES OF DSC 
5.1.1.1 DETERMINATION OF INCOMPATIBILITIES WITHIN A FORMULATION 
One of the factors on which the stability of a formulation depends, is the compatibility of the active 
drug with the other components of the mixture. The formulation of a stable and effective dosage 
form requires careful selection of the excipients used to facilitate administration, promote constant 
release and bioavailability of the drug and to protect the active moeity from the environment. 
Although usually regarded as inert; excipients can readily interact with drugs and affect the solid 
state stability of a drug, either directly as a chemical reaction between the drug and excipients or, 
most often, indirectly by adsorption of moisture and/or catalysis [76]. The evaluation of drug-
excipient compatibility is therefore an essential aspect of any preformulation study prior to large 
scale development trials, thereby improving the efficiency of dosage form development. 
~ 
In preformulation studies it is possible to derive information about potential physical or chemical 
incompatibilities between the active ingredients and the so-called inert excipients. These reactions 
mayor may not lead to the inactivation of the active ingredient in the formulation. Additional 
information regarding the effects of storage at elevated temperatures, the necessary 
physicochemical parameters of a drug substance, its kinetic rate profile and physical characteristics 
can also be obtained. The identification of hygroscopic differences during preformulation is also 
important, as moisture is considered to be the most deleterious environmental factor causing 
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instability in solid dosage forms. 
Ideally the method used should be relatively fast and require only small amounts of drug substance. 
Results should enable accurate prediction and be easily interpreted [77]. Unless an incompatibility 
is obvious, it is necessary to carry out stability studies that usually take weeks or months. The two 
commonly employed compatibility screening techniques are quantitative assay- after isothermal 
stress testing of drug-excipient mixtures, and thermal analysis using either DSC or differential 
thermal analysis (DTA) [78,79]. 
Thermal analysis has significant advantages over the conventional technique of isothermal stress 
testing [80]. No long term storage of mixtures and subsequent chromatographic analysis is 
required, and only a few milligrams of drug are needed per individual experiment. Thermal 
analysis can therefore be valuable during the early stages of a preformulation programme where 
time is of the essence, only small amounts of drug are available or no chromatographic methods 
of analysis have been developed. Using thermal analysis it is pGssible to obtain stability data 
rapidly. 
According to the literature [76,78,79,81], DSC has become one of the screening methods of first 
choice for studying drug-excipient interactions since it allows the fast evaluation of possible 
incompatibilities within the formulation derived from appearance, shift or disappearance of melting 
endotherms or exotherms and/or variations in the corresponding enthalpy [76]. In general DS_C can 
distinguish between those excipients that are unlikely to cause problems and those that may cause 
problems in the formulation. This allows a more rational approach to be established in early 
formulation designs. 
DSC data may be used to predict compatibility from the differences in the heats of melting of the 
drug alone and in a mixture with excipients [77]. The method assumes that when an incompatibility 
occurs, the melting peak area and heat of melting of drug in the mixture will be decreased. The 
melting peak and heat of melting stay the same if the drug-excipient mixture is compatible. The 
potential for incompatibility is proportional to the decrease in the heat of melting. 
Thermal analysis does not replace the chemical methods for determination of the concentration of 
a drug in a dosage form or stability tests involving long-time observation. It does however 
represent a valuable tool in the first step of a formulation since it can provide an early alert to 
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compatibility problems and indicate the best direction to pursue for a successful dosage form 
[76,78,81]. 
There are however a lot of problems associated with DSC which do not make the technique 
applicable on its own. It must be kept in mind that the results of such tests may have no or hardly 
any connection with results under normal conditions. Predictions are diffic,ult ~s degradation 
reactions or transformations shown in accelerated thermal analyses may not appear at all at room 
temperature [78]. Several workers have found that the results obtained by DSC screening are not 
conclusive and frequently require further investigation. Reasons for this include the unrealistically 
high temperatures and heating rates used, the lack of moisture stress and difficulty in interpreting 
thermograms [77,78,80]. The shortcomings of DSC are the inability to give good estimates of the 
extent and significance of the destabilizing effects and the inability to determine stabilizing effects. 
An additional disadvantage of DSC screening is the uncertainty as to whether or not the observed 
interaction is chemical in nature. 
Several researchers have suggested that to substantiate DSC findings, other more direct and 
conclusive techniques have to be used in conjunction, such as the quantitative assay 6fmixtures 
of the active ingredient after isothermal stress tests [78,80,82]. In its simplest form, isothermal 
stress testing involves the exposure of binary drug-excipient mixtures to elevated temperatures and 
moisture levels to accelerate drug aging and drug-excipient interactions [80]. After a specific 
storage time, the samples can then be analyzed by visual comparisons as well ,!s_ by 
chromatography. 
In summary DSC can be used as a quick screening tool for preformulation studies to study the 
potential incompatibilities of ingredients in the solid state. 
5.1.1.2 PURITY DETERMINATION 
DSC provides a rapid and accurate method for purity determination. However it is limited to those 
compounds that do not decompose on melting. There is also the possibility that the impurity may 
form a solid solution and thus invalidate the analysis [83]. 
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5.1.1.3 IDENTIFICATION OF SOLVATES 
During the process of crystallization, solvent may 'become incorporated into the crystal structure. 
Hydrates form when water is the solvent of crystallization. Water is a highly polar molecule and 
can therefore interact strongly with ions or polar molecules by ion-dipole or dipole-dipole 
interactions respectively. Due to such interactions, water may become adsorbed ooto the surface 
of a crystal or may occupy a position within the lattice. 
The presence of solvent in the crystal structure usually modifies the pharmaceutical properties such 
as solubility, dissolution rate, bioavailability, chemical stability, powder flow and compaction. 
Therefore the characterization and analysis of the solvent of crystallization are important in 
preformulation studies [84]. 
DSC has been widely used for the identification of solvates. The desolvation endotherm in DSC 
includes such steps as the breakage of the solvate bonds and ¥apl}rization of the solvent. Upon 
desolvation the crystal structure may rearrange through the breakage and formati()p of 
intermolecular forces which include van der Waals interactions and/or hydrogen Donds;ln which 
case the rearrangement of the desolvated structure will also be included in the desolvation process. 
The area under the desolvation peaks in the DSC curve yields the enthalpies of the desolvation 
transition [84]. 
5.1.2 INTERPRETATION OF RESULTS 
When two substances are mixed, the purity of each may be reduced and generally broader, slightly 
lower melting endotherms result. If the curve of the mixture is a simple superposition of those of 
the single components, an incompatibility is highly improbable. If the solid-solid interaction is 
extremely weak or non-existent, the reduction of the melting point is usually inconsequential. On 
the other hand, any large shift in melting point signifies that a strong solid-solid interaction has 
occurred, although it does not necessarily indicate an incompatibility [76,80]. 
A peak which is smaller than anticipated could be indicative of an interaction while extra thermal 
effects, or a component peak which has disappeared completely may also indicate incompatibility. 
If one of the components degrades before the melting point of the other one it may be possible that 
the latter substance reacts with the decomposition products. More reliable conclusions can be made 
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if duplicate samples of the mixtures are stored in the DSC holders at elevated temperatures for a 
few weeks [78]. 
5.1.3 DSC FOR SUPPOSITORIES 
DSC is useful as a support technique for the development of suppositories. Tbe development of 
procedures as both predictive and ongoing physical stability tests, for both bases and formulated 
products, can be undertaken. The initial choice of the suppository base is easily made with DSC. 
The checking of manufacturing reproducibility is also efficient. Furthermore the identity and 
uniform distribution of the drug substance may be determined [85]. 
The ideal melting point for suppositories is approximately 32°e. Triglyceride suppository bases 
generally exhibit a broad, irregularly shaped DSC endotherm peak at around 30-38°C. This peak 
corresponds to the melting temperature of the base. The broad shape is attributed to the fact that 
the triglycerides are a heterogenous mixture of compounds >{)f s.imilar properties, but with a 
pol ydisperse molecular mass distribution [81]. 
Fatty suppositories are complex mixtures with different crystalline modifications, and undergo slow 
transitions into the higher melting form during storage. Elevation of melting ranges and large 
increases in melting times of suppositories after storage result in a reduction of the release rate of 
drug in vitro and an unpredictable response in vivo [8,62]. If the melting point of the J!lass 
increases to above 37°C, this may lead to products which become ineffective on storage. The 
hardening effect which may result in little or no suppository melting, can cause local irritation, a 
defaecatory reflex, or bowel obstruction [86]. 
As the suppositories age, some endotherms reduce in size or disappear and are replaced by others 
due to the decomposil>ion products. Storage for a short time at elevated temperatures successfully 
simulates the effects of ageing on the DSC thermograms. Comparing the results oftherma~ analysis 
with physical hardening data allows prediction of shelf-life hardening [86]. 
5.2 THE APPLICATION OF DSC TO AMOXYCILLIN SUPPOSITORIES 
In this investigation, DSC was used as a rapid screening tool during the preformulation studies of 
amoxycillin suppositories, in order to detect potential interactions and incompatibilities between 
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amoxycillin trihydrate and the semisynthetic bases which were used to formulate amoxycillin 
suppositories. 
5.2.1 EXPERIMENTAL 
5.2.1.1 REAGENTS 
Amoxycillin trihydrate, compacted (Clinimed, East London, RSA), the Novata BD, Novata 299, 
Witepso[ W35 and Suppocire A32 suppository bases described in Section 2.2.1 and amoxycillin 
suppositories from the batches manufactured for dissolution testing (Section 4.2.1.1) were used in 
the DSC analysis. 
5.2.~.2 PROCEDURE 
Tests were carried out on each of the unformulated suppository_bases, amoxycillin trihydrate 
powder, freshly manufactured suppositories, suppositories which had been stored at room 
temperature for one month and physical mixtures of unmelted base and drug. The whole 
suppositories and flakes of base were size reduced with a stainless steel blade. Physical mixtures 
were made up by homogenizing amoxycillin powder with base, using a blade, in a ratio of 1 to 
3, which was the ratio of drug to base in the suppositories. 
A Perkin-Elmer DSC7 Differential Scanning Calorimeter (Norwalk, Connecticut, USA) was used 
to investigate the thermal properties of the suppository bases and amoxycillin. The instrument was 
calibrated using indium and all experiments ran at a rate of lOoC per minute. 
Samples weighing between 8 and 12 mg' were placed in aluminium pans and compared to an empty 
reference pan. The aluminium sample pan lids were not crimped in place, but were placed loosely 
on top of the sample pan. The test runs were carried out at a rate of lOoC per minute, over a 
temperature range of 50°C to 200°C under nitrogen purge. 
5.2.2 DSC RESULTS 
Figures 5.1 and 5.2 illustrate examples of the DSC thermograms obtained after heating various 
samples from 50°C to 200°C. 
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Figure 5.1 DSC thermograms of amoxycillin trihydrate and Suppocire A32 suppository base 
(a) amoxycillin trihydrate powder 
(b) one month old amoxycillin 
suppository 
(c) suppository base 
(d) physical mixture of amoxycillin 
and base 
(e) newly manufactured amoxycillin 
suppository 
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Figure 5.2 DSC thermograms of amoxycillin trihydrate and Novata J?D suppository base 
(a) amoxycillin trihydrate powder 
(b) one month old amoxycillin 
suppository 
(c) suppository base 
(d) physical mixture of amoxycillin 
and base 
(e) newly manufactured amoxycillin 
suppository 
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Amoxycillin trihydrate exhibited a broad endotherm, which peaked at approximately 120°C (Figure 
5.1(1a) and 5.2(1a». 
The broad, irregular endotherm, occurring from 30°C to 38°C, which is typical of semisynthetic 
suppository bases [81] was not obvious in these thermograms, because of the limitation of the 
instrument not to respond to temperatures below 40°C. The unformulated suppository bases did 
~ - ~ 
not produce any endotherms beyond 40°C when analyzed (Figure 5. 1 (IIc) and 5.2(IIc». 
The physical mixtures of amoxycillin and suppository base exhibited a single endotherm peak at 
approximately 150°C in the case of the mixtures containing Suppocire A32, Witepso[ W35 and 
Novata 299, illustrated in Figure 5. 1 (IIId) , whereas the mixture containing Novata BD exhibited 
an endotherm at approximately 130°C as well as an endotherm at approximately 150°C, illustrated 
in Figure 5.2(IIId). 
All of the freshly made amoxycillin suppositories exhibited a siqgle,)rregularly shaped endotherm, 
which occurred at 150°C. This endotherm was roughly superimposable over that of the physical 
,-
mixture. In comparison, the amoxycillin suppositories which had been stored for a month exhibited 
an additional, lower melting point endotherm. Figures 5.1(IV) and 5.2(1V) are typical examples 
of these endotherms. 
5.2.3 DISCUSSION 
The endotherms which resulfed when the physical mixtures of amoxycilli~ and suppository base 
and the amoxycillin suppositories were analyzed suggest a number of possible alternatives. These 
DSC results could indicate degradation of amoxycillin or suppository base, or an interaction 
between amoxycillin and suppository base, or a transformation in the polymorphic form of 
amoxycillin. 
The single broad endotherm of amoxycillin trihydrate (Figures 5.1 (Ia) and 5.2(la» and the absence 
of endotherms in the results from the unformulated bases (Figure 5.I(Ic) and 5.2(1c)) suggest that 
the separate and individual degradation of these substances under DSC conditions was not 
responsible for the endotherms which resulted when these substances were combined. 
When amoxycillin and a suppository base were combined in a physical mixture, melting 
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endotherms appeared and possibly shifted, indicating a conceivable interaction between these 
compounds. Such an interaction may have resulted in degradation of the amoxycillin, explaining 
the shift in the endotherm at 150 0 e (Figures 5<.1.(III) and 5.2(III», and the slightly smaller 
endotherm at 120 0 e (Figure 5.2(III». 
The theory of an interaction between the drug and the suppository base is supported by the fact 
r - ~ 
that the melting endotherms of an amoxycillin suppository were further altered by ageing of the 
suppository (Figure 5.1(iv) and Figure 5.2(iv», suggesting increased interaction on storage. Each 
of the newly manufactured amoxycillin suppositories exhibited an endotherm at approximately 
150 o e, while the suppositories that had been stored for a month exhibited an additional endotherm 
at approximately 120o e. 
If these results do indicate an interaction between drug and base, this interaction may be due to 
a chemical reaction, such as a reaction between the free hydroxyl groups of the suppository base 
and reactive functional groups on the amoxycillin molecule, or Jt meY be catalyzed by the elevated 
temperatures of the DSe analysis. 
It is known that on storage, the semisynthetic suppository bases generally exhibit higher melting 
times and increased melting ranges due to hardening of the bases [81]. The difference between the 
endotherms of a newly manufactured suppository and one which has been stored for some time 
could be due to some endotherms becoming smaller or disappearing, to be replaced by others due 
to decomposition products. 
Finally, the shift in endotherm may be due toa change in the crystalline form of amoxycillin, 
caused by an interaction between amoxycillin and the base. 
While the shift in elldotherm signifies that either degradation, transformation or some sort of 
interaction has occurred, it does not necessarily indicate- an incompatibility. When the DSe results 
are compared with the results of the in vitro release experiments, it becomes apparent that a 
reaction or interaction which has occurred during storage, has caused a change in the amount of 
drug released from each type of suppository. The hypothetical interaction or reaction may have 
been favourable, as in the case of Novata BD, where drug release improved on storage (from 87% 
to 99 %); or it may have been unfavourable, as in the case of Novata 299, Witepso! W35 and 
Suppocire A32, where the amount of drug released decreased on storage (85% to 74%, 50% to 
99 
31 %, and 44% to 7% respectively). Although not obvious in the DSC results, these latter bases 
with many free hydroxyl groups could have interacted more readily with amoxycillin. The potential 
interaction did not cause degradation of the amoxyciHin, as approximately 100% of the drug was 
accounted for. 
The greater the stress to which a sample is exposed, the greater is the risk of alteriRg that sample. 
The interactions or transformations which were seen under the accelerated conditions therefore may 
not be comparable with the results that occur at room temperature, since these results may not 
appear at all under normal conditions. 
5.2.4 CONCLUSION 
Thermal analysis proved useful for the determination of possible interactions or reactions between 
amoxycillin and semisynthetic suppository bases. However the fact that the transformations or 
interactions which occur under accelerated conditions are not n~essarily comparable with the 
results that occur at room temperature, should be kept in mind when interpreting the result~. 
When analyzed separately, amoxycillin and the suppository base do not degrade under DSC 
conditions. However in a physical mixture of drug and base, the shift of the amoxycillin endotherm 
from 120°C to 150°C illustrated in the DSC results indicates that some sort of interaction occurs 
between amoxycillin and the suppository bases under accelerated thermal analysis. Degradat!o_n or 
another polymorphic form of the drug may be occurring as a result of this interaction. 
An interaction between substances generally results in a decrease in size and melting point of an 
endotherm, but an interesting result was the development of a large, second endotherm. The 
appearance of this second endotherm may be interpreted to support the change, after storage for 
a month, in drug release from the various suppositories during dissolution testing. This endotherm 
may indicate an interaction between the suppository base and amoxycillin. This interaction may 
be favourable and result in improved drug release, as in the case of the Novata BD suppositories, 
or it may be unfavourable and cause decreased drug release, as was observed with the Novata 299, 
Witepso! W35 and Suppocire A32. 
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CHAPTER SIX 
DETERMINATION OF AMOXYCILLIN IN BIOLOGICAL FLUIDS 
6.1 INTRODUCTION 
The analysis of amoxycillin in biological samples requires a selective, sensitive, accurate and rapid 
technique. The antibiotic may be present in a complex biological matrix of plasma, serum, urine, 
tissue or bile from which its concentration must be selectively determined [34]. The optimal 
antibiotic level should exceed the minimum inhibitory concentration by as large a margin as 
possible to ensure that a sufficient level of antibiotic is present in infected tissues. Routine 
monitoring of antibiotics generally involves quantitation of drug levels in the microgram 
concentration range, as the administered doses are high and antibiotics are generally metabolized 
to only a small extent [34]. An analytical technique must be sensitive enough to determine drug 
concentrations in this range. Pharmacokinetic and other in vivo studies generate a large number 
~ -..;...-
of samples which necessitates the development of an assay method with a high sample throughput 
requiring a minimum of supervision for routine determinations. The choice of a metho.gshould 
ultimately be determined by these considerations as well as an evaluation of factors such as the 
stability and recovery of the compound of interest and the precision of the assay. 
Several methods used to monitor amoxycillin have been discussed in Section 3.1.1. The 
conventional method of monitoring antibiotics in body fluids has been microbiological assay [1,2]. 
However, the microbiological assays available are tedious and have limited selectivity, specificity 
and accuracy at lower concentration levels. These considerations have prompted the development 
of other methods for the assay of antibiotics such as immunoassays, gas-liquid chromatography, 
high performance thin layer chromatography, derivative spectrophotometry, spectrophotometry and 
fluorimetry [34,86]. 
These methods are seldom used since HPLC has proved to be superior in terms of selectivity, 
sensitivity, accuracy, speed of analysis and specificity. 
6.1.1 HPLC ANALYSIS OF AMOXYCILLIN IN BIOLOGICAL FLUIDS 
Perusal of the literature has revealed that HPLC has been used increasingly for the determination 
of antibiotics in body fluids as it is uniquely suited to the separation of closely related compounds 
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when compared to nonselective techniques such as bioassays and immunoassays. HPLC permits 
the simultaneous assay of a drug, its prod rug or its metabolites, whether they are active or inactive 
[87]. This allows direct comparison of pharmacokinetics or penetration into tissues following drug 
administration [34]. HPLC has unlimited potential; it can deal with a variety of drugs, and both 
low and high molecular weight compounds. Reversed phase chromatography, which is most 
commonly used, affords a great selectivity by the choice of the mobile phase _composition and 
column packing type. 
However, HPLC does have a limited capacity as samples cannot be concurrently assayed, as with 
bioassays and immunoassays [34]. Sample cleanup is required in most instances, so that the drug 
is extracted from the biological matrix. A further shortcoming is the lack of versatility when 
different drugs have to be regularly analyzed as changing from one method to another takes some 
time .. Furthermore HPLC requires expensive equipment, although this is partly compensated by 
its low running costs [34]. 
Numerous HPLC methods have been described for the analysis of amoxycillin in biological ~uids 
(Table 6.1) [34]. Using UV detection, limits of quantitation of 0.5 jLg/mL and lower h<ive been 
determined in plasma, serum and urine [42,43,49,89-91]. 
To improve assay performance and obtain lower limits of detection, pre- or post column 
derivatization has been used [92-94], as well as column switching [94] and ion pairing [43,94_-~6]. 
Amoxycillin does not have intrinsic fluorescent properties, but post-column derivatization with 
fluorescamine allows fluorescent detection to be used [92,94]. These HPLC derivatization methods 
are sensitive and specific, but require lengthy sample workup and often complex instrumentation. 
The selection of adequate separation for HPLC analysis of a compound is dependent on the polarity 
and ionizable functionlll groups of the drug, and the biological matrix from which the drug is to 
be separated. The chromatography of amoxycillin has been performed on C8 and CI8 alkyl bonded 
phases with mixtures of acetonitrile or methanol and phosphate buffers as the mobile phase. A 
summary of selected methods is shown in Table 6.1. The organic modifier content in the mobile 
phase depends on the polarity of the drug and on the type of reversed phase packing. The choice 
of pH for the extraction technique and separation stages is critical. The pH of the buffer component 
of the mobile phase is a determinant in the retention of ionizable drugs. 
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Table 6.1 Examples of HPLC methods used for in vivo analysis of amoxycillin 
Ref Body fluid or Sample treatment Stationary Mobile phase Derivatization A (om) Limit of 
tissue phase detection 
42 Chinchilla middle Perchloric acid precipitation C8 MeOH-phosphate buffer - UV 230 0.5 Ilg/mL 
ear fluid, plasma 
~ 
pH 3-AcN 
43 Plasma Baker-1O C 18 SPE cartridge, C I8 MeOH-phosphate buffer - UV 229 0.1 Ilg/mL 
IPA pH 6-IPA 
89 Plasma Sep-Pak C I8 SPE cartridge C8 MeOH-phosphate buffer - UV 225 0.5 Ilg/mL 
pH 7 
90 Plasma, saliva, Perchloric acid precipitation C8 MeOH-phosphate buffer - UV 225 0.5 Ilg/mL 
unne pH 4.6 I 
91 Plasma, middle Bond-Elute C I8 SPE C8 AcN-phosphate buffer pH - UV 210 Q, 125 Ilg/mL I 
ear fluid cartridge 5-IPA 
: 
92 Urine ' .. Dilution CI8 MeOH-acetic acid Post-column Fluorescence 2.5 Ilg/mL 
I 
fl uorescamine 3951485 I 
93 Plasma, urine Perchloric acid precipitation, C8 MeOH-phdsphate buffer Post-column UV 310 0.025 Ilg/mL 
I dichloroethane pH 8 ~ . imidazole and 
mercuric chloride J 
94 Plasma, urine Perchloric acid precipitation CI8 MeOH-phosphate buffer Column Fluorescence 0.01 Ilg/mL 
I (plasma) pH 7.4-IPA switching, post- 372.51470 
column 1 
fl uorescamine 
, 
95 Urine Dilution, filtration CI8 MeOH-phosphate buffer- Post column UV 270 1 Ilg/mL 
IPA degradation with 
1 " 
sodium 
hypochlorite 
- ----- ----
~-.- .. -_ .. _-- ~----.-L-_~ __________ ._. 
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Table 6.1 Continued 
Ref Body fluid or Sample treatment Stationary Mobile phase Derivatization A (run) Limit of 
tissue phase detection 
96 Bovine milk Dilution Phenyl AcN-MeOH-phosphate buffer- - 200-340 UV 100 ppb 
~ IPA photodiode 
array 
97 Serum Direct injection Silica AcN -phosphate buffer pH 2 - - -
98 Plasma Cs AASP SPE cartridge CIS MeOH-phosphate buffer pH - UV 234 0.025 j.tg/mL 
with on-line elution 7.6-IPA 
99 Urine Sep-PakSPE CI8 CI8 AcN -phosphate buffer pH 7. I - UV 229 7.5 j.tg/mL 
cartridge, IP A 
100 Urine - - - Derivative UV 240-340 -
spectrophotometry 
101 Catfish, salmon Trichloroacetic acid CI8 AcN-phosphate buffer pH 5.6 Precolumn Fluorescence 0.002 j.tg/mL 
tissue precipitation, Sep-Pak trichloroacetic acid 358/440 
cartridge and formaldehyde 
I 
102 Bovine milk Et4NCI and AcN CI8 AcN-phosphate buffer gradient - UV 214 2-5 ppb 
deproteinization i' , 
L __ .... _ 
. __ ...... -----
-- --
---_ ...... ------_ .. - .----- '----- - --
IP A = Ion Pairing Agent SPE = Solid Phase Extraction 
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6.1.2 SAMPLE PREPARATION FOR HPLC 
6.1.2.1 INTRODUCTION 
Biological fluids are complex mixtures of proteins, carbohydrates and lipids. The biological sample 
is usually pretreated prior to chromatography to deplete the sample of proteins~ <lng to extract the 
compound of interest quantitatively. 
Techniques for sample pretreatment prior to HPLC assay include simple dilution of sample in an 
appropriate solvent, protein precipitation, filtration, solvent extraction and use of cartridges of 
various types that allow pre-chromatography or enrichment of the sample [49]. Generally the type 
of pretreatment and the degree of sample cleanup is dictated by the efficiency and selectivity of 
the technique used for analysis. The more specific and efficient the chromatographic procedure, 
the less sample extraction and sample cleaning are necessary. In addition to cleaning up the 
sample, the extraction steps are also necessary to improve thed~tection limit of the assay by 
concentrating the drug [49]. 
6.1.2.2 DIRECT INJECTION 
Direct injection of biological samples is the simplest and most rapid way of introducing them onto 
an HPLC system. However direct injection results in a rapid increase in backpressure and a 
deterioration of column performance due to precipitation of proteins on the column. Beyond the 
deleterious effects these biological matetials have on the injector, the colum!} packing material and 
the pump, their presence will frequently interfere with the separation of the antibiotic under study. 
Consequently, some form of sample preparation is almost always required [49,86]. 
A method for direct application of untreated serum or urine samples onto silica columns, to reduce 
.. 
the number of pretreatment steps was proposed by Admovics [96]. This simple approach. did not 
lead to the rapid deterioration of the column as might be expected, as the eluents were almost 
totally aqueous and thus did not precipitate serum proteins onto the column. However this method 
was only suitable for the detection of plasma concentrations between 20 and 100 JLg/mL which are 
not sufficiently sensitive for most kinetic studies. In addition if the aqueous mobile phase contained 
organic modifiers at concentrations greater than 15%, precipitation of proteins occurred. 
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6.1.2.3 J)II.trrI()~ 
Dilution is mainly applicable to biological t1uids in which the antibiotic concentration is high, and 
there is little or no protein present, for example urine and bile. In these body fluids, dilution by 
an appropriate solvent is often sufficient to eliminate background interferences [49], although in 
urine samples the many endogenous compounds present in high concentrati0!l~ way produce a 
multitude of chromatographic peaks such that resolution of the compound under investigation from 
these endogenous materials becomes a problem [87]. 
The dilution solvent may be water, but because the ionic strength may affect the retention time of 
an antibiotic, it may be useful to adjust the ionic strength of the diluting solvents to those of the 
biological samples under investigation [49]. If dilution alone is used prior to chromatography, a 
guard column must be installed in front of the analytical column [871. 
Simple dilution should not be applied to serum or plasma. As \\'ithfUrect injection, eluents which 
contain a high proportion of organic moditier will, after numerous injections, cause precipitation 
of the serum or plasma protein, followed by obstruction and rapid deterioratioIfof the 
chromatographic column. 
The determination of amoxycillin in urine using HPLC has included diluting the urine sample and 
then subjecting it to analysis [89,91,94]. However, at 230 nm which is the wavelength often used 
for detection of amoxycillin, endogenous compounds have a high molar absorptivity, suggesting 
that this approach lacks adequate selectivity [89,98]. 
6.1.2.4 S()I.VENT EXTRACTI()~ 
Organic solvents of lClw polarity can be used to selectively extract some drugs from biological 
matrices by solvent partitioning, for example interfering llrine components have been extracted into 
n-amyl alcohol-dichloroethane [92] in an attempt to decrease the sensitivity limit. The most widely 
used solvents are di-ethyl ether, ethyl acetate, methylene chloride and chloroform [87]. The 
compound of interest is removed from the biological matrix by use of a suitable solvent system and 
specific pH conditions, thereby allowing selective extraction of the desired components and leaving 
behind unwanted materials. The solvent is then removed by evaporation and the dried residue is 
reconstituted in a small volume of the mobile phase or a similar solvent for injection onto the 
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HPLC system. Extraction methods for isolating and concentrating antibiotics from a sample matrix 
may vary from a simple one step extraction to complex back extractions requiring several 
manipulations. 
Liquid-liquid extraction works well for lipophilic substances such as chloramphenicol [87]. 
Penicillinase-resistant penicillins such as isoxazolyl penicillins and nafcillin can--be {!xtracted from 
body fluids into organic solvents of medium polarity, such as chloroform and methylene chloride. 
These penicillins are concentrated in the aqueous phase while the plasma or serum lipids are 
extracted into the organic phase [34]. 
However the measurement of penicillins such as amoxycillin and ampicillin in biological fluids is 
more challenging since their amphoteric nature makes extraction into organic solvents difficult 
[34,43,97]. Amoxycillin exists as a zwitterion over almost the entire pH range [98] and is a 
hydrophillic molecule with relatively high water solubility. The drug is also slightly soluble in 
polar solvents such as ethanol, methanol and acetone. AmoxyciHin I-sunstable in the strongly acidic 
solutions required for the drug to be present in the unionized form (PH values below 2.4) [4~]. As 
a consequence of these physicochemical properties it is almost impossible to extract amoxycillin 
from plasma by liquid-liquid extraction [43]. 
6.1.2.5 DEPROTEINIZATION 
Polar compounds are often directly determined in plasma and serum following precipitation of 
proteinaceous material [34]. This technique is used to deproteinize the sample and to solubilize the 
drug [87]. Either acids or organic solvents may be used as precipitants [49,91]. Acids such as 
perchloric acid, trichloroacetic acid and trifluoroacetic acid and organic solvents such as 
acetonitrile, methanol, dimethylformamide and 2-propanol have been used. These techniques 
involve mixing a smail amount of plasma or serum (50~~001Ll) with the same volume or excess of 
the deproteinizing agent [491. 
Protein precipitation by addition of perchloric acid has been described by several authors 
[42,90,93,94]. Vree et al [90] circumvented the problem of the difficult extractability of 
amoxycillin by directly injecting onto the chromatograph the supernatant obtained after 
deproteinization of the sample with perchloric acid. This method is rapid and suitable for 
immediate analysis of plasma, urine and saliva samples, and is ideal for drug monitoring purposes. 
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A post-column derivatization procedure using imidazole and mercuric chloride was reported by 
Carlqvist and Westerlund [93]. The plasma and urine samples were purified by protein 
precipitation with perchloric acid, followed by extr~ction with dichloroethane. This method allowed 
a sensitivity of 200 ng/mL in urine and 25 ng/mL in plasma, but the column had to be repacked 
every 15 injections due to column deterioration. 
A change in pH, caused by acid precipitation, may cause degradation of the sample. Amoxycillin 
is unstable under acidic conditions and must be analyzed immediately after preparation, thus 
precluding automated injection [34,93,98]. In order to enhance the stability of amoxycillin, the 
samples may be neutralized prior to injection. Although neutralization may improve stability when 
a large number of samples are being analyzed, reinjection of the samples the following day is not 
reliable. Erdman et al [42] used this method of neutralization after precipitation, before injecting 
middle ear effusion and plasma samples onto HPLC columns. Potassium chloride was added to 
precipitate the unreacted perchlorate. 
The risk of preparing an unstable sample by protein precipitation is minimised if the precipitation 
is performed with the same organic solvent as is used in the mobile phase, instead of an ~Gicf [49]. 
Organic solvents, although less effective precipitants, are mostly employed for highly protein 
bound antibiotics to avoid co-precipitation [103]. The relative order of their protein precipitating 
capability is acetonitrile> acetone > ethanol > methanol, which is approximately inversely 
related to their polarity [103]. Relatively high organic solvent volumes must be added to ensure 
complete precipitation of proteins [103]. Sample dilution which occurs with the addition of the 
precipitating agent may be problematic if low concentrations of antibiotics are to be measured. 
Therefore excess solvent can be back extracted. For example if acetonitrile is used, methylene 
chloride is added to remove the remaining acetonitrile from the supernatant [49]. The use of the 
organic solvents methanol and acetonitrile, to precipitate protein in biological samples containing 
IHactam antibiotics has been described by several researchers [104-107] . 
.. 
The suitability of protein precipitation by acids or organic solvents, for the assay of large numbers 
of samples is limited since the column performance tends to deteriorate after the direct injection 
of between 30 to 40 samples [43,90,93]. The column life may be extended to some extent, when 
deproteinized samples are injected, by adding a short guard column packed with large-sized 
molecules of alkyl bonded phase [34]. 
lOS 
As an alternative to precipitation, proteins may be removed by ultrafiltration through filters with 
a 25000 to 50000 molecular mass cut-off, although small protein molecules and other interfering 
materials may still pass through the filter [49,S7,9'8J. This is a relatively simple method, and has 
several advantages over precipitation, but it should be kept in mind that analysis of ultrafiltrate will 
provide a measure of non-protein-bound drug, as opposed to total drug concentration [S7, 103]. It 
is also necessary to determine whether drug is adsorbed to the membrane mat~iah 
Blanchard [103] performed an evaluation of various techniques for deproteinizing plasma samples. 
Several types of protein precipitants were assessed, as well as protein removal by ultrafiltration. 
Ultrafiltration, by means of centrifugation in ultrafiltration cones, provided nearly complete 
removal of plasma proteins. The protein precipitation data indicated that only very small quantities 
of 10% trichloroacetic acid and 6% perchloric acid were needed to remove more than 9S% of the 
plasma protein. At a 1: 1 (v/v) ratio of precipitant to plasma only methanol and saturated 
ammonium sulphate failed to remove more than 90% of the plasma protein. 
6.1.2.6 SOLID PHASE EXTRACTION (SPE) 
A variety of analytes can be isolated from complex matrices using bonded phase extraction 
techniques. These methods are rapid and can often avoid the use of solvent extraction and protein 
precipitation. By avoiding the use of highly acidic protein-free filtrate, the resultant drug stability 
allows assay using autoinjection. Solid phase extraction has offered a potential solution to th~ non-
extractability of amoxycillin. 
A sorbent with strong affinity for organic compounds will retain and concentrate those compounds 
from very dilute samples [lOS]. The first step of the bonded phase extraction method involves the 
activation of the extraction material then application of the diluted sample onto the bonded phase 
resin, to retain analytes together with interfering compounds. Following this a selective solvent is 
usually used to remove interferences and then another solvent is chosen to wash out the target 
analytes. 
SPE has gained popularity in sample preparation due to its better selectivity and easy operation 
[91]. SPE has a number of advantages compared to traditional solvent extraction: it is simple, 
inexpensive and uses very little solvent. SPE does however have some limitations. The interaction 
between sample matrix and analytes often results in low recovery and solid and oily compounds 
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in a sample matrix may plug the SPE cartridge, or can block pores in the sorbent so that it 
becomes overloaded [108]. Sorbents suffer from high carryover values, and batch to batch 
variation of the sorbents leads to poor reproducibiJity. The SPE technique is limited to semi-
volatile compounds, with boiling temperatures substantially above that of the solvents [108]. 
Only a few reports have detailed SPE methods for extracting amoxycillin from human biological 
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fluids [43,89,91,98,99]. Lee and Brooks [89] performed a study which detailed a sensitive and 
selective HPLC assay for the determination of amoxycillin in human plasma using such a bonded 
phase extraction. Yuan et al [91] used SPE for measuring amoxycillin in middle ear fluid and 
plasma. Chulavatnatol and Charles [99] described a selective and precise method for assaying 
amoxycillin in urine which used a SPE process combined with ion pairing and 10nkman et at [43] 
used similar principles for determination of the drug in plasma. No internal standard was used in 
eithe~ study. Krauwinkel et al [98] were the first to report the use of SPE followed by on-line 
elution to the HPLC column, for the determination of amoxycillin in human plasma. 
6.1.2.7 ION PAIRING 
Polar ionized compounds are often difficult to isolate from biological tluids for subsequent 
analysis. Although it is often possible to adjust the pH of weak acids or bases to give the 
unionized, extractable form, the drastic extraction conditions needed for those compounds with pI<" 
values outside the range 3-9 can lead to problems of solute stability [109]. Additionally, for aprotic 
molecules and materials that are ionized at all pH values, pH adjustment techniques are not 
possible. Although the primary equilibrium may involve the formation o~ an ionized solute, the 
physicochemical nature of this ionized species can be altered by introducing a second equilibrium, 
leading to the formation of ion pairs. Ion pairs possess a low aqueous solubility and they tend to 
move from areas of high polarity to areas of low polarity. Ion pair formation can be highly specific 
and the combination .. of ion pair formation and distribution can contribute great selectivity to an 
extraction procedure [109]. 
Amoxycillin, a polar compound, elutes early in reversed phase HPLC systems, often resulting in 
blank chromatograms [93]. Because it is an amphoteric compound, it can be considered a 
potentially good candidate for ion pairing processes [43,94,109]. 
Tetrabutyl ammonium (TBA) ions have been shown to be a very good counter ion for the 
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formation of ion pairs with acidic groups in bulky molecules [43,109]. 10nkman et al [43] 
described a quantitative method for the determination of amoxycillin in plasma, which used ion 
pair extraction on octadecyl disposable columns with TBA as the counter ion and methanol as the 
eluent. The TBA-amoxycillin ion pair was retained by the CIS extraction column and hydrophilic 
components of the plasma were washed from the column with a phosphate buffer that contained 
TBA to keep the amoxycillin in the ion paired state. The TBA-amoxycillin ion pair was then eluted 
~ - ~ 
from the column with methanol. 
Carlqvist and Westerlund [94] described the determination of amoxycillin in plasma and urine 
based on ion pairing principals. Clean-up of the biological fluids was obtained by a heart cut from 
the first column, where the mobile phase contained hexyl sulphate. In the second column, the 
organic anion was exchanged for a large quarternary ammonium compound, amoxycillin was then 
retai~ed as an ion pair. Adequate selectivity and sensitivity was obtained by post column 
derivatization with fluorescamine. 
6.1.2.8 CONCLUSION 
Direct injection and simple dilution have a detrimental effect on the analytical column, acidic 
protein precipitating agents are unsuitable since they catalyze degradation of amoxycillin, and 
liquid-liquid extraction is difficult because of the polar nature of the drug. From this examination 
of the methods available for the preparation of biological samples prior to HPLC analysis, it would 
appear as if the most appropriate and efficient method would be either protein precipitation or solid 
phase extraction using cartridges or a combination of the two techniques .. 
6.2 METHOD DEVELOPMENT 
6.2.1 EXPERIMENTAL 
6.2.1.1 REAGENTS 
The analytical reagents used are as listed in Section 3.2.1.1. Additional chemicals which were used 
were ceftazidime pentahydrate (Glaxo Pharmaceuticals, RSA), cephalexin hydrate (Sigma Chemical 
Company, RSA) and sodium dihydrogen phosphate (Merck, RSA). Drug free serum was obtained 
from the South African Blood Transfusion Service (PE, RSA). All reagents were at least of 
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analytical grade. 
6.2.1.2 HPLC SYSTEM 
The modular HPLC system described in Section 3.2.1.2 (System B) was optimized for in vivo 
analysis of amoxycillin (System C). 
SYSTEM C 
An Iso-Chrom LC pump (Spectra-Physics, San Jose, CA, USA) with a Waters Intelligent Sample 
Processor (WISP) Model 710B Automated Sample Injection System (Waters Associates, Milford, 
MA, USA), a Water 490 Programmable Multiwavelength Detector (Waters Associates, Milford, 
MA,. USA) and a model 561-3002 strip-chart recorder (Perkin-Elmer Corp., Norwalk, Conn., 
USA) were used. Separation was achieved on an Inertsil ODS-2 4.6x250 mm HPLC column (GL 
Sciences Inc., Tokyo, Japan), maintained at various controlledlemp6fatures. A guard column kit, 
part number 1603, with Perisorb RP-18 pellicular packing material (C-603) (Upchurch Scientific, 
W A) was used. An analytical filter, model A340 (Upchurch Scientific, W A) was used in-line 
between the pump and autosampler. 
6.2.1.3 COLUMN SELECTION 
As discussed in Section 3.2.1.4, the analytical column is an integral component of an HPLC 
system. The polar nature of the serum matrix made it necessary to review,the stationary phase in 
order to optimise retention of amoxycillin and the internal standard, and minimise retention of 
unwanted serum contaminants. 
6.2.1.4 MOBILE PHASE SELECTION AND PREPARATION 
The variables involved in mobile phase selection and preparation were discussed in Section 
3.2.1.5. The mobile phases described in several published HPLC analyses (Table 6.1) were 
examined, and compared with the mobile phase used for in vitro work. None provided the desired 
conditions, and several alterations were made to the organic phase, pH and temperature, in order 
to optimise the mobile phase. 
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6.2.1.5 PREPARATION OF STOCK SOLUTIONS 
Stock solutions of amoxycillin 1.0 mg/mL were prepared as described in Section 3.2.1.8. 
A stock solution of 0.02 M potassium dihydrogen phosphate pH 4.5 used for extractions was 
prepared by accurately weighing 2.72 g KH2P04 and dissolving it in HPLC,.gratie water, then 
making to volume in a 1 litre volumetric flask. 
Stock solutions of 0.2 mg/mL sulphadimidine, the internal standard were made up by accurately 
weighing 20 mg sulphadimidine and dissolving it in KH2P04 0.02 M, then making to volume in 
a 100 mL volumetric flask. The ultrasonic cleaner (Model 8845-30, Cole-Parmer Instrument 
Company, Illanois, USA) was used to ensure rapid and complete solution of the drug. A 10 mL 
aliquot was then further diluted to 100 mL with KH2P04, to yield a 0.02 mg/mL solution. 
6.2.2 SOLID PHASE EXTRACTION METHOD DEVELOPMENT 
6.2.2.1 METHOD OBJECTIVES 
When deciding on a choice of extraction method several objectives, including the required purity 
of the isolate, the final concentration of the isolate, the final solvent required and a definition of 
the actual isolates, should be examined [110]. The definition of the isolate must include all speci~s 
that are to be extracted, including both amoxycillin and the internal standard, sulphadimidine. 
The required purity of the isolate has a major influence on the complexity of the extraction 
procedure developed [110]. If the isolate is extracted prior to analysis, the selectivity of the final 
analytical technique will largely determine the selectivity of the extraction method. For example, 
if the final analysis uses highly selective detection, ~~ extraction method may be required to 
provide only a gross cleanup of major matrix contaminants. Conversely a relatively non-selective 
final analysis may require that the extraction method be highly selective for the isolate, in order 
to remove analytical interferences. 
The choice of extraction method may also be affected by the desired final solvent for the purified 
isolate. For example if analysis of the purified isolate requires an aqueous environment, a non-
polar sorbent for isolate retention may not be the optimum choice, because aqueous solvents often 
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lack the strength to elute the isolate from the sorbent. An ion-exchange or polar interaction would 
be a better choice in such a case. 
6.2.2.2 ISOLATE CONSIDERATIONS 
The skeletal structure and functional groups of the isolate molecule must be ex~tne9 as these may 
indicate the type of interactive mechanisms that can be used for the selective retention of the isolate 
on a SPE cartridge. 
The presence of polar atoms indicates a potential for retention by polar interactions. Amine or 
hydroxyl groups are important because these will hydrogen bond or interact ionically not only with 
the functional groups on sorbents, but also with the polar silica substrate. Other ionizable groups 
on the isolate molecule indicate that a potential for retention by ion exchange exists. Based on the 
dissociation constants of these groups, an ion exchange molecule can be selected that will be the 
best choice for retention and subsequent elution. AmoxyciIlil1 h~~polar oxygen, nitrogen and 
sulphur atoms, which are not localized, but spread over the molecular structure, suggesting that 
the drug may be retained by polar interactions. However since it also has ionizable hydroxyl, 
amine and carboxylic acid groups it would seem that ion-exchange extraction methods would be 
appropriate for the retention and isolation of the drug. If the isolate has areas of carbon/hydrogen 
content only, the isolate would probably be retained by non-polar interactions; the aromatic ring 
of amoxycillin adds a further possibility of non-polar interactions. 
The solubility characteristics of the -isolate should be known. The best elutJon solvents are those 
in which the isolate is highly soluble. Amoxycillin is soluble 1 in 400 of water and 1 in 200 of 
methanol but insoluble in acetonitrile [6,7]. Solubility information also helps in selecting solvents 
for elution of interfering material from sorbent material that retains the isolate. Solvents in which 
the isolate is not soluble are excellent for washing remaining matrix interferences from the 
retention sorbent without eluting the isolate. 
The stability of the isolate in various solvents should also be examined as well as any pH 
requirements to ensure isolate stability. For example, amoxycillin undergoes hydrolysis in water 
and methanol and is most stable at pH 7 [43]. If the isolate is stable in a limited number of 
solvents, or within a limited pH range, extraction mechanisms appropriate to these limitations 
should be chosen. Penicillins are unstable compounds, sensitive to nucleophilic and electrophilic 
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attacks, and can undergo degradation during the analysis process. Degradation can be prevented 
by rapid sample pretreatment and storage of clinical samples at -70°C or below [34,94]. 
Other considerations are protein binding and adsorptive properties of the isolate. Some isolates 
have a tendency to adsorb to certain materials or surfaces. Often when retention of a drug on a 
non-polar sorbent is either irreproducible or weaker than anticipated, the problej,ll is.binding of the 
drug to proteins that pass through the sorbent unretained. 
6.2.2.3 MATRIX CONSIDERATIONS 
The nature of the sample matrix may also influence the choice of sorbents and procedures. For 
example blood is a polar, aqueous matrix, consisting of a high percentage of proteins, fats, salts 
and a. variety of polar substances, all of which may influence the resultant retention. It is important 
to identify any major matrix components that are similar in structure to the compound of interest 
or share chemical properties with the isolate, and to identify in wilat way these substances differ 
from the drug so that efficient separation can be achieved. 
6.2.2.3.1 SERUM, PLASMA AND WHOLE BLOOD 
Plasma and serum are commonly extracted by non-polar or ion-exchange SPE. Sample 
pretreatment usually involves dilution with an equal volume of water or a suitable buffer b_e!ore 
applying the sample to the extraction sorbent. Protein binding of isolates may be a problem and 
should be considered if recoveries of aqueous standards are high but recoveries from samples are 
low [110]. 
Whole blood is handled in a similar way to serum and plasma samples. The difference is the 
presence of the whole..red blood cells, which are chemically active, in that many drugs and natural 
-
products are taken up into the cells and are therefore not available to the sorbent surface unless the 
cell is disrupted by the addition of an organic solvent or dilution with buffers. The difficulty of 
protein binding common in serum and plasma is even greater in whole blood samples [110]. 
6.2.2.3.2 URINE 
The extraction of urine is usually by means of non-polar and/or ion-exchange methods. Urine 
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samples may be pretreated by diluting with at least an equal volume of water or appropriate buffer 
before applying the sample to the sorbent. The high and variable salt content of the urine matrix 
often complicates the use of ion-exchange as the first extraction mode. This problem may be 
bypassed by first retaining the isolate on a non-polar sorbent, allowing easy removal of the salt 
through an aqueous wash, followed by isolute elution and subsequent use of an ion-exchange 
compound. Urinary pigments are also present at high levels in the matrix. Some,oftbese will retain 
on ion-exchangers, others on non-polar sorbents [ItO]. 
6.2.2.3.3 PROTEINS 
Proteins are often a major hinderance in the development of an HPLC method. The important 
properties of proteins are their solubility characteristics which are limited to very polar solvents, 
their .molecular weights which range into millions, their sensitivity to pH and their often globular 
nature. Most commercially available sorbents are of porosity in the 60 to 100 A range. Therefore, 
proteins above 15000 to 20000 molecular weight tend to be too large to penetrate most pores of 
the sorbent, and are exposed to a minimum of the available active functional groups on the s?rbent 
surface. For this reason, most proteins pass unretained through such sorbents, especially rion-polar 
ones such as CIS. Retention of the isolates on these non-polar sorbents from polar sample matrices, 
followed by washing the sorbent with large amounts of water or buffers is one of the best 
approaches for removing large amounts of protein from samples. 
When a drug is protein bound, its active sites that would normally interact with the sorbent to 
produce retention are not available for interaction with the sorbent. In addition, if the protein to 
which the drug is bound is not retained on the s6rbent, the drug is carried through the sorbent bed 
by the protein instead of being retained. Protein binding should be suspected whenever drug 
standards retain well on the sorbent, but drug present in the sample matrix does not. Amoxycillin 
is 20% protein bound.[2,6]. 
There are a few effective strategies for overcoming protein binding, thus freeing the drug for 
retention in the desired manner. The first approach is a change in the pH of the sample. Protein 
binding is often pH dependent and changing the pH may release the isolate. The addition of protein 
denaturing agents such as urea or methanol, or precipitants such as acetonitrile, methanol or 
perchloric acid may also free drug bound to proteins. In some cases protein precipitation may 
precipitate the isolate from solution, therefore this approach should be used with caution. 
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6.2.2.4 SORBENT TESTING 
The sorbent should be systematically tested in order to select the most appropriate sorbent type and 
method of extraction. The retention of standard solutions similar to the sample matrix should be 
optimised. The elution of standards should then be optimised and a wash solvent identified that will 
remove unwanted contaminants and matrix components, but not elute the isolate ... The blank matrix 
should be tested by pretreating the matrix as planned with wash solvent and eluent. The solvent 
yielding the cleanest eluent would be the most selective for the isolate of interest. Finally spiked 
samples can be tested. 
Various types of SPE cartridges were tested, and the results are shown in Table 6.2. 
The ~rug was not retained on the Cs, CIS end-capped, cyano or phenyl columns under the standard 
extraction method applied (Section 6.2.2.10. Of the CIS cartridges, the best yield of drug and the 
cleanest eluent was obtained when the Sep-PaJc® CIS cartridges-we~used. 
Table 6.2 Retention of amoxycillin on various SPE cartridges 
SPE cartridge Extent of amoxycillin retention 
Isolute® CI8 + 
Supelco® C I8 + 
Sep-Pak® C I8 ++ 
Isolute® C8 -
Isolute® C 18 · end-capped -
Isolute® CN -
Isolute® phenyl -
= Drug not retained 
+ = Small amount ·of drug retained 
+ + = Large amount of drug retained 
6.2.2.5 SAMPLE PREPARATION AND LOADING 
Sample preparation prior to loading onto the SPE cartridge can involve simple dilution with an 
appropriate solvent in order to reduce viscosity, or addition of a buffer to control pH and possibly 
suppress ionisation, or protein precipitation to remove some of the protein from the sample before 
extraction. 
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Several techniques of extracting amoxycillin from human plasma and serum by protein precipitation 
with either methanol or acetonitrile were examined. Spiked samples were precipitated with either 
methanol or acetonitrile, but the resultant chromatograms were not sufficiently clean, and the 
amoxycillin peak was obscured. After several injections the supernatant from the precipitated 
samples tended to cause an increase in column backpressure. Precipitation with acids was not 
attempted because of the well documented instability of amoxycillin following -acid precipitation 
[42,90,93,94]. Precipitation alone did not yield the clean extracts necessary to achieve the 
sensitivity required for the assay. 
Precipitation followed by solid phase extraction was used, to prevent clogging of the columns and 
to release protein-bound drug. This was achieved by adding an equal volume of acetonitrile or 
methanol to a 1 mL serum sample and then mixing with a vortex mixer (Maxi Mixer®, Model M-
16710-12, Thermolyne Corporation, Iowa, USA), followed by centrifugation at 2000 x G for 10 
minutes, with a General Purpose Centrifuge (Model HN-SII. Interantional Equipment Company, 
MA, USA). The supernatant was then extracted. Precipitation wit-tracetonitrile resulted in cleaner 
extracts than with methanol although the amount of drug recovered was low. This may have been 
due to the drug being trapped in the precipitate, or the fact that the eluotropic strength of the 
protein-free solution containing acetonitrile or methanol was sufficient to prevent retention of 
amoxycillin on the SPE cartridge. Recovery did not increase when the eluotropic strength was 
decreased by diluting the supernatant with water. 
Simple dilution of the sample with an aqueous solution containing an internal standard, before 
loading it onto the extraction cartridge was attempted. Solutions of different pH were compared 
as sample diluents, but the pH of the buffer did not significantly influence the amount of drug 
recovered, possibly because the use of a buffer to suppress ionisation would be unsuccessful as 
amoxycillin is amphoteric. The addition of an ion pairing agent to the diluting solution, as 
suggested by someresearchers [6,14] did not result in a noticeably greater retention of the drug 
on the column or higher recoveries. It was decided to dilute the sample with KH2P04 (0.02 M, 
pH4.5), as described by Lee and Brooks [89]. The internal standard was dissolved in the KH2P04 
solution. 
Sample loading is a function of the number of active sites available on the packing material. The 
amount of sample that can be loaded depends on the concentration of all components in the sample, 
solvent strength and choice of packing material. Overloading of the packing material results in 
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breakthrough and poor results, as the packing material in the cartridge has a finite capacity. When 
the amount of sample loaded onto the packing material exceeds the packing material's capacity, 
the excess sample elutes, resulting in poor separation, poor sample recovery and lack of 
reproducibility. 
When following the method of Lee and Brooks [89], recovery was poor wh~I! a.. 2 mL diluted 
sample was loaded onto a 1 mL cartridge. However, recovery increased when the same sample was 
loaded onto a 3 mL cartridge, confirming that the former method had overloaded the I mL 
cartridge. By halving the volume of solvents used in cartridge preparation, the volume of the 
sample loaded and the wash and elution volumes, recovery of amoxycillin from a I mL cartridge 
was optimised. 
6.2.2.6 EXTRACTION CARTRIDGE PREPARATION 
The preparation of non-polar C lS extraction cartridges prior to appligltion of the biological samples 
involves the wetting of the hydrophobic stationary phase, followed by conditioning. The wetting 
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solvates and opens the hydrocarbon chains increasing the surface area available for interactiOn with 
the compound of interest and creates the proper phase interface between sorbent and sample. The 
cartridge is solvated with a suitable solvent such as methanol, ethanol, propanol or acetonitrile with 
typical solvation volumes 1 mLi 100 mg sorbent. The organic solvent is discarded as waste. 
Conditioning the cartridge pre-equilibrates the cartridge and provides optimum conditions for 
retention of the analyte by removing excess solvating solvent from the ,stationary phase. The 
cartridge is usually flushed with a volume of water or buffer, equal to the volume used for 
solvation and this is discarded to waste. The cartridge should not be allowed to dry out prior to 
application, or breakthrough and variable recovery may result. 
Various solvation and conditioning steps were attempted, to determine the optimum seqllence for 
cartridge preparation. Acetonitrile and methanol have been described most often as solvating agents 
[43,91,99,101]. Both solvents resulted in similar recoveries of drug and volumes slightly greater 
or less than those recommended did not alter the results noticeably so long as the solvation was 
balanced by the conditioning step. The solvating step was essential; if it was omitted, the aqueous 
conditioning solution was unable to pass through the cartridge. 
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The conditioning step was equally important; if it was omitted, and the sample was loaded 
immediately after the column had been wetted, the solvating solvents tended to precipitate protein 
in the sample, blocking the inlet frit of the camid.ge. Water and several buffers were used to 
condition the cartridges. Retention was better when pH control was used. The most favourable 
results were achieved when either 0.02 M KH2P04 pH 4.5 or a phosphate buffer of pH 7 were 
used. 
The final wetting and conditioning steps adopted were solvation with 2 mL methanol, followed by 
pre-equilibration with 400 JLL KH2P04 pH 4.5 (0.02 M). 
6.2.2.7 DETERMINATION OF THE WASH SEQUENCE 
There are two possible strategies for isolation and cleanup of sample components. The 
chromatographic conditions can be chosen so that the compound of interest will either be 
unretained while the matrix interferences are adsorbed or retaiIled .. ;.while the matrix interferences 
pass through the cartridge unretained. The first strategy is often used when the desired sample 
.-
component is present in high concentration, and the compound of interest is eluted before the 
remaining compounds. The second method is used when the compound of interest is present at low 
concentration, or multiple components of differing polarities need to be isolated. The compound 
of interest is retained, while unwanted components are eluted with a solvent which is weak in 
relation to the compound of interest. The compound of interest is then eluted with a solve_n! of 
higher eluotropic strength. 
The latter approach was used in this study. Various wash sequences were investigated, in order 
to optimize the retention of amoxycillin and the internal standard, and ensure that as many 
endogenous serum contaminants were removed as possible. It was not possible to elute the drug 
with an organic solve~t. or a mixture of aqueous and organic solvents, directly after loading the 
sample, since the organic portion tended to react with -residual proteins on the column, .causing 
precipitation and blockage of the SPE cartridge. Careful use of the wash solvents was important. 
If the cartridge was washed with a small volume « 1 mL) of water, the drug was removed along 
with some of the serum contaminants, whereas a small volume of KH 2P04 or phosphate buffer pH 
7 removed interferences, but did not elute amoxycillin. If a large volume of either was used, the 
amoxycillin was eluted along with contaminating interfering compounds. A compromise was 
reached by washing first with 600 JLL KH 2P04 ph 4.5 (0.02 M) to remove most of the 
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interferences, then washing with 200 J.d water to remove further contaminants, without eluting the 
drug. 
6.2.2.8 DETERMINATION OF THE ELUTION MIXTURE 
The small amount of sample contaminants that remained on the extraction cartridge required the 
r - ~ 
selective elution of amoxycillin from the cartridge. Water, buffer, methanol and acetonitrile were 
used in various combinations to find the most efficient elution mixture. Acetonitrile proved to be 
a poor eluent, more than likely because amoxycillin is insoluble in acetonitrile whereas buffers 
generally promoted retention. Solutions of water and methanol achieved the most efficient elution 
profile. Water alone did not have sufficient eluotropic strength to elute the maximum amount of 
amoxycillin, even though it was able to wash a small amount from the cartridge. Methanol, being 
a "stronger" solvent was able to elute a satisfactory amount of drug, but this yield was improved 
by the addition of water to the elution mixture. The recovery of drug improved as the fraction of 
water was increased, for example more drug was recov,ered".with an 80:20 mixture of 
water:methanol than a 20:80 mixture. 
Different volumes of the elution mixture were tested. The most effective elution possible requires 
a minimum of two bed volumes of eluting solvent, for example a 100 mg sorbent bed requires at 
least 240j.t1 of solvent for quantitative isolute elution [34]. 
A final elution mixture of 1 ml of 15:85 methanol:water was employed and the eluent was injected 
directly onto the analytical column~ Smaller elution volumes resulted in h~gher concentrations of 
analytes, which were however accompanied by greater interference from contaminants, so it was 
decided to analyze more dilute eluents, rather than overload the analytical column with unnecessary 
contamination. It was noted that a number of serum contaminants were eluted by the same solvents 
that were used to el~te the amoxycillin. These contaminants could not be removed by selective 
washing, without significant loss of the drug, therefore they were allowed to be eluted. with the 
amoxycillin, and the mobile phase composition was altered to control the separation of these 
compounds from the drug. 
Evaporation and reconstitution of samples was investigated. Samples were evaporated to dryness 
in a rotary vacuum centrifuge (Savant, Hicksville, NY, USA) and reconstituted in a small volume 
of mobile phase. The aim of this step was to concentrate the tinal sample for analysis, and reduce 
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the size of the solvent front. However since detection of amoxycillin at the lower limits of the 
concentration range, with a final elution volume of 1 mL and injection of a 200 JLL aliquot was 
adequate, it was decided that the time-consul11ing evaporation step that also has stability 
' .. 
implications, was unnecessary. 
6.2.2.9 FLOW RATE 
Flow rate also affects column efficiency. If the sample flows through the SPE cartridge too quickly 
it will not have enough time to interact with the packing material and some of the sample will elute 
with the solvent. This commonly causes poor separation, low retention and poor sample recovery. 
The flow rate was determined by measuring the time taken for one SPE cartridge volume (1 mL) 
of solvent to move through the cartridge. The flow rate chosen for column preparation was gravity 
(approximately 0.3 mLiminute). The wash solvent was allowed to flow with gravity, but the 
column was dried on the vacuum manifold, at a flow rate of 1 mLiminute before the elution 
solvent was applied. The tlow rate of the elution solvent was maintained at 1 mLiminute. 
6.2.2.10 INTERNAL STANDARD 
Although chromatographic conditions for the separation of amoxycillin and salicylic acid as internal 
standard had been optimised in Chapter 3, salicylic acid was not suitable as an internal standard 
under the chromatographic conditions used for in vivo analysis, since the salicylic acid peak was 
obscured by serum contaminants. -
Cefadroxil, 60 jLg/mL [91], hydroflumethiazide, 50 jLg/ml [42] and benzoic acid, 0.025 mM [43] 
have been used as internal standards. in other in vivo analyses. Benzoic acid, salicylic acid, 
ceftazidime, cephale.zin and sulphadimidine were tested as potential internal standards. Aqueous 
solutions of these drugs were assayed, using HPLC Sy'stem C, to determine their elution time in 
relation to amoxycillin. 
Aqueous samples of salicylic acid, benzoic acid and sulphadimidine were detected, but detectable 
amounts of aqueous ceftazidime and cephalexin were not eluted after 40 minutes. Spiked serum 
samples were diluted with KH 2P04 pH 4.5 (0.02 M) containing each of the potential internal 
standards, and extracted. Benzoic acid and salicylic acid eluted before amoxycillin, amongst the 
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large interfering serum peaks, and were therefore not considered suitable. Sulphadimidine was 
eluted after amoxycillin, was clear of any other serum peaks and was therefore selected as the 
internal standard for this in vivo method. 
6.2.2.11 FINAL SERUM EXTRACTION METHOD 
The solid phase extraction method described by Lee and Brooks [89] was adapted for the purposes 
of this study. Serum was used instead of plasma, since the recovery of amoxycillin from serum 
was greater than from plasma. The final serum extraction method involved activation of the 
extraction material (Sep-Pak Vac® C lK cartridges) with 2 mL methanol followed by 400 J-tL of 0.02 
M KH2P04 pH 4.5; dilution of a 1 mL serum sample with 1 mL 0.02 M KH2P04 pH 4.5 
containing 0.01 mg/mL internal standard; application of 1 mL of the diluted plasma onto the 
extra.ction cartridge; clean-up with 600 J-tL 0.02 M KH2P04 pH 4.5 and 200 J-tL water; and elution 
with 1 mL of water:methanol (85:15). Each SPE cartridge was used once only, then discarded. 
6.2.3 OPTIMIZATION OF CHROMATOGRAPHIC CONDITIONS 
6.2.3.1 COLUMN SELECTION 
Various extraction combinations, including the method of Lee et at [89] were carried out using 
HPLC System B with a Nova-Pak® Cl8 4 J-tm 3.9x150 mm column. However optimal resolution 
was difficult to achieve because all analytes, including amoxycillin, eluted rapidly and close 
together despite use of varying mobile phase composition. Decreasing the ,amount of methanol in 
the mobile phase did not significantly improve the chromatogram. It was decided that a longer 
column would improve resolution and allow for better retention characteristics. An Inertsil ODS-2 
column (GL Sciences Inc., Tokyo, Japan) was tested using the mobile phase described in Section 
3.2.2.5. The resolutign improved significantly, but the column backpressure was over 3000 psi and 
too high for use with the autosampler, therefore it was' decided to change the mobile ph.ase. 
6.2.3.2 MOBILE PHASE PREPARATION AND SELECTION 
The major interferences on the chromatogram (Figure 6.1) were two large serum peaks, S2 which 
was eluted just after the solvent front and had a more or less constant retention time, and S 1 which 
tended to elute at the same time as amoxycillin. The aim of these mobile phase manipulations was 
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to optimize the separation of amoxycillin from these serum peaks. 
The mobile phase was prepared by the method described in Section 3.2.2.2. A methanol-buffer 
combination resulted in a higher backpressure than an acetonitrile-buffer combination, therefore 
it was decided to change the organic phase from methanol to acetonitrile. Using a mobile phase 
of 5:95 acetonitrile:O.05 M phosphate buffer pH 7 as a reference standard, the effect of various 
r - -
changes in mobile phase on the retention of amoxycillin, internal standard and serum peaks of a 
serum sample extracted using the method described in Section 6.2.2.11, was investigated. The 
results are shown in Table 6.3. 
As anticipated, an increase in the proportion of acetonitrile decreased the retention time of all 
components. The maximum amount of acetonitrile which still allowed separation of all components 
was }O% v/v. A decrease in the amount of acetonitrile increased the retention times of the 
analytes. This improved separation to some extent, but the long retelltion times often resulted in 
very broad peaks which were poorly resolved. At ambient tempet3ture, the best resolution was 
provided by a 5:95 mixture (PH 7). 
The pH of the mobile phase also influenced retention and resolution. Optimum resolution was 
achieved with a pH 8 buffer. However, since the analytical column manufactures advocate the use 
of buffers within the range 2 to 7 to prolong column life, it was decided to compromise with a 
buffer of pH 7, which still provided adequate resolution. 
6.2.3.3 EFFECT OF TEMPERATURE 
A column heater was used, when it was noted that increasing the temperature tended to lower the 
backpressure of the analytical column as well as decrease the retention times of both the drug and 
serum peaks. In mos!",. cases a temperature increase caused the serum peak S 1 to be eluted faster 
than the drug peak, so that the amoxycillin eluted beyond the major interfering serum pe.aks. The 
effect of temperature on retention times is summarised in Table 6.3. It was decided to use the 
analytical column at a constant temperature of 25°C. 
Table 6.3 The effect of mobile phase composition and temperature of analytical column 
Mobile Phase pH Column Retention time (min) 
Compositiona temperature 
51 RTb Amoxycillin Resolutiond 
RT< 
5:95 7 25°C 14.8 17.2 yes r-
5:95 7 50°C 11.4 16.4 yes 
4:96 7 25°C 11.0 17.4 yes 
4:96 7 50°C 11.2 16.4 yes 
6:94 7 25°C 12.8 9.2 no 
6:94 7 50°C 8.8 9.2 no 
7.5:92.5 7 25°C 14.0 6.4 no 
7.5:92.5 7 50°C 6.0 6.0 no 
10:90 7 25°C 7.2 4.4 no 
10:90 7 50°C 5.6 4.0 no 
5:95 8 25°c 14.8 22.0 yes 
5:95 8 50°C 10.0 14.8 yes 
5:95 6 25°C 14.0 6.4 no 
5:95 6 50°C 9.6 6.0 no 
5:95 5 25°C 15.6 5.2 no 
5:95 5 50°C 10.0 4.4- -- no 
5:95 3 25°C 18.0 9.2 no 
5:95 3 50°C 10.8 6.0 no 
4:96 8 25°C 18.4 32.0 yes 
4:96 8 50°C 10.4 18.8 yes 
• Mobile phase composition is represented by ratio of acetonitrile to phosphate buffer 
b Retention time of serum peak S I, in minutes. 
C Retention time of amoxycillin, in minutes. 
d Resolution of amoxycillin peak from the major serum interferences S I and S2. 
6.2.3.4 FINAL CHROMATOGRAPHIC CONDITIONS 
HPLC 
Mobile Phase 
Flow Rate 
Attenuation 
Recorder Input 
Injection Volume 
Temperature 
Retention Time 
System C 
Acetonitrile:0.05 M phosphate buffer pH 7 (5:95) 
1.0 mLimin 
0.02 AUFS 
10 mV 
100 ILL 
25°C 
Amoxycillin 18 minutes, sulphadimidine 22 minutes 
-
-
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Typical chromatograms of blank serum and serum spiked with amoxycillin are shown in Figure 
6.1. These chromatograms were generated using the conditions listed above. 
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Figure 6.1 
Time (mins) Time (mins) 
Typical chromatogram of (A) blank serum and (B) spiked serum, with (a) 
amoxycillin, (b) sulphadimidine and serum peaks S 1 and S2 
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6.3 METHOD VALIDATION AND IN VIVO STABILITY 
6.3.1 INTRODUCTION 
The development of an analytical method for in vivo samples involves validation of the method and 
an assessment of the stability of the drug in biological samples, as well as the Ln_-process stability 
of extracted samples. Thus a study was conducted to validate the assay and to determine the 
stability of amoxycillin trihydrate in serum and the stability in the aqueous-methanolic eluent after 
solid phase extraction. 
The stability of amoxycillin has been discussed (Sections 1.3 and 3.3.1). The results of this in vivo 
stability study were important in determining optimum storage conditions and the length of time 
for which serum samples could be stored after donation. The investigation into in-process stability 
allowed a decision to be made about the length of time for which samples could be refrigerated 
or left in the autosampler during an extended run. 
6.3.2 EXPERIMENTAL 
6.3.2.1 REAGENTS 
All reagents and equipment used have been described in Sections 3.2.1.1 and 6.2.1.1. 
6.3.2.2 CHROMATOGRAPHIC CONDITIONS 
Chromatographic conditions were as listed in Section 6.2.3.4. 
6.3.2.3 EXTRACTION PROCEDURE 
The extraction procedure was as described in Section 6.2.2.11. 
6.3.2.4 CALIBRATION CURVES 
Calibration curves were constructed on the days that samples were assayed. Aqueous stock 
solutions of amoxycillin trihydrate 1.0 mg/mL and sulphadimidine 0.1 mg/mL were prepared on 
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each assay day as described in Section 6.2.1.5. The stock solution of amoxycillin trihydrate was 
used to spike blank, drug-free serum to achieve a concentration of 6/Lg/rnL. Concentrations of 4.8, 
2.4, 1.2 and 0.6 /Lg/mL were obtained by the serial dilution of this serum stock solution. Six 
samples of each concentration were extracted, and then assayed. The calibration curve is shown 
in Figure 6.2. 
6.3.2.5 LINEARITY 
Linearity over the concentration range studied was established by the extraction of standards 
prepared as described in Section 6.3.2.4. Six samples of each concentration were extracted and 
assayed. The results are summarized in Table 6.4. 
6.3.2.6 PRECISION AND ACCURACY 
The precision of the assay was determined by calculating the per~flt relative standard deviation 
(RSD) of the peak height ratios (drug to internal standard) of six replicate samples of standards. 
The results are shown in Table 6.4. 
Accuracy was assessed by anal ysis of three replicate serum samples at two concentrations, that had 
been prepared by an independent analyst. The mean measured concentrations were compared with 
the known spiked concentrations. Sample concentrations were calculated by interpolation of_Qeak 
height ratios from the calibration curve. The results are shown in Table 6.5. 
6.3.2. 7 PERCENTAGE RECOVERY 
The percentage recovery from spiked serum samples was assessed by comparing peak heights of 
samples with the peale heights of aqueous reference sample~ containing amoxycillin. Replicate 
samples of two serum concentrations were extracted. Ref'erence samples were prepared by diluting 
the amoxycillin aqueous stock solution to concentrations equivalent to 100% recovery. The peak 
heights of amoxycillin in the test samples were then compared to those of the reference samples. 
6.3.2.8 LIMIT OF QUANTITATION AND DETECTION 
The limit of quantitation was determined by diluting spiked serum until the amoxycillin peak on 
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the HPLC trace was detectable but no longer measurable. The lower limit of quantitation was taken 
to be twice this value, based on a signal to noise ratio of 3. 
6.3.2.9 STABILITY 
A blank serum sample was spiked with amoxycillin trihydrate stock solution ancL th~ spiked serum 
was diluted to 1.2 and 6.0 jlg/mL by serial dilution. Aliquots of each solution were set aside for 
storage at -70°C, -15°C, 4°C and 21°C. 
On Day 1, Day 3, Day 7 and Day 14 spiked serum samples were allowed to thaw to room 
temperature, then these were extracted and assayed in triplicate. The sample stored at 21°C was 
only assayed on Day 1. The concentration of amoxycillin in each sample was calculated, as well 
as th~ percentage drug remaining. 
Aliquots of the amoxycillin eluents of samples of both concentrations which were extracted on Day 
o were stored at room temperature and at 4°C, and were assayed again at 12, 24 and 48 ho~rs to 
determine in-process stability. The concentration of drug was calculated, as well as the percentage 
of drug remaining after storage. 
6.3.2.10 STATISTICAL INTERPRETATION OF THE DATA 
The statistical procedure used was that described in Section 3.3.2.9. 
6.3.3 RESULTS AND DISCUSSION 
6.3.3.1 LINEARITY AND CALIBRATION CURVES 
A calibration curve was constructed by linear regression of a plot of peak height ratio versus time 
after the extraction of replicate serum standards. The validation data are shown in Table 6.4. The 
linear regression equation was y=O.5046x-O.1579 with a correlation coefficient of 0.9997. The 
calibration curve for amoxycillin in serum is shown in Figure 6.2. 
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Table 6.4 Linearity and precision data for amoxycillin in serum 
Calibration Standards 
Concentration Peak Height Ratio %RSD 
(#tg/mL) Mean ± SD (n=6) 
0.6 0.17 ± 0.01 5.9% 
1.2 0.50 ± 0.03 6.0% 
2.4 1.10 ± 0.06 5.5% 
4.8 2.48 ± 0.18 7.3% 
6.0 3.06 ± 0.15 4.9% 
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Figure 6.2 Calibration curve of amoxycillin in serum (y = 0.5046x - 0.1579; R2 = 0.9997) 
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6.3.3.2 PRECISION AND ACCURACY 
The extraction method was found to be precise, with ,RSD values less than 8 % at all concentrations 
(Table 6.4) and accurate, with a percentage bias ~3% (Table 6.5). The percentage bias was 
calculated as the difference between calculated concentration and spiked concentration as a 
percentage of the spiked concentration. The assay results for precision and accuracy are acceptable 
r - ~ 
according to the definition of Peng and Chiou [132], since both %RSD and percentage bias are 
~10%. 
Table 6.5 Accuracy data for the extraction of amoxycillin from serum 
Spiked Concentration Calculated Concentration (pg/mL) Percentage 
(pg/mL) Mean ± SD (n=3) bias 
3.6 3.52 ± 0.08 -2.3% 
5.4 5.38 ± 0.10 -0.4% 
6.3.3.3 LIMIT OF QUANTITATION 
The detection limit of amoxycillin in serum was 0.3 Ilg/mL, determined with a 200 ilL injection 
volume and a sensitivity of 0.02 AUFS. This corresponds with an on-column load of 30 ng. The 
lower limit of quantitation was taken to be 0.6 Ilg/mL, with a 60 ng on-column load. 
6.3.3.4 PERCENTAGE RECOVERY 
Results from percentage recovery studies are shown in Table 6.6. The mean percentage recoveries 
at the upper and lower limits of the concentration range were 81 % and 86% respectively. 
Table 6.6 Percentage recovery data after the extraction of amoxyciIlin from serum' 
Spiked Sample Reference Samples Extracted Samples Percentage 
Concentration (pg/mL) MIl" ± SD (n=3) MIl" ± SD (n=3) Recovery 
0.6 4.67 ± 0.58 4.00 ± 0.00 86% 
6.0 96.67 ± 2.31 78.00 ± 9.54 81% 
* Mean peak height of amoxycillin 
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6.3.3.5 STABILITY 
Calibration curves were constructed in a simiJarmanner to that described in Section 6.3.2.4 on 
each day of the stability study, and the results are tabulated in Table 6.7. 
Table 6.7 Linearity data from spiked serum 
Day Slope Y -intercept Correlation Coefficient 
0 0.5402 -0.1579 0.9997 
1 0.3487 -0.1452 0.9987 
3 0.2957 0.1601 0.9914 
7 0.3247 0.0773 0.9917 
14 0.8859 -0.1878 0.9997 
The concentration of amoxycillin remaining in the serum samples after storage was calculat~, from 
the calibration data. The stability data of the serum samples containing amoxyeilIin, 'stored at 
21°C, 4°C, -15°C and -70°C for two weeks, are shown below in Tables 6.8 and 6.9. 
Table 6.8 Stability data for amoxycillin 1.2 Ilg/mL in serum stored over a 14 day period 
Day Concentration (pgimL), Mean ± SD (n=3) 
21 0 C 40 C _150 C _70 0 C 
0 1.20 ± 0.09 1.20 ± 0.09 1.20 ± 0.09 1.20 ± 0.09 
1 0.85 ± 0.10 0.88 ± 0.03 1.15 ± 0.06 1.15 ± 0.06 
3 - 0.85 ± 0.18 1.08 ± 0.02 1.15 ± 0.06 
7 - 0.66 ± 0.05 L08 ± 0.13 1.10 ± 0.17 
14 - 0.27 ± 0.03 1.06 ± 0.05 1.10 ± 0.26 
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Table 6.9 Stability data for amoxycillin 6.0 {lg/mL in serum stored over a 14 day period 
'. Day Concentration (pg/mL), Mean ± SD (n=3) 
21 0 C 40 C _15 0 C _70 0 C 
0 5.90 ± 0.79 5.90 ± 0.79 5.90 ± 0.79 5.90 ± 0.79 
1 4.92 ± 0.19 5.11 ± 0.10 5.90 ± 0.05 5.90 ± 0.05" 
3 - 4.22 ± 0.77 5.93 ± 0.06 5.92 ± 0.08 
7 - 2.38 ± 0.03 5.91 ± 0.01 5.90 ± 0.10 
14 - 0.40 ± 0.05 5.88 ± 0.03 5.89 ± 0.07 
The percent of amoxycillin remaining in each serum sample was calculated from the measured 
perce,ntage difference in response. The results are shown in Table 6,10. 
Table 6.10 Percent drug remaining in serum after storage ~ 
-,' 
Day 21 0 C 40 C _15 0 C _70 0 C 
1.2 6.0 1.2 6.0 1.2 6.0 1.2 6.0 
pg/mL pg/mL pg/mL pg/mL pg/mL pg/mL pg/mL pg/mL 
0 100% 100% 100% 100% 100% 100% 100% 100% 
1 71 % 83% 73% 87% 96% 100% 96% 100% 
3 - - 71 % 72% 90% 101 % 96% 100% 
7 - - 55% 40% 90% 100% 92% 100% 
14 - - 23% 7% 88% 100% 92% 100% 
The significance and relevance of each change in concentration was determined using the method 
of Timm et al [52]. T~e results from the determination of percent change from initial concentration 
of amoxycillin 1.2 {lg/mL and 6.0 {lg/mL, after storage at 21°C, 4°C, -15°C and -70°C for 14 
days, are depicted in Figures 6.3 and 6.4 respectively. 
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Percentage change from initial concentration of a spiked serum sample containing 
amoxycillin 1.2 JLg/mL 
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Percentage change from initial concentration of a spiked serum sample containing 
amoxycillin 6.0 JLg/mL 
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After storage for 24 hours at room temperature, both the 1.2 Ilg/mL and 6.0 Ilg/mL serum samples 
showed a significant and relevant change in concentration, indicating that the serum samples were 
unstable under these conditions. Similarly, all solutions stored in the refrigerator, were unstable 
after 24 hours. 
The 6.0 Ilg/mL samples which were stored at -15°C and -70°C were stable for Jw'o weeks when 
stored at both -15°C and -70°C, with the results indicating a change from initial concentration 
which was either not significant and not relevant (a) or significant but not relevant (b) (Figure 3.3). 
The 1.2 Ilg/mL samples were stable after being frozen for 24 hours, but after three days, only the 
sample stored at -70°C was stable. After this time all other samples were unstable, according to 
the definition of Timm et al [52]. In the case of the samples stored at -70°C for 7 and 14 days, 
and the sample stored at -15°C for 7 days, it was decided that the drug was not stable (e), but the 
confidence interval was wide, indicating poor precision and the need for processing a higher 
number of replicates. 
In summary, serum samples should be stored at -15°C or below, immediately after-donat:iOn. The 
samples should be extracted within three days of donation. 
In order to determine the in-process stability of the extraction procedure, samples of the eluent 
obtained, by extraction of the spiked serum sample, were stored at room temperature and 4 o~ for 
48 hours, in order to determine the change in amoxycillin concentration. Each sample was 
analyzed in triplicate. The res-ults are snown in Tables 6.11 and 6.12. 
Table 6.11 In-process stability data for amoxycillin 1.2 Ilg/mL following extraction 
Time Concentration (J.(g/mL), )\'lean ± SD (n=3) 
(Hours) 
21° C 4° C 
0 1.21 ± 0.09 1.21 ± 0.09 
12 1.22 ± 0.04 1.25 ± 0.01 
24 1.11 ± 0.02 1.22 ± 0.08 
48 0.81 ± 0.18 l.l8 ± 0.02 
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Table 6.12 In-process stability data for amoxycillin 6.0 p.g/mL 
Time Concentration (p.g/IilL), Mean ± SD (n=3) 
(Hours) 
21° C 4° C 
0 5.90 ± 0.79 5.90 ± 0.79 
12 5.47 ± 0.16 5.99 ± 0.11 
24 5.18±0.19 5.41 ± 0.10 
48 5.06 ± 0.12 5.55 ± 0.13 
The percentage amoxycillin remaining in the extracts was calculated from the measured percentage 
difference in response, and the results are shown in Table 6.13. 
Table 6.13 Percent drug remaining in extracts of amoxycillin 
Time 21 ° C 4° C 
(bours) 
1.2 p.g/mL 6.0 p.g/mL 1.2 j.tg/mL 6.0 p.g/mL 
0 100% 100% 100% 100% 
12 101 % 93% 103% 102% 
24 92% 88% 101 % 93% 
48 67% 86% 98% 94% 
'. . 
The significance and relevance of any change in response was determined" and these results are 
depicted in Figure 6.5. 
The lower concentration samples were stable for 48 hours following extraction when stored at 4°C, 
and stable for 24 houts when stored at 21°C. The solutions containing a high concentration of drug 
were stable for only 12 hours at 4°C and unstable under the other storage conditions, according 
to the definition of Timm et at [52]. These results imply that extracted samples should be assayed 
immediately after extraction, and should not be left for long periods in the autosampler during a 
run. If rapid analysis is not possible, they can be refrigerated until use, for up to 12 hours. 
21 C 12 HOURS 1.2 
21 C 24 HOURS 1.2 
21 C 48 HOURS 1.2 
4 C 12 HOURS 1.2 
4 C 24 HOURS 1.2 
4 C 48 HOURS 1.2 
21 C 12 HOURS 6.0 
21 C 24 HOURS 6.0 
21 C 48 HOURS 6.0 
4 C 12 HOURS 6.0 
4 C 24 HOURS 6.0 
4 C 48 HOURS 6.0 
-60 -50 
--~ 
-
-
-- - -"" 
,.. 
-
-
• • 
-
~ 
-
-40 -30 -20 -10 o 10 20 
% Change from Initial Concentration 
Figure 6.5 Percentage change from initial concentration of extracted serum samples 
6.3.4 CONCLUSION 
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A validated method suitable for pharmacokinetic studies was developed for the analysis of 
amoxycillin}n serum. This method involved sample preparation by solid phase extraction, followed 
by analysis using high performance liquid chromatography. The method was found to be precise 
and accurate, with a limit of quantitation of 0.6 iLg/mL, and provided a recovery of drug from 
serum samples of greater than 80%. This method was used to determine the stability of amoxycillin 
in serum under various storage conditions. The relative instability of amoxycillin in serum meant 
that samples had to be assayed immediately, or could be frozen for a maximum of three days 
before analysis if th.is was not possible. The results of the in-process stability investigation 
suggested that once a sample had been extracted it could not be left in the autosampler forextended 
periods, but could be stored at 4°C for up to 12 hours. 
CHAPTER SEVEN 
BIOA V AILABILITY OF AMOXYCILLIN IN RECTAL DOSAGE 
FORMs 
7.1 INTRODUCTION 
7.1.1 OPTIMISING RECTAL ABSORPTION 
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The factors that control the rate of absorption from the rectum are not fully understood, although 
the absorption mechanism of most drugs from the colorectum is thought to be similar to that in the 
upper part of the gastrointestinal tract. Some types of drugs such as antibiotics and antitumour 
agents seem to have a different mechanism according to the absorption site within the 
gastrointestinal tract [111]. The suggestion of a different absorption mechanism has been proposed 
to account for the relatively low bioavailability of rectally administered bacampicillin compared 
.-
to that of an oral dose [112]. 
The luminal surface of the rectum is covered by a membrane formed by a layer of cells consisting 
of columnar epithelium, endocrine and goblet cells [113]. After rectal administration, drugs may 
be absorbed either across the epithelial cells or via the tight junctions connecting the mucosal cells 
[113]. It has been recognized that drug absorption after rectal administration occurs according to 
the pH partition theory [114]. There is no experimental proof of carrier mediated drug transport, 
thus colorectal absorption: is a simple diffusion process through the lipoidal membrane [27,114], 
with maximal absorption occurring at a pH conducive to the formation of non-ionised drug 
molecules [31]. 
There are several possible methods of improving the rectal absorption of drugs which are poorly 
.. 
absorbed due to their ionic structure, low lipophilicity'or high molecular weight. These methods 
include the addition of surfactants, non-surfactants, solvents, cosolvents as permeation enhancers 
and the use of prodrugs. 
The high sensitivity of the colorectal mucous membrane to membrane active adjuvants may be 
exploited for the formulation design of poorly absorbed drugs [27,114]. The use of surfactant and 
non-surfactant adjuvants to enhance drug absorption is well documented in the literature 
[27,114,115]. Surfactants seem to stimulate rectal absorption [113], although many, such as sodium 
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lauryl sulphate, appear to damage the rectal membrane causing a lasting effect on rectal drug 
absorption which may limit their use in formulation design [113,115]. 
The enhancing action of non-surfactant adjuvants such as salicylic acid or salicylate has been 
observed [115]. Nishihata et al [115] described studies of salicylate as an adjunct to enhance the 
rectal absorption of theophylline. The absorption of theophylline depended ou the simultaneous 
absorption of salicylate, and increased with increasing concentrations of salicylate [114]. Unlike 
sodium lauryl sulphate which causes damage to the rectal epithelium and alters subsequent 
absorption, the effect of salicylate is seen only when the compound is included in the formulation 
[115]. The mechanism of the enhancement of rectal absorption of theophylline by salicylate is still 
unclear, but it is possible that salicylate reduces the lipophilicity or increases the permeability of 
the membrane, perhaps by interacting with calcium or magnesium ions [113,115]. 
During studies of the mechanism involved in the adjuvant action of salicylate, the enhancing effects 
of certain agents, or co-adjuvants, on the promoting action of s-alkylates was observed, increasin~ 
the options available for devising efficient drug delivery systems [116]. Sodium chloride, for 
",' 
example, facilitated the adjuvant action of sodium salicylate in enhancing rectal airipicillin 
absorption in rats after administration of a micro-enema (0.25 mLlkg) [116]. 
Murakami et al [117] investigated the effect of co-administration of dicloxacillin sodium and other 
isoxazolyl penicillins on the rectal absorption of ampicillin sodium in healthy volunteers, _l!sing 
suppositories with Witepsot HIS as a base. Isoxazolyl penicillins were shown to enhance the 
urinary recovery of rectally administered ampicillin, possibly as a result of the formation of 
penicillin-calcium complexes resulting in improved mucosal permeability [117,118], 
Bergstrom et at [119] investigated the cl inical efficacy of suppositories containing sodium 
ampicillin using sOcWum decanoate as an absorption promoter. The clinical effect of rectally 
administered ampicillin was similar to that of orally administered amoxycillin, when used for the 
treatment of otitis media in children, which retlects adequate rectal absorption of ampicillin. 
When fatty suppositories or aqueous micro enemas are unfavourable vehicles due to poor dissolution 
and release characteristics of a drug, the addition of water miscible solvents such as polyethylene 
glycol or propylene glycol may be used to improve absorption [31]. 
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Sj6vall et al [120] investigated the prodrug approach to enhancing the rectal absorption of 
ampicillin. Rectal administration of the prod rug bacampicillin resulted in mean ampicillin 
bioavailability of 30% relative to an oral suspension, indicating incomplete rectal absorption of 
bacarnpicillin despite oral and rectal absorption rates being similar [112,118,121]. However 
bacarnpicillin shows greatly improved rectal absorption when compared to ampicillin, probably 
because despite adequate water solubility, it has greater lipophilicity [121]. r _ ~ 
Bioavailability depends not only on the formulation, but also on the administration route. In many 
suppositories the drug is in suspension in the vehicle which means that absorption by the rectal 
route is governed by particle size, solubility in water and interfacial tensions [18]. The factors 
which influence the rate and extent of drug absorption when a drug is administered in a suppository 
dosage form have been discussed in Section 2.1.2.2. Apart from these factors which may affect 
drug.release and dissolution, potential barriers to the passage of dissolved drug into venous blood 
or lymph also exist in the unstirred water layer, the mucous layer, the cellular structure of the 
mucous membrane and the walls of lymph vessels and blood capillaries [24]. 
7.1.2 ORAL ABSORPfION OF AMOXYCILLIN AND OTHER 6-LACTAMS 
Although arnoxycillin is completely ionized at all pH values and has low lipid solubility, 
arninopenicillins such as amoxycillin are well absorbed from the alimentary tract [2]. 
The mechanism by which amino-IHactams are absorbed is not clearly understood. Sj6val et al 
[120] observed that oral alloxycillin is better absorbed than would be, anticipated if passive 
diffusion were the only absorptive process. It has been postulated, mainly from in situ rat gut 
experiments, that amoxycillin and various IHactams are absorbed by an active and consequently 
saturable carrier mediated absorption ·mechanism [120,122,123,124]. This suggests that dose-
dependent absorption of amoxycillin supports the concept of a capacity-limited and probably 
specialized transport system in man. The results of Tsuji et al [122] and Arancibia et.. al [125] 
supported these findings. 
Mizen et al [124] observed that the uptake of amoxycillin was facilitated, whereas cyclacillin was 
absorbed via an active transport process from the gastrointestinal tract after oral dosing. Tsuji et 
al [122] have suggested that a specialized transport mechanism that deviates from the pH-partition 
hypothesis may contribute to the absorption of zwitterionic antibiotics. This mechanism is thought 
140 
to occur in addition to the simple diffusion transport responsible for the absorption of unionized 
species of the monobasic B-lactam antibiotics. This deviation can be explained by passive transport 
of the undissociated molecule through both the <i1}ueous diffusion barrier layer adjacent to the 
gastrointestinal membrane surface and the lipid barrier of the gastrointestinal membrane, suggesting 
two compartment diffusion [122]. However, the gastrointestinal absorption of amino-B-lactams, 
which have very low lipid solubility and are completely ionized in all alimentary.tfaGt areas, cannot 
be predicted by this mechanism of passive diffusion of the unionized species. These results also 
suggest that there may be a specific area in the alimentary tract of mammals for the absorption of 
B-lactam antibiotics [122]. 
It has been shown that the permeability of the rat small intestine to amoxycillin depends on the 
concentration of the drug in the perfusate [123]. At higher concentrations (> 100 jLg/mL) passive 
diffusion is the dominant absorption mechanism. The relation between amount absorbed and the 
initial drug concentration suggests that the absorption of amoxycillin follows the simultaneous 
kinetics of a simple diffusion process predominant at high concentrations, and a Michaelis-Menten 
process which can onI y be seen at low concentrations [123,126]. Thus it is suggested that 
facilitated diffusion and not active transport is involved in the absorption of small 'doses of 
amoxycillin. Tsuji et al [123] did not demonstrate the nature of the transport mechanism, but 
showed that a saturable, rate-limiting step in the absorption process of amoxycillin must be 
considered. Torres-Molina et al [21] were in agreement with the saturable absorption theory, 
although the saturation phenomena did not completely explain their findings and a limiting _step 
which prevents carrier saturation seemed to be in operation [21]. 
It has been suggested that active transport of some B-lactams takes place via a dipeptide carrier 
system [127], in an active window of the small intestine [126]. Muranushi et al postulated that two 
different carrier-mediated transport sy'stems may exist for oral cephem antibiotics, an H+ ion 
gradient dependent and an independent mechanism [127]. Their study concluded that ceftibutem 
is absorbed mainly through the oligopeptide transport route in the small intestine, in which the 
driving force is the transmembrane H ~ ion gradient represented by the existence of an acidic 
microclimate pH at the surface of the small intestine [127]. 
Amoxycillin pharmacokinetic data could be described using a single compartment open model with 
first order absorption [122,128,129]. Couet et at [126] have proposed a pharmacokinetic model 
for a different amino-B-lactam, cefatrizine, which incorporated a saturated rate of absorption. This 
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Michaelis-Menten type model incorporated a time factor to predict the reduction in the extent of 
absorption observed in vivo. This model is also applicable to other amino-6-lactam antibiotics and 
drugs that are absorbed by a carrier-mediated transport mechanism in the small intestine [126]. 
7.2 PHARMACOKINETIC PARAMETER ESTIMATION 
Parameters such as Cmax, tmax and area under the plasma concentration time curve (AVC"") were 
used to define the rate and extent of oral bioavailability. Cmax and tmax were derived directly from 
the serum concentration time curve. 
AVC was calculated using the linear trapezoidal method: 
AUC = L ( Cn + Cn- 1 ) X (t n - t ) 2 n-l Eq. 7.1 
where Cn = plasma concentration at time (tn). 
The AVC calculated was the area under the serum curve to the last measurable concentration. To 
obtain the total area under the curve from time zero to infinity (AUC""), Equation 7.2 was used 
to calculate the area from the last measurable concentration to infinity and this was added to the 
AUC obtained from Equation 7. L 
AUCn- oo = Eq. 7.2 
where Cn = the last measurable concentration,- 'and 
kel = the slope of the terminal portion of a semilogarithmic concentration-time plot. 
The elimination rate constant (kel) describes the total removal of drug from the body as a result of 
biotransformation and excretion, if the drug follows one compartment kinetics. The ~I was 
calculated by linear regression of the terminal slope of a semiJog plot of serum concentration 
versus time. Calculation of the absorption rate constant (kJ was based on the method of Wagner-
Nelson [130J. 
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The serum half life (tl/2) of a drug is a function of its elimination and distribution. The tl/2 was 
calculated using Equation 7.3. 
Eq. 7.3 
The apparent clearance was reported as a ratio of clearance and bioavailability (F). An estimate 
of clearance was calculated by use of the following equation: 
where F = absolute bioavailability. 
C1 TOT 
F 
DOSE 
AUC; 
The volume of distribution (VD(area) was calculated using Equation 7.5. 
VDarea = DOSE 
F kel x AUC; 
where F = absolute bioavailability.. 
7.3 PILOT STUDIES 
Eq. 7.4 
Eq. 7.S 
Two pilot studies were performed to assess the bioavailability of amoxycillin in oral and rectal 
dosage forms. In Study L an amoxycillin capsule (250 mg) was administered to a single volunteer 
to determine whether the extraction technique and HPLC method were suitable for the 
determination of amoxycillin in serum. Amoxycillin suppositories (250 mg) were administered to 
two volunteers in Study 2, in order to determine the extent of rectal absorption of the drug. 
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7.3.1 EXPERIMENTAL 
7.3.1.1 HPLC SYSTEM 
Drug analysis was performed by HPLC using the system described in Section 6.2.3.4. 
7.3.1.2 STOCK SOLUTIONS 
Aqueous and serum stock solutions were prepared as described in Section 6.2.1.5. 
7.3.1.3 CALIBRATION CURVES 
Calibration curves were constructed on the days on which samples were analyzed. Calibration 
standards were prepared as described in Section 6.3.2.4. The linearity data for these analyses are 
shown in Tables 7.1 and 7.4. _ 
7.3.2 IN VIVO TRIAL 
7.3.2.1 VOLUNTEERS, DOSING AND SAMPLING SCHEDULE 
All human studies were conducted in accordance with the Declaration of Helsinki al].Q. its 
subsequent Amendments [131], following approval by the Rhodes School of Pharmaceutical 
Sciences Departmental Ethics Committee. 
A pilot study (Study 1) using one female volunteer was conducted to establish the effectiveness of 
the analytical method for measuring serum concentrations of amoxycillin, after the oral 
administration of a c@mmercially available amoxycillin trihydrate capsule formulation (Amoxil® 
250 mg, Smith-Kline Beecham). 
A pilot study (Study 2) using one male and one female volunteer was conducted to determine the 
amoxycillin concentrations which could be expected in serum following the administration of a 
suppository containing 250 mg amoxycillin, formulated in either Novata BD or Novata 299 
semisynthetic bases. Amoxycillin suppositories were prepared immediately prior to use using 
Novata BD and Novata 299 semisynthetic bases, as described in Section 2.2.2. 
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The subject in Study 1 received one capsule containing 250 mg amoxycillin, and the subjects in 
Study 2 were dosed with a suppository containing 250 mg amoxycillin. Subjects fasted overnight 
and ingested 200 mL water at the time of dosing. Suppositories were inserted to a standard depth. 
Blood samples were withdrawn at 0, 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 240, 360, 480 
and 720 minutes after dosing. Additional samples taken at two predetermined tjlJle~ were used as 
ex vivo standards for quality control purposes. 
7.3.2.2 COLLECTION AND STORAGE OF BLOOD SAMPLES 
An indwelling 3.3 mm cannula (Mandrin Vasocan®, B Braun, Melsunger, Germany) was inserted 
into a suitable vein in the forearm and secured with Micropore® surgical tape (3M Medical 
Prod~cts Division, Johannesburg, SA) to allow complete mobility of the forearm. 
A 10 mL blood sample was withdrawn directly from the buttertly"by syringe aspiration and the 
catheter needle was closed with a sterile stylet (Mandrin Vasotix® Vasocan®, B Braun, Melsunger, 
Germany) to prevent coagulation of blood inside the cannula. The blood sample was transferred 
to a sterile evacuated blood collecting tube (Radem Medical (Pty) Ltd, Sandton, RSA) for serum 
collection. The tube was stoppered and blood samples were left to stand for 30 minutes to clot. 
The serum was separated by centrifugation at 3000 rpm (1600xG) for 20 minutes. One millilitre 
of serum was transferred to a clean, labelled tube for analysis and the remaining serum was 
transferred into a second labelled glass tube for storage. Both samples were frozen at -15°C until 
analyzed. Analysis was performed ·within 2 days of sampling in all cases, as stability had been 
established for that period (Section 6.3.3.5). 
7.3.2.3 ANALYSIS OF SERUM 
One millilitre aliquots of serum were allowed to thaw at room temperature and wer.e mixed 
thoroughly on a vortex mixer (Maxi Mixer®, Model M-1671O-12, Thermolyne Corporation, Iowa, 
USA) before being analyzed. The samples were prepared for analysis using the method described 
in Section 6.22. An aliquot (200 ILL) of the final extract was injected onto the HPLC system. 
Assay performance was continuously monitored during the period of analysis of the biological 
samples by inclusion of quality control samples containing known concentrations of the analyte. 
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These in vitro samples were stored under identical conditions to those of the trial samples. 
Additional blood was obtained from all trial subjects at predetermined sample times and were 
analyzed at different times during the course of the analytical run. The ex vivo samples were stored 
under identical conditions to those of the trial samples. 
Trial samples, in vitro standards and ex vivo standards were analyzed in a randomized order. 
7.3.3 RESULTS OF IN VIVO STUDIES 
7.3.3.1 ANALYTICAL 
The l}nearity data from the calibration curves constructed for Study 1 and Study 2 are shown in 
Table 7.1. 
Table 7.1 Calibration data from peak height ratios 
Study Slope Y -intercept Correlation 
Coefficient 
Study 1 0.5007 3.9525 0.9985 
Study 2 0.4862 2.1978 0.9982 
The results ofthe quality control samples analyzed to assess the performance of the assay indicated 
that all in vitro and ex vivo standards had a RSD of less than 9% and the percent bias was not 
greater than 7%. The results shown in Tables 7.2 and 7.3 indicate that the performance of the 
assay procedure was consistent and precise throughout the run, and acceptable for the 
determination of pharfnacokinetic parameters [132]. 
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Table 7.2 In vitro standards for Study 1 and Study 2 
"< 
Standard Study 1 Study 2 
concentration 
(pg/mL) Mean concentration % % Mean concentration % % 
(pg/mL) ± SD (n=3) RSD Bias (pg/mL) ± SD (n=3) RSD Bias 
6.0 5.78 ± 0.07 1.20 -3.66 5.79 ± 0.39 - &.68 -3.50 
1.2 1.28 ± 0.04 3.12 6.67 1.13±0.1O 8.76 -5.83 
Table 7.3 Ex vivo standards for Study 1 and Study 2 
Sample Concentration (pg/mL) 
time 
(min) Study 1 Study 2 
Subject Mean ± SD % % Subject Mean ± % % 
sample (n=3) RSD Bias sample SD (n=3) RSD Bias 
-
30 0.65 0.62 ± 0.05 8.23 -4.62 0.00 0.00 - -
120 2.92 2.91 ± 0.16 5.33 -0.34 0.00 0.00 - -
.' 
7.3.3.2 IN VIVO STUDY 1 
The concentration of amoxycillin measured in serum at predetermined time intervals foIlow!~g a 
single 250 mg oral dose of amoxycillin, is shown in Table 7.4. 
Table 7.4 
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Concentration of amoxycillin measured in serum after oral administration of a 
single capsule containing 250 mg amoxycillin 
Time (min) Concentration (JLg/mL) 
0 0.00 
15 0.27 
30 0.65 
45 1.49 
60 3.04 
75 3.67 
90 4.26 
105 3.21 
120 2.92 
150 2.20 
180 2.33 
240 1.07 
360 0.65 
480 0.27 
720 0.00 
The serum concentration time profile and semilogarithmic serum time profile from. Stu~y 1 are 
shown in Figure 7.1. 
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profile showing amoxycillin following administration of a single amoxycillin 
capsule (250 mg) 
400 
148 
7.3.3.3 PHARMACOKINETICS 
Pharmacokinetic parameters were determined follgwing the administration of a single amoxycillin 
capsule (250 mg) to a 25 year old female volunteer, of mass 53 kg and height 1.6 m. These 
parameters are shown in Table 7.5. 
Table 7.5 Pharmacokinetic parameters from Study 1 
Parameter Subject 
Cmax (,ug/mL) 4.26 
t",.. (hr) 1.50 
AUC'" 10.3850 
Ie. (hr- I ) 0.7948 
k,,1 (hr- I ) 0.5663 
Clearance/F (Llkg/hr) 0.5047 
VD(area/F (Llkg) 0.8911 
tl12 (hr) 1.22 
The Cmax of 4.26 jLg/mL was reached within 1 to 2 hours after dosing, and was slightly lower than 
the average peak plasma concentration of 5 /Lg/mL that has been previously reported [4,6]. The 
t1l2 of 1.22 hours approximated the previously quoted value of 1 hour [4]. The VD(area) of 0.89 
Llkg was larger than the 0.3 Lkg-1 reported in the literature [4]. 
These results demonstrate that the ItPLC method was suitable for the determination of amoxycillin 
following an oral dose, and sensitive enough to be applied to the measurement of pharmacokinetic 
parameters. 
7.3.3.4 IN VIVO STUDY 2 
No amoxycillin was detectable in the serum of the volunteers that had been adminIstered a 
suppository. 
Bioavailability would mainly be influenced by drug availability or release of drug from the dosage 
form, and by the characteristics of the particular absorption sites encountered following oral and 
rectal administration. The poor rectal absorption of amoxycillin necessitated further investigations 
to determine whether the absence of amoxycillin in serum after the administration of a rectal 
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suppository was due to formulation inadequacies or absorption factors. 
7.3.4 CLINICAL TRIAL 
7.3.4.1 INTRODUCTION 
In order to determine whether amoxycillin was absorbed rectally, without the influence of 
suppository dosage form variables, a commercially available amoxycillin suspension was 
administered both orally and rectally in a crossover study. It was assumed that a suspension would 
be more bioavailable than a suppository. By using an aqueous enema or micro enema from which 
drugs are readily available for absorption, it may be possible to circumvent the process of drug 
release and apply the drug directly to potential absorption sites in the rectal wall. A solution would 
have been preferable to a suspension, since dissolution into rectal t1uid would be unnecessary, but 
preparation of a small volume solution containing 250 mg amoxycillin was not possible due to the 
limited solubility of the drug (1-10 mg/mL) [4,6]. 
The clinical trial was conducted in accordance with the Declaration of Helsinki and- its subsequent 
Amendments [131], following approval by the Rhodes University Ethical Standards Committee. 
A copy of the trial protocol is appended (Appendix 1). 
7.3.4.2 VOLUNTEERS 
Three healthy, adult Caucasian male volunteers participated in the study. lI}clusion and exclusion 
criteria are listed in Section 2.4 of the protocol. Demographic details of subjects are listed in Table 
7.6. Each volunteer was provided with details of the trial (Appendix 2) and was required to sign 
an informed consent form (Appendix 3), 
Table 7.6 Demographic data of subjects 
Parameter Subject 1 SUbject 2 Subject 3 Mean ± SD 
Mass (kg) 78.2 84.4 92.8 85.1 ± 7.3 
Height (m) 1.82 1.83 1.76 1.80 ± 0.03 
Age (years) 23 19 22 21.3 ± 2.1 
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A complete medical history was taken, and a physical evaluation conducted at the time of the initial 
visit and on the day following the completion of the trial. The haematological examination, clinical 
chemistry and urinalysis were performed by Drs <}u. Buisson and Partners, Grahamstown. These 
parameters were evaluated and subjects with abnormal results were not admitted into this study. 
The medical practitioner in attendance completed a declaration to the erfect that the volunteers were 
in good health and able to participate in the trial (Appendix 4). 
7.3.4.3 TREATMENTS 
Each subject received a single dose of 250 mg Amoxil SF® suspension (250 mg/5 rnL) (Smith-
Kline Beecham, RSA) rectally, or 250 mg Amoxil SF® suspension orally. One hour prior to the 
rectal dose, a Lenolax® enema (Lennon Ltd, Port Elizabeth, RSA) was self-administered by each 
volunteer, in order to evacuate the bowel prior to administration of the rectal suspension. The 
rectal suspension was administered by means of an enema bottle. Subjects were asked to lie on 
their stomachs for two hours following administration of the rectal suspension, after which they 
~ -:;;...-
were allowed to sit up. The subjects were requested to report any loss of dosage after 
administration. 
Since amoxycillin has a serum half life of approximately one hour [5], a washout period of 48 
hours was considered sufficient for the purposes of this trial, as after 6.62 half lives more than 
99 % of the drug is removed from the serum [133]. 
7.3.4.4 DOSAGE AND SAMPLING SCHEDULE AND COLLECTION AND STORAGE OF 
BLOOD SAMPLES 
The dosage and sampling schedules were as listed in Section 2.11 of Appendix 1. Blood samples 
were collected and s~ored following the procedure described in Section 7.3.2.2. 
7.3.4.5 ANALYSIS OF SERUM 
Serum samples, in vitro and ex vivo quality control standards were analyzed as previously 
described in Section 7.3.2.3 using solid phase extraction followed by HPLC. 
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7 .3.5 RESULTS 
7.2.5.1 ANALYTICAL RESULTS 
The linearity data from the calibration curves that were constructed on each day of assay are shown 
in Table 7.7. 
Table 7.7 Calibration data from peak height ratios of drug/internal standard 
Dosage Fonn Slope Y -intercept Correlation 
Administered Coefficient 
Rectal Suspension 0.6467 0.0760 0.9979 
Oral Suspension 0.7533 0.2413 0.9949 
The in vitro and ex vivo quality control results are shown in Tables-9.8 and 7.9 respectively. The 
term subject sample in Table 7.8 refers to the concentration measured following the analysi~ of a 
subject serum sample for the first time. The ex vivo samples were analyzed in triplicate and are 
reported as a mean concentration. 
Table 7.8 In vitro standards for oral and rectal study 
Standard Oralstudy- Rectal study 
concentration 
(lLg/mL) Mean % % Mean % % 
concentration RSD Bias concentration RSD Bias 
(lLg/mL) ± SD (lLg/mL) ± SD 
(n=3) (n=3) 
6.0 5.38 ± 0.28 5.15 -10.33 6.10 ± 0.09 1.50 1.67 
1.2 ~ 1.15 ± 0.10 8.73 -4.17 1.21 ± 0.13 10.44 0.83 
-
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Table 7.9 Ex vivo standards for oral and rectal studies 
Sample Concentration ("g/mL) 
time 
(min) Oral study Rectal study 
Subject Mean ± SD % % Subject Mean± % % 
sample (n=3) RSD Bias sample SD (n=3) RSD Bias 
r 
Subject 1 
30 1.22 1.22 ± 0.07 5.91 0.00 0.00 0.00 - -
180 2.33 2.41 ± 0.10 4.18 3.43 0.00 0.00 - -
Subject 2 
45 2.97 2.74 ± 0.28 10.17 -7.74 0.00 0.00 - -
150 2.55 2.39 ± 0.16 6.52 -6.27 0.00 0.00 - -
Subject 3 
75 4.56 4.21 ± 0.47 11.24 -7.68 0.00 0.00 - -
240 0.53 0.60 ± 0.03 4.22 13.20 0.00 0.00 - -
The ex vivo and in vitro quality control samples used to assess the precision of the analytical 
method indicated that the method was consistent for the duration o(the run. The results show RSD 
values less than 12% and a percent bias less than 14% for these quality control samples. Although 
these values are slightly greater than the 10% suggested by Peng and Chiou [132], they are 
acceptable for the purposes of this study since low concentrations (0.6 to 6.0 Ilg/mL) of the drug 
were anal yzed. 
7.3.5.2 CLINICAL TRIAL 
The serum concentrations following oral dosing, are presented in Table 7.10 and the serum 
concentration time curves are depicted in Figure 7.2. The mean serum concentrations of the three 
subjects are shown in Figure 7.3. 
Table 7.10 
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Concentration of amoxycillin measured in serum of three volunteers after the oral 
administration of a single dose of 250 mg amoxycillin suspension 
Time Concentration (J.l.gimL) 
(min) 
Subject 1 Subject 2 Subject 3 Mean ± SD 
0 0.00 0.00 0.00 0.00 ± 0.00-
15 0.31 0.21 0.10 0.21 ± 0.11 
30 1.22 2.33 4.09 2.55 ± 1.45 
45 1.33 2.97 4.25 2.85 ± 1.46 
60 4.41 3.82 4.35 4.19 ± 0.32 
75 4.88 4.56 4.56 4.67 ± 0.18 
90 5.00 4.46 4.30 4.58 ± 0.37 
105 4.88 3.61 3.93 4.14 ± 0.66 
120 3.98 3.56 3.66 3.73 ± 0.22 
150 3.29 2.55 2.29 2.71 ± 0.52 
180 2.33 1.80 1.64 1.92 ± 0.36 
240 0.74 1.01 0.53 0.76 ± 0.24 
360 0.00 0.00 0.00 0.00 ± 0.00 
480 0.00 0.00 0.00 0.00 ± 0.00 
720 0.00 0.00 0.00 - B.OO ± 0.00 
In the oral dose study, absorption of the drug was fairly rapid, with the Cmax occurring between 
75 minutes to 90 minutes after ingestion of the suspension, with concentrations ranging between 
4.56 JLg/mL and 5.00 JLg/mL. Detectable amounts were present up to 4 hours following 
administration. In previously reported studies, a peak serum concentration of 5 JLg/mL occurred 
from between 60 to 120 minutes after ingestion of a 250 mg oral dose, and amoxycillin was 
detectable in the serum for up to 8- holirs [4,5,6). 
Following administration of the rectal suspension, no amoxycillin was detectable in the serum. 
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subjects 1 to 3 showing amoxycillin following administration of a single (250 mg) 
oral dose of amoxycillin suspension 
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7.3.5.3 DATA ANALYSIS 
The pharmacokinetic parameters were calculated as described in Section 7.2. Results are presented 
in Table 7.11. 
Table 7.11 Pharmacokinetic parameters 
Parameter SUbject 1 Subject 2 Subject 3 Mean ± SD 
Cmax (J.l.g/mL) 5.00 4.56 4.56 4.70 ± 0.25 
t.n.x (hr) 1.50 1.25 1.25 1.33 ± 0.14 
AVC'" 11.3522 11.4686 10.8516 11.2241 ± 0.3278 
k. (hr- I ) 0.7363 0.8176 1.0860 0.8800 ± 0.1830 
~I (hr- I ) 0.8167 0.6297 0.9593 0.8019 ± 0.1653 
Clearance IF (Llkg/hr) 0.3053 0.2870 0.2759 0.2894 ± 0.0148 
VDCa"",/F (Llkg) 0.3739 0.4558 0.2876 0.3724 ± 0.0841 
til: (hr) 0.8485 0.1005 0.7224 0.8905 ± 0.1925 
7.2.6 DISCUSSION 
No amoxycillin was detectable in serum following the administration of a suppository containing 
250 mg amoxycillin. This negative result suggested that either the semisynthetic suppository base 
used to formulate the suppository was preventing efficient drug release, or detectable amounts of 
amoxycillin were not absorbed through the rectal mucosa. In order to discern which of-these 
factors was inhibiting absorption, .a clinical trial was conducted, in which an oral and a rectal 
suspension were administered. 
In order to allay the subjects' apprehension, the rectal study was conducted before the oral study. 
A fleet enema was used to evacuate the bowel prior to administration of the rectal suspension, so 
.. 
that the presence of faecal matter would not interfere with drug absorption, or cause premature 
expulsion of the suspension. The rectal suspension was conveniently administered with a fleet 
enema bottle. Experiments prior to the trial contirmed that the complete 250 mg per 5 mL dose 
was delivered. The subjects were asked to lie on their stomachs for two hours after dosing with 
the rectal suspension, and no subject reported leakage of the dosage form from the rectum during 
or after this time. These factors ensured minimal loss of the dosage form and it is therefore 
unlikely that the lack of amoxycillin in the serum was due to an inadequate quantity of amoxycillin 
present in the rectum. 
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The extraction process was sensitive and precise and allowed measurement of amoxycillin in serum 
following the administration of a single 250 mg dose of oral suspension to three subjects. 
Pharmacokinetic parameters were calculated from<these data. 
The mean Cmax of 4.67 jlg/mL was slightly lower than the average of 5 jlg/mL quoted in previous 
reports [4,5,6]. The range quoted for tmax is between 1 and 2 hours, which is consistent with the 
mean tmax of 1.25 hours [4,6J. The mean YD.rea (0.3724 Llkg) is slightly greater than the 
previously reported value of 0.3 Llkg [4]. 
It was anticipated that an amoxycillin suspension would be more bioavailable than a capsule. When 
the data obtained after administration of a capsule (Study 1) and the oral suspension (Clinical 
Study) were compared, the mean Cmax obtained after administration of the suspension was higher 
(4.67.jlgJmL) than that following administration of the capsule (4.26 jlg/mL), and the ~x occurred 
sooner (1.25 hours versus 1.5 hours) as expected. The serum half life of amoxycillin calculated 
following administration of the capsule (1.22 hours) was sJ.ight!y longer than that observed 
following the oral suspension (0.89 hours). It is possible that this difference is consisten~. with 
normal intra- and inter-individual variation. The ratio of AVe'" capsule/AVC"" susp';nsion was 0.92, 
indicating that the suspension is a slightly more bioavailable dosage form than the capsule. It must 
be borne in mind, however, that data for Study 1 was obtained from only one subject. 
A suspension was used to determine whether amoxycillin is absorbed rectally, since this s~quld 
be more bioavailable than a suppository. The lack of detectable amoxycillin in the serum samples 
following administration of the rectal suspension may be attributed to the differences in structure 
and surface area of the upper gastrointestinal traCt and colorectum. The upper gastrointestinal tract 
has a greater surface area than the colo rectum since the colorectum has no microvilli. There is a 
minimal amount of fluid in the rectu·m for dissolution, thus given the limited solubility of 
amoxycillin it is unli~ly that complete dissolution of the drug in the rectal tluid occurred. The lack 
-
of drug in the serum may also be due to different absorption mechanisms for amoxycill~n in the 
upper part of the gastrointestine and in the colorectum [110]. It has been suggested that a 
specialized, saturable transport system for amoxycillin, which is probably carrier mediated exists 
in the upper gastrointestine of man [120,128,1291. The absorption of low concentrations of drug 
has been attributed to a Michaelis-Menten process, while passive diffusion is the dominant 
absorption mechanism at high concentrations [123,126]. The small dose of 250 mg used in this 
study was probably absorbed by facilitated diffusion following oral administration, but since this 
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transport mechanism may be absent in the colorectum, this may explain why amoxycillin was not 
absorbed in this region. 
Since the absorption of amoxycillin is thought to be a facilitated process [21,123,126,127], the 
difficulties involved in rectal absorption of the drug may be overcome by addition of a chemical 
adjunct to the suppository that would promote drug partitioning into the rectal ~mucosa and affect 
the intrinsic diffusional barriers of the rectal membrane. Most chemical enhancers are active by 
spacial disruption of the normally ordered arrangement of the intercellular molecules [134]. 
Dimethylsulfoxide, for example, is an effective transdermal penetration enhancer which might be 
useful in promoting rectal absorption. Fatty acids such as oleic acid have been used as transdermal 
penetration enhancers, as they disturb the intercellular layers in the stratum corneum [134] and 
decanoic acid has been used to enhance the rectal absorption of phenolsulfonphthalein [135]. 
Surf~ce active agents enhance the penetration of compounds primarily by adsorbing at interfaces 
and thus interacting with biological membranes. Sodium lauryl sulphate is an example of a surface 
active agent which has been associated with lipid modification.arul..clisorganization of the stratum 
cornea and enhanced permeation [134]. However sodium lauryl sulphate has been implica~,ed in 
permanent damage to the rectal membrane causing a lasting effect on absorption [113, 1151; thereby 
discounting its usefulness as a permeation enhancer in rectal drug delivery systems. Isoxazolyl 
penicillins and salicylates have been successfully used as penetration enhancers in certain rectal 
dosage forms [115,116,117]. Further studies should focus on identifying a suitable penetration 
enhancer to be included in a rectal amoxycillin formulation. 
In vitro studies using live tissue such as isolated intestinal and rectal memb(ane [73,135] could be 
used to simulate a living system as closely as possible in order to investigate absorption 
mechanisms in these regions of the gastrointestinal tract and to further elucidate the mechanism of 
absorption of amoxycillin. Following these investigations, ill vivo studies on animal models such 
as rats, rabbits, pig~ or dogs [66,68,116,117,135,136] would be useful to identify suitable 
penetration enhancers to include in a rectal delivery system for amoxycillin. 
CHAPTER EIGHT 
CONCLUSION 
159 
Amoxycillin is a broad spectrum, semisynthetic antibiotic, suitable for administration to children, 
and used for the treatment of infections such as otitis media, respiratory tract infections and urinary 
tract infections. It is also useful for prophylaxis prior to surgery. Administration- of medication in 
a suppository dosage form may be a useful alternative when patients, especially children, are 
unwilling or unable to take oral medication. 
Amoxycillin was formulated in several types of suppository bases, in an attempt to manufacture 
an antibiotic suppository containing 250 mg amoxycillin, suitable for paediatric use. Novata BD, 
Novata 299, Witepso[ W35, Suppocire A32 and theobroma are fatty suppository bases with slightly 
different physicochemical characteristics. In vitro dissolution testing differentiated between the 
release profiles of amoxycillin from these bases with the greatest amount of amoxycillin being 
released from the Novata ED suppositories; 85 % of the 250 fig bf drug was released from the 
newly made suppositories and 99% was released from those which had been stored for a month. 
The amount of drug released from the other types of suppository bases was lower; 85% and 74% 
were released from the Novata 299 new and aged suppositories respectively, 44% and 7% from 
the Suppocire A32, 50% and 31 % from the Witepso[ W35 and 8% and 11 % from the theobroma 
suppositories. These results gave an indication of a change in drug release on storage and also 
allowed a decision to be made regarding the suppository bases most suitable for formulatioB with 
amoxycillin. 
The DSC results suggest the possibility of a transformation or interaction between amoxycillin and 
the semisynthetic suppository bases. It is uncertain whether this interaction or transformation would 
also occur at room temperature, as it may be a result of the accelerated DSC conditions. However, 
a comparison of the -endotherms of a newly manufact~red suppository and one which had been 
stored for a month confirmed that a change did occur during storage. The development ora second 
endotherm on storage supports the change in drug release observed in the in vitro dissolution tests. 
The extraction and HPLC methods developed and described in this thesis have the necessary 
accuracy, sensitivity and precision for the selective determination of amoxycillin in aqueous 
solution and serum, and are thus suitable for the elucidation of the pharmacokinetics of the drug 
in humans. 
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Various pharmacokinetic parameters were calculated from the oral studies following the 
administration of a commercially available amoxycillin capsule (250 mg) and amoxycillin 
suspension (250 mg). These values were comparable with pharmacokinetic values previously 
reported in the literature. 
The mean Cmax measured following administration of the oral suspension was slightly higher (4.67 
JLg/mL) than that obtained following administration of the capsule (4.26 JLg/mL), and both were 
slightly lower than the 5 JLg/mL quoted in previous reports [4,5,6]. The range quoted for ~x is 
1 to 2 hours, which is consistent with the mean ~x of 1.25 hours observed after administration 
of the oral suspension, and the ~x of 1.55 hours observed after administration of the capsule. 
Amoxycillin is reported to have a half life of one hour [4,5,6J; the t1l2 following administration of 
the capsule was slightly longer at 1.22 hours and that following administration of the oral 
susp~nsion was shorter, at 0.89 hours. The ratio of AVe"" capsule/AVC""suspension was 0.92, indicating 
that the suspension was slightly more bioavailable than the capsule. The mean value for volume 
of distribution (VDarea/F=0.37 Llkg) calculated from the data oLthe clinical study was slightly 
greater than the previously reported value of 0.3 Llkg [4], but it must be borne in mind that the 
former value was calculated from oral and not IV data. The VDarea/F calculated for the single 
subject that took the capsule was larger than both of these values, at 0.89 Llkg. The mean 
clearance calculated following administration of the oral suspension (0.289 Llkg/hr) was 
approximately half of that calculated following administration of the capsule and the mean kel and 
k.. were greater (0.802 hr-! versus 0.566 hr-! and 0.880 hr-! versus 0.795 hr-! respectively): !!Iese 
differences are more than likely a result of the small sample population used in these studies. 
No rectal absorption of amoxycillin was obserVed, following the administration of amoxycillin 
suppositories and rectal suspension. The lack of absorption from either rectal formulation suggests 
an absorption related, rather than a formulation related obstacle. There is limited information on 
the rectal administration of amoxycillin, which is more than likely due to the intrinsic problem with 
rectal absorption of the drug. Suggestions of carrier mediated absorption following oral 
administration have been made, and it is possible that the transport mechanism of simple diffusion 
which is reported to take place in the colorectum is insufficient for the absorption of detectable 
amounts of amoxycillin. Further investigations into the use of permeation enhancers or prodrugs 
to improve rectal absorption of the drug should be pursued. In addition studies using in vitro 
membrane techniques and animal models should be undertaken to elucidate the absorption 
mechanism(s) of amoxycillin. 
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(c) Dr R Dowse, B.Pharm, PhD 
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Rhodes University 
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Dr A. Kench, MB.CHB 
School of Pharmaceutical Sciences 
Rhodes University 
Grahamstown 
1.3 REGISTERED NURSES 
(a) Sr Penny Bernard 
(b) Sr Lyn Hopewell 
2. PROTOCOL 
2.1 BACKGROUND INFORMATION 
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Amoxycillin is a broad spectrum B-lactam antibiotic, used for the treatment of conditions such as 
otitis media, respiratory tract infections, urinary tract infections, sexually trqnsmitted diseases such 
as gonorrhoea, enteric infections and endocarditis. It is also used for surgical prophylaxis and the 
prophylaxis of infective endocarditis. 
The pharmacokinetic} and bioavailability of amoxycillin after oral dosing have been well 
documented, but the bioavailability from a rectal dosage-form has yet to be investigated. The usual 
adult oral dose is 250 to 500 mg of the trihydrate three times daily, while the paediatric dose is 
125 to 250 mg three times daily. A peak plasma concentration of about 5 {tg/mL is observed 1 to 
2 hours after a dose of 250 mg, with detectable amounts present up to 8 hours. 
Amoxycillin is contraindicated in patients with penicillin or cephalosporin hypersensitivity, 
glandular fever and lymphatic lymphoma. Gastro-intestinal side effects including diarrhoea, nausea 
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and vomiting may occur, particularly after oral dosing, but these effects are unlikely after a single 
dose. 
2.2 OBJECTIVES 
The main objective of this study is to determine the bioavailability of amoxycimn gfter rectal and 
oral administration. 
2.3 STUDY DESIGN 
Patients will receive a rectal dose of 250 mg amoxycillin suspension, then following a 48 hour 
washout period, they will receive an oral dose of 250 mg amoxycillin suspension. 
2.4 STUDY POPULATION 
2.4.1 NUMBER OF SUBJECTS 
Three (3) healthy male volunteers will be included in the clinical trial. 
2.4.2 INCLUSION CRITERIA 
(a) Caucasian males between 18 and 45 years of age. 
(b) Normal in terms of medical history and physical examination. 
(c) Normal laboratory values (unless the clinical investigator considers an abnormality to be 
clinically irrelevant). 
2.4.3 EXCLUSION CRITERIA 
.. 
(a) Regular use of medication, abuse of alcoholic beverages or participation in another trial 
60 days preceding the study. 
(b) Treatment within the previous 3 months with any drug known to have a well defined 
potential of toxicity to any of the major organs. 
(c) A major illness during 3 months preceding the study. 
(d) History of hypersensitivity to penicillin or cephalosporin antibiotics. 
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2.S MEDICAL AND CLINICAL LABORATORY EXAMINATION 
The subjects will be examined before the study qnd assessed for their suitability to participate. 
They will undergo the same examinations within 1 to 2 days after the study. The examinations will 
be carried out by the attending physician or a registered nursing sister, and will include the 
following: 
(a) Medical history and physical examination. 
(b) Vital signs: general medical and cardiovascular system examination. 
(c) Haematological status: haemoglobin, haematocrit, red blood cell count, white blood cell 
count, platelet count and differential count. 
(d) Clinical chemistry: alanine transaminase, aspartate transaminase, alkaline phosphatase, 
glutamyl transferase, sodium and potassium chlorides, total protein, albumin, creatinine, 
glucose, total bilirubin, conjugated bilirubin and urea. 
(e) Urinalysis and microscopic examination: pH, protein, glucose, blood and cell count. 
~ - ;...-
2.6 WRITTEN CONSENT FORM 
Preceding the trial, the nature, purpose and risk of participating will be explained to all subjects 
(Appendix 2). They will be informed that they may withdraw from the study at any time. They 
will sign a consent form in the presence of two witnesses (Appendix 3). Volunteers who are minors 
will obtain written consent from a parent or guardian. 
2.7 DROP-OUTS 
If any subject fails to complete the study due to a side effect, the reason must be specified by the 
medical practitioner 1n writing. 
2.8 DOSAGE FORMS 
Amoxil SF® suspension, containing the equivalent of 250 mg amoxycillin per 5 mL (SmithKline 
Beecham Pharmaceuticals (Pty) Ltd, RSA) will be administered as a 5 mL oral dose, and 
a 5 mL rectal dose, administered via an enema bottle. 
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2.9 STUDY PERFORMANCE 
The study will be performed in the Biopharmaceutks. Research Institute Clinic, Rhodes University, 
Grahamstown. Subjects will receive detailed, written instructions concerning the trial performance 
and restrictions (Appendix 2). Subjects will receive one dose of each treatment (Section 2.8) per 
trial phase. 
On the first trial day, the subjects will report to the clinic at 06h30, having fasted from 24hoo of 
the previous day. On arrival, each volunteer will self-administer a fleet enema (Lenolax® Lennon 
Ltd, RSA). An indwelling cannula (Mandrin Vasocan®, Melsungen, Germany) will be inserted into 
an arm vein and a zero-time sample collected. At 08hOO the subjects will receive the dose of the 
preparation for that phase, with 200 ml water. A standard breakfast will be served 2 hours after 
druK administration. A standard lunch will be served 4 hours after dosing. Subjects will remain 
sedentary in bed for the first 5 hours after administration and then may be ambulatory. 
On the second trial day volunteers will arrive at the clinic at 06h30 on the day of the trial, having 
fasted from 24hoo of the previous day. An indwelling needle will be inserted into an arm vein and 
a blood sample will be withdrawn. An oral suspension will then be administered at 08hoo. Blood 
samples will be collected as in phase 1. All conditions pertaining to meals and confinement to the 
clinic are as listed in phase 1. 
2.10 SUBJECT RESTRICTIONS 
All subjects must refrain from taking medication, including OTe drugs for at least one week 
preceding phase one of the study and, except for the test drug, during the study. Ingestion of 
alcohol and caffeine containing beverages and foods will not be permitted 48 hours before the 
study, during the tri;u period and 24 hours thereafter. Strenuous exercise will not be allowed 24 
hours before the trial, during the trial period or 24 hours thereafter. During the trial, ~fluid and 
food intake will be standardized to minimise individual variations. 
2.11 BLOOD SAMPLING 
On each trial day of phase one and phase two, blood samples (10 mL) will be collected before 
dosage administration, and at the following times after administration: 
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15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 240, 360, 480 and 720 minutes. 
At two sampling times, an additional 10 mL sample will be withdrawn. These samples will be used 
as ex vivo controls during analysis. 
After each sample, the cannula will be sealed with a stylet (Mandrin Vas-ofix® Vasocan®, 
Melsunger, Germany) to prevent the blockage of the needle due to blood coagulation. Blood 
samples will be collected in sterile evacuated blood collection tubes for serum collection (Radem 
Medical (Pty) Ltd, Sandton, RSA). 
2.11 ADVERSE REACTIONS 
If any side effects or adverse reactions are reported, the medical practitioner will decide whether 
or not to withdraw the subject from the study and to initiate appropriate treatment if required. Any 
unusual events will be recorded. 
2.12 DRUG ANALYSIS 
2.12.1 SPECIAL INVESTIGATIONS 
All clinical, haematological and urinalysis determinations will be performed by Drs du BuissPD and 
Partners, Grahamstown. 
2.12.2 DRUG ASSAY METHOD 
Quantitative analysis of amoxycillin in serum samples will be performed at the Biopharmaceutical 
Research Group labotatory, Rhodes University, Graha~stown by means of high performance liquid 
chromatography. 
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APPENDIX 2 
VOLUNTEER INFORMATION 
1. PLACE 
The trial will be conducted in the BRI Clinic, Rhodes University. 
2. DATE 
The initial phase will take place on Monday 16 December and the second phase on Wednesday 18 
December 1996. 
3. STUDY 
The aim of this study is to determine and compare the rate and extent to which amoxycillin"enters 
the blood stream after a single oral dose and a single rectal dose. 
4. STUDY INFORMATION 
Amoxycillin is a broad spectrum penicillin antibiotic. Amoxycillin is generally well tolerated ~nd 
has few side effects. Side effects which may occur are diarrhoea, nausea and vomiting. It is 
essential that the volunteer is not allergic to penicillin, as amoxycillin may cause a hypersensitivity 
reaction in an allergic person. 
STUDY SUPERVISORS: 
MEDICAL 'PRACTITIONERS: 
NURSING SISTERS: 
Miss J.A. Webster 
Dr A. Kench 
Sr Penny Bernard 
Sr Lyn Hopewell 
6. CONDITIONS OF PARTICIPATION IN THE TRIAL 
To participate in this trial a volunteer must fulfil the following requirements: 
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(a) Must be in good health; established on the basis of an interview, physical examination, 
urine and blood analysis. 
(b) Must not have a history of gastrointestinal, hepatic, renal, cardiovascular, respiratory or 
endocrine disease. 
(c) Must not have had any major illness for at least 3 months preceding the trial. 
(d) Must not take any medication for one week preceding the trial and up to_ the last phase of 
the trial. 
(e) Must refrain from ingesting any alcohol or caffeine containing beverages or food (eg Milo, 
coffee, tea, Coke, chocolate) for 48 hours before the start of each phase, until the end of 
that particular phase. 
(f) Must follow all instructions pertaining to diet before and during each phase of the trial. 
(g) Must refrain from any abnormal or strenuous exercise on the day before each phase and 
for the duration of that phase. 
(h) Must have no history of asthma or related syndromes, or penicillin allergy. 
7. CONDITIONS OF THE TRIAL 
Phase 1 
Volunteers will arrive at the clinic at 06h30 on the day of the trial, having fasted from 24hOO the 
previous day. An enema will be self administered. An indwelling needle will be inserted into an 
arm vein, by a qualified nursing sister, and a blood sample will be withdrawn. The rectal 
suspension will then be administered at 08hOO am, by a medical practitioner, to the volunteer. 
Blood samples will then be withdrawn at the specified times. 
A standard breakfast will be served 2 hDurs after dosing. Volunteers will remain sedentary for the 
first 5 hours after dosing, after which they may be ambulatory. A standard lunch will be served 
4 hours after dosing. The volunteers will have to remain at the clinic for the duration of the trial. 
Phase 2 
Volunteers will arrive at the clinic at 06h30 on the day of the trial, having fasted from 24hOO of 
the previous day. An indwelling needle will be inserted into an arm vein and a blood sample will 
be withdrawn. An oral suspension will then be administered at 08hOO. Blood samples will be 
collected as in phase 1. 
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All conditions pertaining to meals and confinement to the clinic are as listed in phase 1. 
8. BWOD SAMPLING 
Blood samples (10 mL) will be withdrawn at the following times after dosing for both phase 1 and 
phase 2: 
0, 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 240, 360, 480 and 720 minutes. 
At two sampling times, an additional 10 mL sample will be withdrawn. These samples will be used 
as ex vivo controls during analysis. After each sample, the cannula will be sealed to prevent the 
blockage of the needle due to blood coagulation. 
9. SIDE-EFFECTS AND ADVERSE REACTIONS 
Subjects are asked to report the occurrence of any side-effects after administration of the res~~ctive 
dose. If any side effects or adverse reactions are reported, the medical practiticJner will decide 
whether or not to withdraw the subject from the trial, or initiate the appropriate therapy. 
10. ADDITIONAL REMARKS 
(a) Volunteers may ask any questions regarding his personal involvement in the trial. 
(b) The volunteers have the right to refuse to participate or may withdraw at any stage without 
jeopardising his standing. 
(c) Volunteers must follow all instructions given either by the medical practitioner or 
supervisor of the trial. 
11. REMUNERATION 
Volunteers will receive a gratuity for participating in the trial. 
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APPENDIX 3 
CONSENT FORM 
I, ...................................... , .... , . . . . . . . . hereby 
give permission that the drug mentioned below may be administered to me. r - ~ 
I undertake to comply with all the relevant conditions contained in the volunteer information form 
and confirm that I accept any consequence arising as a result of my withholding or misrepresenting 
any information required of me. I have been fully informed by the medical practitioner regarding 
the possible side-effects of the drug. 
The "formulations which will be administered to me are: 
(a) A 5 mL oral dose of Amoxil SF® suspension, manufactured by SmithKline Beecham 
Pharmaceuticals (Pty) Ltd. 
(b) A 5 mL rectal dose of Amoxil SF® suspension, manufactured by SmithKline'Beecham 
Pharmaceuticals (Pty) Ltd. 
My consent is freely given and I realise that it may be withdrawn at any time. I also declare that 
I have made the necessary arrangements regarding attendance of lectures and other academic 
activities. 
VOLUNTEER 
NAME ......................... " SIGNATURE ........ " ......... . 
MEDICAL PRACTITIONER 
NAME ........................... SIGNATURE ..... " ........... . 
TRIAL SUPERVISOR 
NAME ........................... SIGNATURE .................. . 
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APPENDIX 4 
DECLARA TION BY MEDICAL PRACTITIONER 
1, Dr. ....................................................... . 
have examined the volunteer 
and on the basis of an interview, physical examination, serum and urine analysis have found the 
said volunteer to be in good health and able to participate in the abovementioned trial. 
Signed .................... . 
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